

Mozambique Country Operational Plan FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Summary of Planne	l anding	by Agono,	ana rana		•	
	ı	unding Source	!			Total All
						Funding
A				Funding	Applied	Sources and
Agency	GAP	GHP-State	GHP-USAID	Source Total	Pipeline	Applied
						Pipeline
						Amount
State		890,000		890,000	1,569,653	2,459,653
USAID		175,430,231		175,430,231	4,681,685	180,111,916
DOD		8,184,270		8,184,270	237,846	8,422,116
PC		3,012,056		3,012,056	308,627	3,320,683
HHS/CDC	3,075,000	187,200,465		190,275,465	2,910,688	193,186,153
HHS/HRSA		5,801,877		5,801,877	109,602	5,911,479
State/AF		271,519		271,519	501,481	773,000
Total	3,075,000	380,790,418	0	383,865,418	10,319,582	394,185,000

Summary of Planned Funding by Budget Code and Agency

	Agency							
Budget Code	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	Total
CIRC		2,880,147	25,082,377	1,667,187	0	0	13,324,426	42,954,137
НВНС	43,400	682,361	12,848,789	300,000	0	85,000	7,326,286	21,285,836
HKID	21,700	0	0	0	30,000	80,000	18,283,438	18,415,138
HLAB		87,700	2,488,465	0	0	0	754,706	3,330,871
HMBL		0	409,939	0	0	0	0	409,939
HMIN		0	0	0	0	0	0	0
HTXD		44,100	9,303	0	0	0	24,504,340	24,557,743
HTXS	43,400	2,867,670	66,044,087	1,524,067	0	0	59,441,650	129,920,874
HVAB	0	0	0	0	115,000	42,500	2,748,274	2,905,774
HVCT	21,700	1,081,500	17,386,996	379,778	0	0	10,686,684	29,556,658
HVMS	586,200	144,339	13,549,050		2,752,056		9,684,283	26,715,928



	890,000	8,184,270	190,275,465	5,801,877	3,012,056	271,519	175,430,231	383,865,418
PDTX	43,400	39,706	12,730,859	461,578	0	0	3,110,532	16,386,075
PDCS	43,400	38,971	4,552,774	0	0	0	4,823,855	9,459,000
OHSS	21,700	41,780	2,093,926	637,800	0	21,519	4,621,096	7,437,821
мтст	0	17,198	10,337,032	0	0	0	6,073,034	16,427,264
IDUP		0	0	0	0	0	0	0
HVTB	43,400	192,648	12,701,367	351,467	0	0	442,336	13,731,218
HVSI	0	66,150	4,721,489	480,000	0	0	401,186	5,668,825
HVOP	21,700	0	5,319,012	0	115,000	42,500	9,204,105	14,702,317



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount			
нвнс	20,418,102			
HKID	18,194,212			
HVTB	13,309,945			
PDCS	9,033,271			
Total Technical Area Planned Funding:	60,955,530			

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	3,047,724
HVSI	3,109,472
онѕѕ	6,501,890
Total Technical Area Planned Funding:	12,659,086

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	42,531,976
HMBL	400,636
HMIN	0
HVAB	2,884,997
нуст	28,498,020
HVOP	14,354,176
IDUP	0
мтст	15,874,730
Total Technical Area Planned Funding:	104,544,535



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	24,187,059
HTXS	126,527,114
PDTX	15,741,034
Total Technical Area Planned Funding:	166,455,207



Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	97 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,004,940
	Number of new ANC and L&D clients	1,036,958
	By Age (Denominator): 10-14	7,079
	By Age (Denominator): <15-19	185,506
	By Age (Denominator): 20-24	285,397
PMTCT_STAT_DSD	By Age (Denominator): 50+	233
	By Number of known positives: 10-14	9
	By Number of known positives: 15-19	1,915
	By Number of known positives: 20-24	7,193
	By Number of known positives: 50+	41
	By Number of new positives: <10	12
	By Number of new positives: 10-14	106
	By Number of new positives: 15-19	3,828
	By Number of new positives: 20-24	9,184
	By Number of new positives: 50+	68
	By Number of new negative: <10	341
	By Number of new negative: 10-14	6,677



By Number of new negative: 15-19	188,751
By Number of new negative: 20-24	234,703
By Number of new negative: 50+	1,003
By Age (Numerator): <10	353
By Age (Numerator): 10-14	6,960
By Age (Numerator): 15-19	197,343
By Age (Numerator): 20-24	252,645
By Age (Numerator): 50+	1,122
PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	146,693
PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	139,701
PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	137,365
PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	134,984
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	6,361
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	354,826
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	13,674
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	6,169
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	50,213
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	3,646



	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 35-39, Female,	6,079
	Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 35-39, Female,	49,062
	Newly Identified Negative	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 35-39, Female,	3,548
	Newly Identified Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 40-49, Female,	6,052
	Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 40-49, Female,	47,008
	Newly Identified Negative	•
	PMTCT_STAT_N_DSD_Age_Sex_	
	KnownNewResult 40-49, Female,	3,502
	Newly Identified Positive	,
	PMTCT_STAT_N_DSD_Age_Sex	
	25-29, Female	376,170
	PMTCT_STAT_N_DSD_Age_Sex	
	30-34, Female	59,502
	PMTCT_STAT_N_DSD_Age_Sex	
	35-39, Female	55,718
	PMTCT_STAT_N_DSD_Age_Sex	
	40-49, Female	53,599
	PMTCT_STAT_TA Number and	
	percentage of pregnant women	
	with known status (includes women	97 %
	who were tested for HIV and	
PMTCT_STAT_TA	received their results) (TA)	
	Number of pregnant women with	
	known HIV status (includes women	400 440
	who were tested for HIV and	423,442
	received their results)	



Number of new ANC and L&	&D 435,380
By Age (Denominator): 10-1	4 5,585
By Age (Denominator): 15-1	9 81,239
By Age (Denominator): 20-2	114,910
By Age (Denominator): 50+	29
By known positives: 10-14	55
By known positives: 15-19	710
By known positives: 20-24	2,407
By new positives: 15-19	1,591
By new positives: 20-24	3,545
By new positives: 50+	6
By new negatives: 10-14	2,994
By new negatives: 15-19	56,710
By new negatives: 20-24	72,536
By new negatives: 50+	132
By Age (Numerator): 10-14	3,254
By Age (Numerator): : 15-19	59,885
By Age (Numerator): 20-24	78,839
By Age (Numerator): 50+	139
PMTCT_STAT_D_TA_Age_ 25-29, Female	Sex 57,036
PMTCT_STAT_D_TA_Age_ 30-34, Female	_Sex 60,496
PMTCT_STAT_D_TA_Age_ 35-39, Female	_Sex 58,723
PMTCT_STAT_D_TA_Age_ 40-49, Female	_Sex 57,362
PMTCT_STAT_N_TA_Age_ nownNewResult 25-29, Fen Known at Entry Positive	
PMTCT_STAT_N_TA_Age_ nownNewResult 25-29, Fen	l 93.514



Newly Identified Negative	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 25-29, Female,	5,011
Newly Identified Positive	-,
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 30-34, Female,	2,353
Known at Entry Positive	,
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 30-34, Female,	56,688
Newly Identified Negative	,
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 30-34, Female,	1,684
Newly Identified Positive	·
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 35-39, Female,	2,299
Known at Entry Positive	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 35-39, Female,	54,899
Newly Identified Negative	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 35-39, Female,	1,674
Newly Identified Positive	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 40-49, Female,	2,301
Known at Entry Positive	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 40-49, Female,	54,021
Newly Identified Negative	
PMTCT_STAT_N_TA_Age_Sex_K	
nownNewResult 40-49, Female,	1,670
Newly Identified Positive	
PMTCT_STAT_N_TA_Age_Sex	101,274
25-29, Female	101,217
PMTCT_STAT_N_TA_Age_Sex	60,796
30-34, Female	00,7 90



	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	57,874
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	56,973
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	8 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	78,300
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,004,940
	New on ART	42,908
	Already on ART at beginning of current pregnancy	35,392
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	12,370
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	423,442



	New on ART	7,335
	Already on ART at beginning of current pregnancy	5,035
	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	430,986
	By Age: 10-14	154,270
	By Age: 15-19	130,506
	By Age: 20-24	82,022
MANAO OIDO DOD	By Age: 25-29	44,336
VMMC_CIRC_DSD	By Age: 50+	1,132
	By circumcision technique: Surgical VMMC	430,986
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	4,666
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	4,670
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	9,345
	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	6,502
	Male 15-19	496
	Male 20-24	496
	Female 15-19	1,000



	Female 20-24	1,000
	FSW	5,200
	мѕм	1,301
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	1,000
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	496
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	1,000
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	496
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	415
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	104
	PrEP_NEW_TA Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	546
PrEP_NEW_TA	Male 15-19	41
	Male 20-24	41
	Female 15-19	84
	Female 20-24	84
	FSW	436
	MSM	109
	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	84
	PrEP_NEW_N_TA_Age_Sex_v2	41



	25-29, Male	
	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	84
	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	41
	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	35
	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	9
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	119,853
	Age/sex: 10-14 Female	43,680
	Age/sex: 15-19 Female	54,706
	Age/sex: 20-24 Female	18,061
	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	150
	Age/sex: 15-19 Male	19



	Age/sex: 10-14 Female	107
	Age/sex: 15-19 Female	23
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	62,076
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,406
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	33,465
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are	313



	T	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Numerator: Number of key	
	populations reached with individual	51
	and/or small group level HIV	51
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: People in	
	prisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	47.044
	and/or small group level HIV	17,841
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	Number of individuals who received	
	T&C services for HIV and received	4 700 045
	their test results during the past 12	1,762,815
	months	
	Service Delivery Point (Facility)	
	Inpatient: 10-14, Female, Negative	686
	Service Delivery Point (Facility)	
	Inpatient: 10-14, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility)	
	Inpatient: 10-14, Male, Negative	640
	Service Delivery Point (Facility)	
	Inpatient: 10-14, Male, Positive	9
	Service Delivery Point (Facility)	
	Inpatient: 15-19, Female, Negative	480
	Service Delivery Point (Facility)	39
	Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility)	317



Inpatient: 15-19, Male, Negative	
Service Delivery Point (Facility)	26
Inpatient: 15-19, Male, Positive	20
Service Delivery Point (Facility)	1,329
Inpatient: 20-24, Female, Negative	1,020
Service Delivery Point (Facility)	129
Inpatient: 20-24, Female, Positive	120
Service Delivery Point (Facility)	736
Inpatient: 20-24, Male, Negative	700
Service Delivery Point (Facility)	74
Inpatient: 20-24, Male, Positive	7-7
Service Delivery Point (Facility)	767
Inpatient: 50+, Female, Negative	101
Service Delivery Point (Facility)	76
Inpatient: 50+, Female, Positive	70
Service Delivery Point (Facility)	657
Inpatient: 50+, Male, Negative	037
Service Delivery Point (Facility)	68
Inpatient: 50+, Male, Positive	
Service Delivery Point (Facility)	651
Inpatient: <1, Negative	
Service Delivery Point (Facility)	9
Inpatient: <1, Positive	
Service Delivery Point (Facility)	5,815
Inpatient: 1-9, Negative	3,010
Service Delivery Point (Facility)	107
Inpatient: 1-9, Positive	107
Service Delivery Point (Facility)	2,696
Pediatric : <5 Negative	2,090
Service Delivery Point (Facility)	156
Pediatric : <5 Positive	130
Service Delivery Point (Facility) TB:	266
15-19, Female, Negative	200
Service Delivery Point (Facility) TB:	11



	15-19, Female, Positive
267	Service Delivery Point (Facility) TB: 15-19, Male, Negative
6	Service Delivery Point (Facility) TB: 15-19, Male, Positive
1,324	Service Delivery Point (Facility) TB: 20-24, Female, Negative
54	Service Delivery Point (Facility) TB: 20-24, Female, Positive
644	Service Delivery Point (Facility) TB: 20-24, Male, Negative
: 29	Service Delivery Point (Facility) TB: 20-24, Male, Positive
1,234	Service Delivery Point (Facility) TB: 50+, Female, Negative
50	Service Delivery Point (Facility) TB: 50+, Female, Positive
1,428	Service Delivery Point (Facility) TB: 50+, Male, Negative
61	Service Delivery Point (Facility) TB: 50+, Male, Positive
2,965	Service Delivery Point (Facility) Index: 10-14, Female, Negative
57	Service Delivery Point (Facility) Index: 10-14, Female, Positive
2,620	Service Delivery Point (Facility) Index: 10-14, Male, Negative
45	Service Delivery Point (Facility) Index: 10-14, Male, Positive
10,316	Service Delivery Point (Facility) Index: 15-19, Female, Negative
407	Service Delivery Point (Facility) Index: 15-19, Female, Positive
5,192	Service Delivery Point (Facility)



Index: 15-19, Male, Negative	
Service Delivery Point (Facility)	004
Index: 15-19, Male, Positive	201
Service Delivery Point (Facility)	20 544
Index: 20-24, Female, Negative	30,541
Service Delivery Point (Facility)	1,230
Index: 20-24, Female, Positive	1,230
Service Delivery Point (Facility)	12 710
Index: 20-24, Male, Negative	12,710
Service Delivery Point (Facility)	543
Index: 20-24, Male, Positive	
Service Delivery Point (Facility)	0.000
Index: 50+, Female, Negative	9,808
Service Delivery Point (Facility)	770
Index: 50+, Female, Positive	170
Service Delivery Point (Facility)	7,262
Index: 50+, Male, Negative	7,202
Service Delivery Point (Facility)	597
Index: 50+, Male, Positive	391
Service Delivery Point (Facility)	2,369
Index: <1, Negative	2,309
Service Delivery Point (Facility)	40
Index: <1, Positive	40
Service Delivery Point (Facility)	15,002
Index: 1-9, Negative	10,002
Service Delivery Point (Facility)	220
Index: 1-9, Positive	220
Service Delivery Point (Community)	
Index Mod: 10-14, Female,	174
Negative	
Service Delivery Point (Community)	3
Index Mod: 10-14, Female, Positive	
Service Delivery Point (Community)	136
Index Mod: 10-14, Male, Negative	



Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	88
Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	34
Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	22
Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	9
Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	494
Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	192
Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	176
Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	68
Service Delivery Point (Community) Index Mod: 50+, Female, Negative	121
Service Delivery Point (Community) Index Mod: 50+, Female, Positive	47
Service Delivery Point (Community) Index Mod: 50+, Male, Negative	121
Service Delivery Point (Community) Index Mod: 50+, Male, Positive	47
Service Delivery Point (Community) Index Mod: <1, Negative	21
Service Delivery Point (Community) Index Mod: 1-9, Negative	489
Service Delivery Point (Community) Index Mod: 1-9, Positive	9



Service Delivery Point (Facility) ANC: 15-19, Negative	61,723
Service Delivery Point (Facility) ANC: 15-19, Positive	1,096
Service Delivery Point (Facility) ANC: 20-24, Negative	127,152
Service Delivery Point (Facility) ANC: 20-24, Positive	2,258
Service Delivery Point (Facility) ANC: 50+, Negative	22
Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,150
Service Delivery Point (Facility) VCT: 10-14, Female, Positive	51
Service Delivery Point (Facility) VCT: 10-14, Male, Negative	862
Service Delivery Point (Facility) VCT: 10-14, Male, Positive	46
Service Delivery Point (Facility) VCT: 15-19, Female, Negative	7,368
Service Delivery Point (Facility) VCT: 15-19, Female, Positive	663
Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,887
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	218
Service Delivery Point (Facility) VCT: 20-24, Female, Negative	18,330
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,427
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,308
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	787



Service Delivery Point (Facility)	
7.952	
VCT: 50+, Female, Negative	
Service Delivery Point (Facility) VCT: 50+, Female, Positive 627	
Service Delivery Point (Facility) 6,638	
VCT: 50+, Male, Negative	
Service Delivery Point (Facility) VCT: 50+, Male, Positive	
Service Delivery Point (Facility) 460	
VCT: <1, Negative	
Service Delivery Point (Facility) VCT: <1, Positive	
Service Delivery Point (Facility) VCT: 1-9, Negative 3,736	
Service Delivery Point (Facility) VCT: 1-9, Positive	
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Female, Negative	
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Female, Positive	
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Male, Negative	
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Male, Positive	
HTS_TST_N_TA_EW_Age_Sex_R sult 15-19, Female, Negative	
HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Female, Positive	
HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Male, Negative	
HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Male, Positive	
HTS_TST_N_TA_EW_Age_Sex_R esult 1-9, Unknown Sex, Negative	



HTS_TST_N_TA_EW_Age_Sex_R esult 1-9, Unknown Sex, Positive	1,773
HTS_TST_N_TA_EW_Age_Sex_R esult <1, Unknown Sex, Negative	22,779
HTS_TST_N_TA_EW_Age_Sex_R esult <1, Unknown Sex, Positive	272
HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Female, Negative	104,919
HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Female, Positive	4,668
HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Male, Negative	44,491
HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Male, Positive	2,003
HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Female, Negative	62,911
HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Female, Positive	2,796
HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Male, Negative	47,481
HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Male, Positive	2,141
HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Female, Negative	62,911
HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Female, Positive	2,796
HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Male, Negative	47,481
HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Male, Positive	2,141
HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Female, Negative	62,911
HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Female, Positive	2,796



HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Male, Negative	47,481
HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Male, Positive	2,141
HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Female, Negative	62,693
HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Female, Positive	2,787
HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Male, Negative	46,974
HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Male, Positive	2,120
HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Female, Negative	30,593
HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Female, Positive	1,377
HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Male, Negative	24,387
HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Male, Positive	1,847
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Negative	18,595
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Positive	746
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Negative	13,448
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Positive	559
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Negative	18,301
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Positive	969
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Negative	13,276



HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Positive	20
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Negative	301
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Positive	32
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Negative	276
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Positive	38
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Negative	219
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Positive	33
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Negative	276
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Positive	17
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Negative	29
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Positive)7
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Negative	56
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Positive	3
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Negative	29
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Positive)7
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Negative	56
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Positive	3



	1
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Negative	1,029
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Positive	107
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Negative	1,056
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Positive	93
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Negative	1,029
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Positive	107
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Negative	1,056
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Positive	93
HTS_TST_N_TA_NdxMod_Age_S ex_Result 25-29, Female, Negative	296
HTS_TST_N_TA_NdxMod_Age_S ex_Result 25-29, Female, Positive	115
HTS_TST_N_TA_NdxMod_Age_S ex_Result 25-29, Male, Negative	234
HTS_TST_N_TA_NdxMod_Age_S ex_Result 25-29, Male, Positive	91
HTS_TST_N_TA_NdxMod_Age_S ex_Result 30-34, Female, Negative	296
HTS_TST_N_TA_NdxMod_Age_S ex_Result 30-34, Female, Positive	115
HTS_TST_N_TA_NdxMod_Age_S ex_Result 30-34, Male, Negative	234
HTS_TST_N_TA_NdxMod_Age_S ex_Result 30-34, Male, Positive	91
HTS_TST_N_TA_NdxMod_Age_S ex_Result 35-39, Female, Negative	296



	,
HTS_TST_N_TA_NdxMod_Age_S ex_Result 35-39, Female, Positive	l 115 l
HTS_TST_N_TA_NdxMod_Age_S ex_Result 35-39, Male, Negative	
HTS_TST_N_TA_NdxMod_Age_S ex_Result 35-39, Male, Positive	91
HTS_TST_N_TA_NdxMod_Age_S ex_Result 40-49, Female, Negative	1 296 1
HTS_TST_N_TA_NdxMod_Age_S ex_Result 40-49, Female, Positive	l 115 l
HTS_TST_N_TA_NdxMod_Age_S ex_Result 40-49, Male, Negative	234
HTS_TST_N_TA_NdxMod_Age_S ex_Result 40-49, Male, Positive	91
HTS_TST_N_TA_PMTCT_Age_Sex	44,955
HTS_TST_N_TA_PMTCT_Age_Sex_ x_Result 25-29, Female, Positive	830
HTS_TST_N_TA_PMTCT_Age_Sex_ x_Result 30-34, Female, Negative	44,955
HTS_TST_N_TA_PMTCT_Age_Sex_ x_Result 30-34, Female, Positive	830
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	44,955
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	830
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	44,955
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	830
HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Female, Negative	1,168
HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Female, Positive	49



HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Male, Negative	1,605
HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Male, Positive	79
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Negative	1,168
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Positive	49
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Negative	1,605
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Positive	79
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Negative	1,168
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Positive	49
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Negative	1,605
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Positive	79
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Female, Negative	1,168
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Female, Positive	49
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Male, Negative	1,605
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Male, Positive	79
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Female, Negative	13,278
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Female, Positive	1,071
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Negative	11,612



	_	
	HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Positive	910
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Negative	13,278
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Positive	1,071
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Negative	11,612
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Positive	910
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Negative	13,278
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Positive	1,071
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Negative	11,612
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Positive	910
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Negative	13,278
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Positive	1,071
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Negative	12,120
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Positive	928
TR STAT DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the	78,693



reporting period.	
Total number of registered new and relapsed TB cases, during the	78,693
reporting period.	70,030
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	4,504
documented HIV status, during the reporting period)	,,,,
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37,025
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,813
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33,310
Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,139
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	39,326
Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB	4,107



	cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Denominator: Total number of	20 120
	registered new and relapsed TB	30,129
	cases, during the reporting period)	
	TB_STAT_TA Percentage of	
	registered new and relapsed TB	
	cases with documented HIV status.	100 %
	Number of registered new and	
	relapsed TB cases with	21,369
	documented HIV status, during the	21,000
	reporting period.	
	Total number of registered new and	
	relapsed TB cases, during the	21,369
	reporting period.	
	Aggregated Age/Sex: Female <15	
	(Denominator: Total number of	1,294
TB_STAT_TA	registered new and relapsed TB	.,
.5_0.,,.	cases, during the reporting period)	
	Aggregated Age/Sex: Male <15	
	(Denominator: Total number of	1,649
	registered new and relapsed TB	,
	cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Denominator: Total number of	8,558
	registered new and relapsed TB	•
	cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+	
	(Denominator: Total number of	9,867
	registered new and relapsed TB	•
	cases, during the reporting period)	
	Aggregated Age/Sex: Male <15	1,471
	(Numerator: Number of registered	



	new and relapsed TB cases with	
	documented HIV status, during the	
	reporting period)	
	Aggregated Age/Sex: Male 15+	
	(Numerator: Number of registered	
	new and relapsed TB cases with	9,369
	documented HIV status, during the	
	reporting period)	
	Aggregated Age/Sex: Female <15	
	(Numerator: Number of registered	
	new and relapsed TB cases with	1,255
	documented HIV status, during the	
	reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Numerator: Number of registered	
	new and relapsed TB cases with	9,229
	documented HIV status, during the	·
	reporting period)	
	HTS_SELF_N_DSD	14,825
	HTS_SELF_N_DSD_Age_Sex_HI	
	VSelfTest 15-19, Female,	554
	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI	
	VSelfTest 15-19, Male,	371
	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI	
HTS_SELF_DSD	VSelfTest 20-24, Female,	1,388
9_3_5.	Directly-Assisted	,
	HTS_SELF_N_DSD_Age_Sex_HI	
	VSelfTest 20-24, Male,	923
	Directly-Assisted	-
	HTS_SELF_N_DSD_Age_Sex_HI	
	VSelfTest 25-29, Female,	1,388
	Directly-Assisted	.,550
	HTS_SELF_N_DSD_Age_Sex_HI	923
	ITTO_OLLI _N_DOD_Age_OeX_III	323



	VSelfTest 25-29, Male,	
	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	1,388
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	923
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	1,388
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	923
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	2,780
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	1,853
HTC_TST_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	14,825
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Directly-Assisted	14,827
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,595,622
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	4,978
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	100
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4,674
	Service Delivery Point (Facility)	98



Inpatient: 10-14, Male, Positive	
Service Delivery Point (Facility)	4.440
Inpatient: 15-19, Female, Negative	1,118
Service Delivery Point (Facility)	100
Inpatient: 15-19, Female, Positive	168
Service Delivery Point (Facility)	440
Inpatient: 15-19, Male, Negative	419
Service Delivery Point (Facility)	00
Inpatient: 15-19, Male, Positive	68
Service Delivery Point (Facility)	2.000
Inpatient: 20-24, Female, Negative	3,986
Service Delivery Point (Facility)	000
Inpatient: 20-24, Female, Positive	600
Service Delivery Point (Facility)	4.000
Inpatient: 20-24, Male, Negative	1,260
Service Delivery Point (Facility)	040
Inpatient: 20-24, Male, Positive	213
Service Delivery Point (Facility)	2 600
Inpatient: 50+, Female, Negative	2,690
Service Delivery Point (Facility)	449
Inpatient: 50+, Female, Positive	449
Service Delivery Point (Facility)	2.053
Inpatient: 50+, Male, Negative	2,053
Service Delivery Point (Facility)	382
Inpatient: 50+, Male, Positive	302
Service Delivery Point (Facility)	4,736
Inpatient: <1, Negative	4,730
Service Delivery Point (Facility)	97
Inpatient: <1, Positive	97
Service Delivery Point (Facility)	42,248
Inpatient: 1-9, Negative	42,240
Service Delivery Point (Facility)	863
Inpatient: 1-9, Positive	003
Service Delivery Point (Community)	5,106



Mobile Testing: 15-19, Female, Negative	
Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	574
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	23,124
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	2,364
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	5,086
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	575
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	23,124
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	2,364
Service Delivery Point (Facility) Pediatric : <5 Negative	24,795
Service Delivery Point (Facility) Pediatric : <5 Positive	1,504
Service Delivery Point (Facility) TB: 15-19, Female, Negative	1,150
Service Delivery Point (Facility) TB: 15-19, Female, Positive	76
Service Delivery Point (Facility) TB: 15-19, Male, Negative	452
Service Delivery Point (Facility) TB: 15-19, Male, Positive	41



Service Delivery Point (Facility) TB: 20-24, Female, Negative	3,236
Service Delivery Point (Facility) TB: 20-24, Female, Positive	240
Service Delivery Point (Facility) TB: 20-24, Male, Negative	2,255
Service Delivery Point (Facility) TB: 20-24, Male, Positive	177
Service Delivery Point (Facility) TB: 50+, Female, Negative	3,423
Service Delivery Point (Facility) TB: 50+, Female, Positive	265
Service Delivery Point (Facility) TB: 50+, Male, Negative	3,931
Service Delivery Point (Facility) TB: 50+, Male, Positive	317
Service Delivery Point (Facility) VMMC: 15-19, Negative	50,211
Service Delivery Point (Facility) VMMC: 15-19, Positive	737
Service Delivery Point (Facility) VMMC: 20-24, Negative	63,634
Service Delivery Point (Facility) VMMC: 20-24, Positive	1,115
Service Delivery Point (Facility) VMMC: 50+, Negative	17,965
Service Delivery Point (Facility) VMMC: 50+, Positive	372
Service Delivery Point (Facility) Index: 10-14, Female, Negative	18,243
Service Delivery Point (Facility) Index: 10-14, Female, Positive	329
Service Delivery Point (Facility) Index: 10-14, Male, Negative	16,056



Service Delivery Point (Facility) Index: 10-14, Male, Positive	288
Service Delivery Point (Facility) Index: 15-19, Female, Negative	20,473
Service Delivery Point (Facility) Index: 15-19, Female, Positive	1,575
Service Delivery Point (Facility) Index: 15-19, Male, Negative	5,708
Service Delivery Point (Facility) Index: 15-19, Male, Positive	409
Service Delivery Point (Facility) Index: 20-24, Female, Negative	56,566
Service Delivery Point (Facility) Index: 20-24, Female, Positive	4,160
Service Delivery Point (Facility) Index: 20-24, Male, Negative	21,790
Service Delivery Point (Facility) Index: 20-24, Male, Positive	1,675
Service Delivery Point (Facility) Index: 50+, Female, Negative	24,434
Service Delivery Point (Facility) Index: 50+, Female, Positive	1,798
Service Delivery Point (Facility) Index: 50+, Male, Negative	18,467
Service Delivery Point (Facility) Index: 50+, Male, Positive	1,371
Service Delivery Point (Facility) Index: <1, Negative	14,590
Service Delivery Point (Facility) Index: <1, Positive	249
Service Delivery Point (Facility) Index: 1-9, Negative	92,283
Service Delivery Point (Facility) Index: 1-9, Positive	1,729





Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	6,593
Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	13,273
Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	4,099
Service Delivery Point (Community) Index Mod: 50+, Female, Negative	8,437
Service Delivery Point (Community) Index Mod: 50+, Female, Positive	3,195
Service Delivery Point (Community) Index Mod: 50+, Male, Negative	11,666
Service Delivery Point (Community) Index Mod: 50+, Male, Positive	4,114
Service Delivery Point (Community) Index Mod: <1, Negative	1,273
Service Delivery Point (Community) Index Mod: <1, Positive	39
Service Delivery Point (Community) Index Mod: 1-9, Negative	29,705
Service Delivery Point (Community) Index Mod: 1-9, Positive	1,035
Service Delivery Point (Facility) ANC: 15-19, Negative	137,506
Service Delivery Point (Facility) ANC: 15-19, Positive	7,185
Service Delivery Point (Facility) ANC: 20-24, Negative	315,914
Service Delivery Point (Facility) ANC: 20-24, Positive	16,268
Service Delivery Point (Facility) ANC: 50+, Negative	360
Service Delivery Point (Facility) ANC: 50+, Positive	22



	very Point (Facility) Female, Negative	11,334
Service Deliv	very Point (Facility) Female, Positive	417
	very Point (Facility) Male, Negative	8,440
	very Point (Facility) Male, Positive	316
	very Point (Facility) Female, Negative	25,082
	very Point (Facility) Female, Positive	3,305
	very Point (Facility) Male, Negative	6,656
	very Point (Facility) Male, Positive	927
	very Point (Facility) Female, Negative	62,746
	very Point (Facility) Female, Positive	8,690
	very Point (Facility) Male, Negative	25,767
	very Point (Facility) Male, Positive	3,689
	very Point (Facility) emale, Negative	30,506
	very Point (Facility) emale, Positive	3,964
	very Point (Facility) ale, Negative	24,709
	very Point (Facility) ale, Positive	3,294
Service Deliv VCT: <1, Ne	very Point (Facility) gative	3,856



Service Delivery Point (Facility) VCT: <1, Positive	140
Service Delivery Point (Facility) VCT: 1-9, Negative	36,924
Service Delivery Point (Facility) VCT: 1-9, Positive	1,388
HTS_TST_N_DSD_EW_Age_Sex Result <1, Unknown Sex, Negative	64.050
HTS_TST_N_DSD_EW_Age_Sex Result <1, Unknown Sex, Positive	1.083
HTS_TST_N_DSD_EW_Age_Sex Result 10-14, Female, Negative	80,653
HTS_TST_N_DSD_EW_Age_Sex Result 10-14, Female, Positive	1,374
HTS_TST_N_DSD_EW_Age_Sex Result 10-14, Male, Negative	71,043
HTS_TST_N_DSD_EW_Age_Sex Result 10-14, Male, Positive	1,186
HTS_TST_N_DSD_EW_Age_Sex Result 15-19, Female, Negative	77,608
HTS_TST_N_DSD_EW_Age_Sex Result 15-19, Female, Positive	5,426
HTS_TST_N_DSD_EW_Age_Sex Result 15-19, Male, Negative	24,738
HTS_TST_N_DSD_EW_Age_Sex Result 15-19, Male, Positive	1,684
HTS_TST_N_DSD_EW_Age_Sex Result 1-9, Unknown Sex, Negativ	409.033
HTS_TST_N_DSD_EW_Age_Sex Result 1-9, Unknown Sex, Positive	6.926
HTS_TST_N_DSD_EW_Age_Sex Result 20-24, Female, Negative	207,266
HTS_TST_N_DSD_EW_Age_Sex Result 20-24, Female, Positive	14,525



HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	78,289
HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Positive	5,661
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Negative	143,558
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Positive	9,938
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Negative	103,271
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Positive	7,288
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Negative	143,442
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Positive	9,958
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Negative	103,271
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Positive	7,276
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Negative	143,465
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Positive	9,944
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Negative	103,178
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Positive	7,274
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Negative	143,207
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Positive	9,942
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Male, Negative	102,807



HTS_TST_N_DSD_EW_Age_Sex Result 40-49, Male, Positive	7,270
HTS_TST_N_DSD_EW_Age_Sex Result 50+, Female, Negative	99,350
HTS_TST_N_DSD_EW_Age_Sex Result 50+, Female, Positive	7,037
HTS_TST_N_DSD_EW_Age_Sex Result 50+, Male, Negative	59,040
HTS_TST_N_DSD_EW_Age_Sex Result 50+, Male, Positive	4,013
HTS_TST_N_DSD_Index_Age_S x_Result 25-29, Female, Negative	40.038
HTS_TST_N_DSD_Index_Age_S x_Result 25-29, Female, Positive	e 2,953
HTS_TST_N_DSD_Index_Age_S x_Result 25-29, Male, Negative	e 28,329
HTS_TST_N_DSD_Index_Age_S x_Result 25-29, Male, Positive	e 2,257
HTS_TST_N_DSD_Index_Age_S x_Result 30-34, Female, Negative	40.030
HTS_TST_N_DSD_Index_Age_S x_Result 30-34, Female, Positive	e 2,969
HTS_TST_N_DSD_Index_Age_S x_Result 30-34, Male, Negative	e 28,317
HTS_TST_N_DSD_Index_Age_S x_Result 30-34, Male, Positive	e 2,260
HTS_TST_N_DSD_Index_Age_S x_Result 35-39, Female, Negative	40.030
HTS_TST_N_DSD_Index_Age_S x_Result 35-39, Female, Positive	e 2,989
HTS_TST_N_DSD_Index_Age_S x_Result 35-39, Male, Negative	e 28,317
HTS_TST_N_DSD_Index_Age_S x_Result 35-39, Male, Positive	e 2,260



HTS_TST_N_DSD_Index_Age_9 x_Result 40-49, Female, Negativ	39.775
HTS_TST_N_DSD_Index_Age_S x_Result 40-49, Female, Positive	2.952
HTS_TST_N_DSD_Index_Age_S x_Result 40-49, Male, Negative	
HTS_TST_N_DSD_Index_Age_S x_Result 40-49, Male, Positive	Se 2,268
HTS_TST_N_DSD_Inpat_Age_S _Result 25-29, Female, Negative	1 2.941
HTS_TST_N_DSD_Inpat_Age_S _Result 25-29, Female, Positive	Sex 499
HTS_TST_N_DSD_Inpat_Age_S _Result 25-29, Male, Negative	2,422
HTS_TST_N_DSD_Inpat_Age_S _Result 25-29, Male, Positive	6ex 433
HTS_TST_N_DSD_Inpat_Age_S _Result 30-34, Female, Negative	1 2.941
HTS_TST_N_DSD_Inpat_Age_S _Result 30-34, Female, Positive	Sex 499
HTS_TST_N_DSD_Inpat_Age_S _Result 30-34, Male, Negative	2,422
HTS_TST_N_DSD_Inpat_Age_S _Result 30-34, Male, Positive	6ex 433
HTS_TST_N_DSD_Inpat_Age_S _Result 35-39, Female, Negative	l 2.941 l
HTS_TST_N_DSD_Inpat_Age_S _Result 35-39, Female, Positive	Sex 499
HTS_TST_N_DSD_Inpat_Age_S _Result 35-39, Male, Negative	Sex 2,422
HTS_TST_N_DSD_Inpat_Age_S _Result 35-39, Male, Positive	Sex 433
HTS_TST_N_DSD_Inpat_Age_S _Result 40-49, Female, Negative	1 2.941 1



HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	499
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	2,422
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	433
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	5,082
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	576
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	23,124
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	2,365
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	5,082
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	572
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	23,125
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	2,363
HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Negative	18,967
HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Positive	6,981
HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Male, Negative	19,034



HTS_TST_N_DSD_NdxM Sex_Result 25-29, Male,	6.953
HTS_TST_N_DSD_NdxM Sex_Result 30-34, Femal Negative	=
HTS_TST_N_DSD_NdxN Sex_Result 30-34, Femal Positive	
HTS_TST_N_DSD_NdxM Sex_Result 30-34, Male,	19,034
HTS_TST_N_DSD_NdxM Sex_Result 30-34, Male,	6.953
HTS_TST_N_DSD_NdxN Sex_Result 35-39, Femal Negative	-
HTS_TST_N_DSD_NdxM Sex_Result 35-39, Femal Positive	_
HTS_TST_N_DSD_NdxM Sex_Result 35-39, Male,	19.034
HTS_TST_N_DSD_NdxN Sex_Result 35-39, Male,	- 6 953
HTS_TST_N_DSD_NdxN Sex_Result 40-49, Femal Negative	•
HTS_TST_N_DSD_NdxN Sex_Result 40-49, Femal Positive	_ • -
HTS_TST_N_DSD_NdxM Sex_Result 40-49, Male,	19.034
HTS_TST_N_DSD_NdxM Sex_Result 40-49, Male,	6.953
HTS_TST_N_DSD_PMT0 Sex_Result 25-29, Femal Negative	_ ~ _



HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 25-29, Female,	6,142
Positive	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 30-34, Female,	114,870
Negative	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 30-34, Female,	6,112
Positive	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 35-39, Female,	114,870
Negative	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 35-39, Female,	6,107
Positive	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 40-49, Female,	114,868
Negative	
HTS_TST_N_DSD_PMTCT_Age_	
Sex_Result 40-49, Female,	6,098
Positive	
HTS_TST_N_DSD_TBC_Age_Sex	0.050
_Result 25-29, Female, Negative	3,658
HTS_TST_N_DSD_TBC_Age_Sex	
_Result 25-29, Female, Positive	283
HTS_TST_N_DSD_TBC_Age_Sex	
_Result 25-29, Male, Negative	5,238
HTS_TST_N_DSD_TBC_Age_Sex	
_ Result 25-29, Male, Positive	417
HTS_TST_N_DSD_TBC_Age_Sex	
_Result 30-34, Female, Negative	3,658
HTS_TST_N_DSD_TBC_Age_Sex	
_Result 30-34, Female, Positive	283
HTS_TST_N_DSD_TBC_Age_Sex	
_Result 30-34, Male, Negative	5,238



HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	417
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	3,658
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	283
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	5,238
HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	417
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	3,658
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	283
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	5,238
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	417
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	49,359
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	6,533
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	38,749
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	5,340
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	49,358
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	6,533
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	38,748
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	5,340



	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	49,358
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	6,533
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	38,748
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	5,340
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	49,358
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	6,533
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	38,748
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	5,340
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Negative	72,453
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 25-29, Male, Positive	1,407
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 30-34, Male, Negative	72,453
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 30-34, Male, Positive	1,407
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Negative	72,453
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 35-39, Male, Positive	1,407
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 40-49, Male, Negative	72,453
	HTS_TST_N_DSD_VMMC_Age_S ex_Result 40-49, Male, Positive	1,407
GEND_GBV_DSD	Number of people receiving post-GBV care	41,172



By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	16,542
By type of service: Sexual Violence (Post-Rape Care)	23,688
By PEP service provision (related to sexual violence services provided)	19,019
<10, Female, Physical and/or Emotional Violence	784
<10, Female, Sexual Violence (Post-Rape Care)	1,594
<10, Male, Physical and/or Emotional Violence	775
<10, Male, Sexual Violence (Post-Rape Care)	760
10-14, Female, Physical and/or Emotional Violence	1,631
10-14, Female, Sexual Violence (Post-Rape Care)	3,890
10-14, Male, Physical and/or Emotional Violence	400
10-14, Male, Sexual Violence (Post-Rape Care)	394
15-19, Female, Physical and/or Emotional Violence	3,173
15-19, Female, Sexual Violence (Post-Rape Care)	3,948
20-24, Female, Physical and/or Emotional Violence	4,709
20-24, Female, Sexual Violence (Post-Rape Care)	5,474
GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Female,	1,596



	Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_Vi	
	olenceType_v3 25-29, Female,	2,340
	Sexual Violence (Post-Rape Care)	2,010
	GEND_GBV_N_DSD_Age_Sex_Vi	
	olenceType_v3 30-34, Female,	1,579
	Physical and/or Emotional Violence	,
	GEND_GBV_N_DSD_Age_Sex_Vi	
	olenceType_v3 30-34, Female,	2,323
	Sexual Violence (Post-Rape Care)	
	GEND_GBV_N_DSD_Age_Sex_Vi	
	olenceType_v3 35-39, Female,	1,580
	Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_Vi	
	olenceType_v3 35-39, Female,	2,319
	Sexual Violence (Post-Rape Care)	
	Number of people receiving	7,045
	post-GBV care	7,045
	By type of service: Physical and/or	
	Emotional Violence (Other	2,632
	Post-GBV Care)	
	By type of service: Sexual Violence	3,840
	(Post-Rape Care)	5,5 10
	By PEP service provision (related	
GEND_GBV_TA	to sexual violence services	3,105
	provided)	
	<10, Female, Physical and/or	135
	Emotional Violence	· -
	<10, Female, Sexual Violence	276
	(Post-Rape Care)	
	<10, Male, Physical and/or	149
	Emotional Violence	
	<10, Male, Sexual Violence	153
	(Post-Rape Care)	



10-14, Female, Physical and/or Emotional Violence	282
10-14, Female, Sexual Violence (Post-Rape Care)	686
10-14, Male, Physical and/or Emotional Violence	70
10-14, Male, Sexual Violence (Post-Rape Care)	75
15-19, Female, Physical and/or Emotional Violence	557
15-19, Female, Sexual Violence (Post-Rape Care)	674
20-24, Female, Physical and/or Emotional Violence	803
20-24, Female, Sexual Violence (Post-Rape Care)	942
GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 25-29, Female, Physical and/or Emotional Violence	271
GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	405
GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 30-34, Female, Physical and/or Emotional Violence	269
GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	404
GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Female, Physical and/or Emotional Violence	268
GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Female,	409
	Emotional Violence 10-14, Female, Sexual Violence (Post-Rape Care) 10-14, Male, Physical and/or Emotional Violence 10-14, Male, Sexual Violence (Post-Rape Care) 15-19, Female, Physical and/or Emotional Violence 15-19, Female, Sexual Violence (Post-Rape Care) 20-24, Female, Physical and/or Emotional Violence 20-24, Female, Sexual Violence (Post-Rape Care) GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 25-29, Female, Physical and/or Emotional Violence GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 25-29, Female, Sexual Violence (Post-Rape Care) GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 30-34, Female, Physical and/or Emotional Violence GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 30-34, Female, Physical and/or Emotional Violence GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 30-34, Female, Sexual Violence (Post-Rape Care) GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Female, Physical and/or Emotional Violence GEND_GBV_N_TA_Age_Sex_Viol enceType_v3 35-39, Female, Physical and/or Emotional Violence GEND_GBV_N_TA_Age_Sex_Viol



	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	485,736
	Age/Sex: 10-14 Male	58,378
	Age/Sex: 15-17 Male	35,066
	By: Age/sex: Male 18-24	16,259
	By: Age/sex: Male 25+	24,770
	Age/Sex: 10-14 Female	64,594
	Age/Sex: 15-17 Female	38,338
	By: Age/sex: 18-24 Female	19,063
	By: Age/sex: 25+ Female	54,315
	Sum of Age/Sex disaggregates	196,376
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	18,062
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	14,811
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	3,527
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	18
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	4,575
	Required only for DREAMS countries - By service, age and	3,111



		1
	sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	29,412
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	7,594
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	5,440
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	18,098
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	14,170
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	10,908
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,160
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,010
	Required only for DREAMS countries - By service, age and	2,260



	sex: Economic Strengthening Male	
	18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	1,931
	Age/Sex: <1	12,936
	Age/Sex: 1-9	161,899
	Program Completion: Active	349,326
	Program Completion: Graduation	136,410
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	31
	Age/Sex: 10-14 Male	6
	Age/Sex: 15-17 Male	3
	By age/sex: 18-24 Male	1
	By age/sex: 25+ Male	2
OVC_SERV_TA	Age/Sex: 10-14 Female	6
	Age/Sex: 15-17 Female	3
	By age/sex: 18-24 Female	1
	By age/sex: 25+ Female	4
	Sum of Age/Sex disaggregates	18
	Age/Sex: <1	1
	Age/Sex: 1-9	17
	Program Completion: Active	31
	Program Completion: Graduated	0
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	76 %
	Number of orphans and vulnerable	367,038



	1	
	children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	485,736
OVC_HIVSTAT_TA	OVC_HIVSTAT_TA Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	0 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	0
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	31
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	25,631
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	820



	Aggregated Age/Sex: Male 15+	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	11,994
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Female <15	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	660
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	11,155
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	
	registered TB cases on ART during	n/a
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	3,432
TB_ART_TA	ART during TB treatment during	
	the reporting period	
	Aggregated Age/Sex: Male <15	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	93
	HIV-positive status who are on	



	the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,537
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	73
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,609
	TB_PREV_DSD TB_PREV_DSD	73 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	227,535
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had	310,802



		1
	not been reported as they did not	
	fulfill the minimum requirements for	
	the previous reporting period).	
	By Age/Sex (Denominator): <15,	8,022
	Female	·
	By Age/Sex (Denominator): <15, Male	7,282
	By Age/Sex (Denominator): 15+, Female	187,326
	By Age/Sex (Denominator): 15+, Male	108,148
	By Age/Sex (Numerator): <15, Female	5,820
	By Age/Sex (Numerator): <15, Male	5,026
	By Age/Sex (Numerator): 15+, Female	139,660
	By Age/Sex (Numerator): 15+, Male	77,061
	TB_PREV_D_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, Already, Positive	62,147
	TB_PREV_D_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, New, Positive	248,627
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, Already, Positive	45,505
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, New, Positive	182,030
	TB_PREV_TA TB_PREV_TA	75 %
TB_PREV_TA	The number of ART patients who completed a course of TB	44,146



		1
l'	ventive therapy or at least 6	
	nths of Isoniazid Preventive	
	erapy (IPT) during the reporting	
peri	iod	
The	number of ART patients who	
were	e newly started on TB	
prev	ventive therapy (including those	
who	newly started on TB	
prev	ventive therapy in this reporting	58,818
peri	iod and those who started in the	00,010
prev	vious reporting period but had	
not	been reported as they did not	
fulfil	Il the minimum requirements for	
the	previous reporting period).	
By A	Age/Sex (Denominator): <15,	4.540
Fem	nale	1,516
By A	Age/Sex (Denominator): <15,	4.00=
Male	e	1,367
By A	Age/Sex (Denominator): 15+,	
Fem		35,451
By A	Age/Sex (Denominator): 15+,	
Male	- '	20,467
By A	Age/Sex (Numerator): <15,	
	nale	1,158
	Age/Sex (Numerator): <15,	
Male		948
	Age/Sex (Numerator): 15+,	27,091
Fem		
	Age/Sex (Numerator): 15+,	14,957
Male	е	,,,,,
TB_	_PREV_D_TA_TherapyType_N	
ewE	ExArt_HIV IPT, Life-long ART,	11,759
Alre	eady, Positive	
тв_	_PREV_D_TA_TherapyType_N	47.054
ewE	ExArt_HIV IPT, Life-long ART,	47,054



	New, Positive	
	TB_PREV_N_TA_TherapyType_N ewExArt_HIV IPT, Life-long ART, Already, Positive	8,829
	TB_PREV_N_TA_TherapyType_N ewExArt_HIV IPT, Life-long ART, New, Positive	35,317
	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	1,373,032
	Denominator: By Aggregated Age/Sex: <15, Female	53,271
	Denominator: By Aggregated Age/Sex: <15, Male	48,195
	Denominator: By Aggregated Age/Sex:15+, Female	895,499
TV TB Den	Denominator: By Aggregated Age/Sex:15+, Male	363,053
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	21,024
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	16,043
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,976
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	933,367



	1	1
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	109,551
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, New, TB Screen - Negative, Positive	301,773
	TX_TB_D_DSD_TBScreen_NewEx istingART_HIV Life-long ART, New, TB Screen - Positive, Positive	27,166
	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	209,466
	Denominator: By Aggregated Age/Sex: <15, Female	7,548
	Denominator: By Aggregated Age/Sex: <15, Male	6,829
	Denominator: By Aggregated Age/Sex: 15+, Female	129,262
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	63,825
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,064
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	3,899
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	164
	TX_TB_D_TA_TBScreen_NewExis	142,313



	tingART_HIV Life-long ART,	
	Already, TB Screen - Negative,	
	Positive	
	TX_TB_D_TA_TBScreen_NewExis	
	tingART_HIV Life-long ART,	16 624
	Already, TB Screen - Positive,	16,634
	Positive	
	TX_TB_D_TA_TBScreen_NewExis	
	tingART_HIV Life-long ART, New,	45,960
	TB Screen - Negative, Positive	
	TX_TB_D_TA_TBScreen_NewExis	
	tingART_HIV Life-long ART, New,	4,062
	TB Screen - Positive, Positive	
	PMTCT_EID_DSD Percent of	
	infants born to HIV-positive women	n/-
	that receive a virological HIV test	n/a
	within 12 months of birth (DSD)	
	Number of infants who had a	
	virologic HIV test within 12 months	78,621
PMTCT_EID_DSD	of birth during the reporting period	
	By infants who received a virologic	00.000
	test within 2 months of birth	62,963
	By infants who received their first	
	virologic HIV test between 2 and 12	15,658
	months of age	
	Sum of Infant Age disaggregates	78,621
	PMTCT_EID_TA Percent of infants	
	born to HIV-positive women that	
	receive a virological HIV test within	n/a
	12 months of birth (TA)	
PMTCT_EID_TA	Number of infants who had a	
	virologic HIV test within 12 months	12,356
	of birth during the reporting period	
	1	
	By infants who received a virologic	9,878



	By infants who received their first virologic HIV test between 2 and 12 months of age	2,478
	Sum of Infant Age disaggregates	12,356
	Number of adults and children receiving antiretroviral therapy (ART)	1,377,372
	Age/Sex: 15-19 Male	7,049
	Age/Sex: 15-19 Female	39,453
	Age/Sex: <1	5,596
	Age/Sex: <1-9	67,259
	Age/Sex: 10-14 Male	11,798
	Age/Sex: 10-14 Female	12,842
	Age/Sex: 20-24 Male	19,009
	Age/Sex: 50+ Male	71,296
	Age/Sex: 20-24 Female	128,436
	Age/Sex: 50+ Female	97,492
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	160,952
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	68,158
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	160,914
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	68,162
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	160,949
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	68,144
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	160,936
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	68,118



	Number of adults and children receiving antiretroviral therapy (ART)	209,459
	Age/Sex: 15-19 Male	1,352
	Age/Sex: 15-19 Female	7,860
	Sum of Age/Sex disaggregations	9,212
	Age/Sex: <1	2,570
	Age/Sex: 1-9	13,256
	Age/Sex: 10-14 Male	1,305
	Age/Sex: 10-14 Female	1,512
	Age/Sex: 20-24 Male	4,086
	Age/Sex: 50+ Male	9,023
	Age/Sex: 20-24 Female	24,241
	Age/Sex: 50+ Female	9,417
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	22,299
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive	11,291
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	22,281
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive	11,338
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	22,309
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	11,309
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	22,415
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive	11,248
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	353,603



	By Age/Sex: <1	4,940
	By Age/Sex: 1-9	14,034
	By Age/Sex: 10-14 Male	2,112
	By Age/Sex: 15-19 Male	2,326
	By Age/Sex: 20-24 Male	11,330
	By Age/Sex: 50+ Male	13,235
	By Age/Sex: 10-14 Female	2,162
	By Age/Sex: 15-19 Female	19,040
	By Age/Sex: 20-24 Female	46,889
	By Age/Sex: 50+ Female	15,790
	Pregnancy status	56,048
	Breastfeeding status	5,300
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	33,260
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	22,435
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	33,224
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	22,394
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	33,122
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	22,360
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	32,964
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	22,211
X_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	68,085
IA_NEW_IA	By Age/Sex: <1	814
	By Age/Sex: 1-9	2,810



	By Age/Sex: 10-14 Male	407
	By Age/Sex: 15-19 Male	576
	By Age/Sex: 20-24 Male	3,228
	By Age/Sex: 50+ Male	1,973
	By Age/Sex: 10-14 Female	429
	By Age/Sex: 15-19 Female	4,908
	By Age/Sex: 20-24 Female	10,196
	By Age/Sex: 50+ Female	2,003
	Sum of Age/Sex disaggregates	23,720
	Pregnancy status	14,399
	Breastfeeding status	910
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Female, Positive	5,863
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Male, Positive	4,418
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Female, Positive	5,864
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Male, Positive	4,412
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Female, Positive	5,827
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Male, Positive	4,385
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Female, Positive	5,689
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Male, Positive	4,264
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral	0 %



	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	892,896
	<15, Undocumented Test Indication, Female	36,739
	<15, Undocumented Test Indication, Male	14,754
	15+, Undocumented Test Indication, Female	599,743
	15+, Undocumented Test Indication, Male	241,661
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	131,747
	<15, Undocumented Test Indication, Female	6,025
	<15, Undocumented Test Indication, Male	2,537
	15+, Undocumented Test Indication, Female	87,663
	15+, Undocumented Test Indication, Male	35,520
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and	90 %



on treatment 12 months after initiation of antiretroviral therapy	
Number of adults and children who are still alive and on treatment at 12 months after initiating ART	300,366
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	333,910
Numerator by Status: Pregnant	53,653
Numerator by Status: Breastfeeding	11,370
Denominator by Status: Pregnant	62,865
Denominator by Status: Breastfeeding	12,170
Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,724
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	83,011
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,494
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and	200,544



	children who are still alive and on	
	treatment at 12 months after	
	initiating ART)	
	Aggregated Age/Sex: <15 Male	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	E 000
	beginning of the reporting period,	5,603
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	00.000
	beginning of the reporting period,	96,228
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	40.407
	beginning of the reporting period,	12,497
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	040
	beginning of the reporting period,	219,039
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and	90 %



	children known to be alive and on	
	treatment 12 months after initiation	
	of antiretroviral therapy	
	Number of adults and children who	
	are still alive and on treatment at	35,307
	12 months after initiating ART	
	Total number of adults and children	
	who initiated ART in the 12 months	
	prior to the beginning of the	
	reporting period, including those	39,429
	who have died, those who have	
	stopped ART, and those lost to	
	follow-up	
	Numerator by Status: Pregnant	7,008
	Numerator by Status:	4.500
	Breastfeeding	1,520
	Denominator by Status: Pregnant	8,583
	Denominator by Status:	4 757
	Breastfeeding	1,757
	Aggregated Age/Sex: <15 Male	
	(Numerator: Number of adults and	
	children who are still alive and on	782
	treatment at 12 months after	
	initiating ART)	
	Aggregated Age/Sex: 15+ Male	
	(Numerator: Number of adults and	
	children who are still alive and on	10,203
	treatment at 12 months after	
j	initiating ART)	
	Aggregated Age/Sex: <15 Female	
	(Numerator: Number of adults and	
	children who are still alive and on	1,788
	treatment at 12 months after	
j	initiating ART)	
Α	ggregated Age/Sex: 15+ Female	22,367
_		·



	1
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	887
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	11,778
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: <15 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	1,965
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	24,639
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
 	·





Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7314	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development		
7315	FHI 360	NGO	U.S. Agency for International Development		
7328	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development		
7387	Arquiplan, Lda	NGO	U.S. Agency for International Development		
7388	Técnicos Construtores (TEC), Lda	Private Contractor	U.S. Agency for International Development		
9564	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	545,632
9568	American Society for Microbiology	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	1,143,268



			for Disease		
			Control and		
			Prevention		
			U.S. Department		
9570	U.S. Department	Other USG	of State/Bureau of		
	of State	Agency	African Affairs		
			U.S. Department		
			of Health and		
	American		Human		
9725	International	NGO	Services/Health		
	Health Alliance		Resources and		
	Twinning Center		Services		
			Administration		
			U.S. Department		
			of Health and		
			Human		
9811	Vanderbilt University	University	Services/Centers	GHP-State	31,899,994
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Association of		Human		
9818	Public Health	NGO	Services/Centers	GHP-State	228,197
	Laboratories		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Ministry of Lincolth	Host Country	Human		
9856	Ministry of Health,	Government	Services/Centers	GHP-State	138,154
	Mozambique	Agency	for Disease		
			Control and		
			Prevention		
40074	U.S. Department	Other USG	U.S. Department		
10971	of Defense	Agency	of Defense		



	(Defense)				
11463	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	260,000
11580	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	27,295,040
12149	World Vision International	FBO	U.S. Agency for International Development	GHP-State	1,760,160
12150	Management Sciences for Health	NGO	U.S. Agency for International Development		
12159	United Nations Development Programme	Multi-lateral Agency	U.S. Agency for International Development		
12165	Health Alliance International	NGO	U.S. Agency for International Development		
12168	Pathfinder International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
12619	American Association of Blood Banks	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	262,482



			Prevention		
12648	United States Pharmacopeia	Private Contractor	U.S. Agency for International Development		
12665	Provincial Directorate of Health, Cabo Delgado	Government	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	274,675
12681	JEMBI	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,037,531
12702	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	667,958
12998	Provincial Directorate of Health, Maputo	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	179,934
13022	FHI 360	NGO	U.S. Agency for International Development	GHP-State	21,359,253
13160	Provincial	Host Country	U.S. Department	GHP-State	551,437



	Directorate of	Government	of Health and		
	Health, Zambezia	Agency	Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
13313	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs		
			U.S. Department		
	Columbia		of Health and		
	University		Human		
13583	Mailman School	University	Services/Centers	GHP-State	24,588,688
	of Public Health		for Disease		
	or rablic riealth		Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Catholic		Human		
13654	University of	University	Services/Centers		
	Mozambique		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Barcelona Centre		Human		
13661	for International	NGO	Services/Centers	GHP-State	300,000
	Health		for Disease		
			Control and		
			Prevention		
			U.S. Department		
	Fundacao ARIEL		of Health and		
13668	Contra a SIDA	NGO	Human	GHP-State	24,300,001
	Pediatrica		Services/Centers		
			for Disease		



	1	1		
		Control and		
		Prevention		
		U.S. Department of Health and		
Center for		Human		
Collaboration in	NGO	Services/Centers	GHP-State	8,250,004
Health		for Disease		
		Control and		
		Prevention		
		U.S. Department		
		of Health and		
Institute Nacional	Host Country	Human		
	Government	Services/Centers	GHP-State	639,000
de Saude	Agency	for Disease		
		Control and		
		Prevention		
		U.S. Agency for		
DevResults	Private Contractor	International		
		Development		
		U.S. Agency for		
Futures Group	Private Contractor	International		
		Development		
EUROSIS -				
Cosultoria e				
Formacao em	Private Contractor			
Gestao, Lda		Development		
Resolve Solution		U.S. Agency for		
Partners (PTY),	Private Contractor			
Ltd		Development		
ASNA		U.S. Agency for		
Construções &	Private Contractor	= -		
Engenharia		Development		
TBD	TBD	Redacted	Redacted	Redacted
Columbia		U.S. Agency for		
University	University	International		
	Collaboration in Health Instituto Nacional de Saúde DevResults Futures Group EUROSIS - Cosultoria e Formacao em Gestao, Lda Resolve Solution Partners (PTY), Ltd ASNA Construções & Engenharia TBD Columbia	Collaboration in Health Instituto Nacional de Saúde DevResults Private Contractor Futures Group Futures Group EUROSIS - Cosultoria e Formacao em Gestao, Lda Resolve Solution Partners (PTY), Ltd ASNA Construções & Private Contractor Engenharia TBD Columbia Host Country Government Agency Private Contractor Private Contractor Private Contractor Private Contractor Private Contractor Private Contractor Private Contractor	Center for Collaboration in Health Instituto Nacional de Saúde DevResults Private Contractor Futures Group EUROSIS - Cosultoria e Formacao em Gestao, Lda Resolve Solution Partners (PTY), Ltd ASNA Construções & Engenharia Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Agency for International Development U.S. Agency for International Development	Prevention U.S. Department of Health and Human Center for Collaboration in Health NGO Services/Centers for Disease Control and Prevention U.S. Department of Health and Human U.S. Department of Health and Prevention U.S. Department of Health and Human Government Services/Centers for Disease Control and Prevention U.S. Agency for Disease Control and Prevention U.S. Agency for International Development Development ASNA Construções & Private Contractor International Development TBD TBD Redacted Redacted U.S. Agency for U.S. Agency for U.S. Agency for International Development Development U.S. Agency for International Development



	Mailman School of Public Health		Development		
14670	Foundation for Community Development, Mozambique	NGO	U.S. Agency for International Development		
14732	FHI 360	NGO	U.S. Agency for International Development		
14739	World Education	NGO	U.S. Agency for International Development	GHP-State	7,619,318
14748	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	500,000
14789	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	20,965,858
14792	ISCISA- Superior Institution of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14806	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	271,519
14822	University of Washington	University	U.S. Department of Health and Human	GHP-State	5,801,877



				1	
			Services/Health		
			Resources and		
			Services		
			Administration		
			U.S. Department		
			of Health and		
	University of		Human		
16052	California at San	University	Services/Centers	GHP-State	1,325,000
	Francisco		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Foundation for		Human		
16671	Innovative New	NGO	Services/Centers		
	Diagnostics		for Disease		
	Diagnostics		Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Provincial	Host Country	Human		
16802	Directorate of	Government	Services/Centers	GHP-State	142,037
10002	Health,	Agency	for Disease	Orn -State	142,037
	Inhambane	Agency	Control and		
			Prevention		
40070	World Food	Multi-lateral	U.S. Agency for	CUD Ctet-	4 044 074
16879	Program	Agency	International	GHP-State	1,044,871
			Development		
			U.S. Agency for		
16900	FHI 360	NGO	International		
			Development		
			U.S. Department		
	Provincial	Host Country	of Health and		
16998	Directorate of	Government	Human	GHP-State	274,676
	Health, Gaza	Agency	Services/Centers		
			for Disease		



		Prevention		
		U.S. Department		
		of Health and		
Provincial	Host Country	Human		
Directorate of	Government	Services/Centers	GHP-State	198,894
Health, Nampula	Agency	for Disease		
		Control and		
		Prevention		
		U.S. Department		
		of Health and		
NAI: intervent I I and I I	Host Country	Human		
-	Government	Services/Centers	GHP-State	3,444,445
Mozambique	Agency	for Disease		
		Control and		
		Prevention		
		U.S. Agency for		
ICF Macro	Private Contractor	International		
		Development		
		U.S. Agency for		
	-	International		
(JSI)	Agency	Development		
N'WETI -		U.S. Agency for		
Comunicação	NGO	International		
para Saúde		Development		
		U.S. Agency for		
JEMBI	NGO	International		
		Development		
REENCONTRO -		-		
-				
	NGO			
Desenvolvimento		Development		
da Criança Orfã				
Associacao	NGO	U.S. Agency for		
	Directorate of Health, Nampula Ministry of Health, Mozambique ICF Macro John Snow Inc (JSI) N'WETI - Comunicação para Saúde JEMBI REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã	Directorate of Health, Nampula Ministry of Health, Mozambique ICF Macro Private Contractor John Snow Inc (JSI) N'WETI - Comunicação para Saúde JEMBI NGO REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã	Provincial Directorate of Health, Nampula Ministry of Health, Mozambique ICF Macro John Snow Inc (JSI) N'WETI - Comunicação para Saúde NGO JEMBI REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfă Proverment Government Agency Moserment Agency John Snow Inc (JSI) Of Health and Human Services/Centers for Disease Control and Prevention U.S. Department of Health and Human Services/Centers for Disease Control and Prevention U.S. Agency for International Development U.S. Agency for International Development	Prevention U.S. Department of Health and Human Provincial Directorate of Health, Nampula Prevention Ministry of Health, Mozambique Host Country Government Agency Mozambique Mozambique Host Country Government Agency Mozambique Mozambi



	Nacional dos		International		
	Enfermeiros de		Development		
	Mocambique (ANEMO)				
17567	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	369,945
17571	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration		
17652	University of California	University	U.S. Agency for International Development		
17723	JHPIEGO	University	U.S. Department of Defense	GHP-State	3,924,897
18099	FHI 360	NGO	U.S. Agency for International Development		
18100	Ajuda de Desenvolvimento de Povo para Povo	NGO	U.S. Agency for International Development		
18101	JHPIEGO	University	U.S. Agency for International Development		
18102	Johns Hopkins University Center	University	U.S. Agency for International	GHP-State	3,595,949



	6		Developer		
	for		Development		
	Communication				
	Programs				
			U.S. Agency for		
18103	FHI 360	NGO	International	GHP-State	15,636,714
			Development		
	Management		U.S. Agency for		
18104	Systems	Private Contractor	International		
	International		Development		
40400	II IDIFOO	11.2 2	U.S. Department	OUD OUT	0.000.500
18108	JHPIEGO	University	of Defense	GHP-State	3,883,509
			U.S. Department		
	African Health		of Health and		
	Profession		Human		
18110	Regulatory	University	Services/Centers		
	Collaborative for Nurses and Midwives		for Disease		
			Control and		
			Prevention		
	Pathfinder International		U.S. Agency for		
18122		NGO	International		
			Development		
			U.S. Agency for		
18123	Counterpart	NGO	International		
	International		Development		
			U.S. Agency for		
18275	John Snow Inc	Implementing	International	GHP-State	6,755,741
	(JSI)	Agency	Development		,
			U.S. Agency for		
18280	FHI 360	NGO	International	GHP-State	6,005,629
			Development		,,-
	Global Health		U.S. Agency for		
18282	Supply Chain	Private Contractor	1 ,	GHP-State	62,646,584
	Program	a.c contractor	Development		-,0.0,00
	N'WETI -		U.S. Agency for		
18311	Comunicação	NGO	International	GHP-State	1,947,948
	Comunicação		memanonai	<u> </u>	



	para Saúde		Development		
18312	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development		
18319	Associação Para o Desenvolvimento Sócio-Económico	NGO	U.S. Agency for International Development		
18336	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	390,000
18366	Abt Associates	Private Contractor	U.S. Agency for International Development		
18367	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	917,411
18368	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development		
18372	Central de Medicamentos e Artigos Medicos (CMAM)	Implementing Agency	U.S. Agency for International Development		
18373	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	220,000
18429	Provincial Directorate of Health, Zambezia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and		



			Prevention		
18454	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18455	TBD	TBD	Redacted	Redacted	Redacted
18456	FHI 360	NGO	U.S. Agency for International Development		
18466	Population Council	NGO	U.S. Agency for International Development	GHP-State	300,000
18478	Mothers to Mothers (M2M)	Implementing Agency	U.S. Agency for International Development	GHP-State	875,000
18503	TBD	TBD	Redacted	Redacted	Redacted
18521	TBD	TBD	Redacted	Redacted	Redacted
18632	Village Reach	NGO	U.S. Agency for International Development	GHP-State	2,600,000
70194	[Placeholder]	TBD	U.S. Department of Defense		
70195	[Placeholder]	TBD	U.S. Department of Defense		
70196	[Placeholder]	TBD	U.S. Department of Defense		
70197	Joint United Nationa Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	307,008



			Prevention		
70198	TBD	TBD	Redacted	Redacted	Redacted
70199	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	197,560
70200	TBD	TBD	Redacted	Redacted	Redacted
70201	TBD	TBD	Redacted	Redacted	Redacted
70202	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70203	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70204	[Placeholder]	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration		
70205	[Placeholder]	TBD	U.S. Peace Corps		
70206	[Placeholder]	TBD	U.S. Peace Corps		
70207	[Placeholder]	TBD	U.S. Agency for		



	1			1	
			International		
			Development		
70208	[Placeholder]	TBD	U.S. Agency for International Development		
70209	TBD	TBD	Redacted	Redacted	Redacted
70210	Global Health Supply Chain Program	Private Contractor	U.S. Agency for	GHP-State	6,187,446
70211	TBD	TBD	Redacted	Redacted	Redacted
70212	TBD	TBD	Redacted	Redacted	Redacted
70213	TBD	TBD	Redacted	Redacted	Redacted
70214	Columbia University Mailman School of Public Health	University	U.S. Agency for International Development	GHP-State	350,000
70216	TBD	TBD	Redacted	Redacted	Redacted
70217	[Placeholder]	TBD	U.S. Agency for International Development		
70218	[Placeholder]	TBD	U.S. Agency for International Development		
70219	[Placeholder]	TBD	U.S. Agency for International Development		
70220	[Placeholder]	TBD	U.S. Agency for International Development		
70221	[Placeholder]	TBD	U.S. Agency for International Development		
70222	[Placeholder]	TBD	U.S. Agency for International		



			Development		
70223	[Placeholder]	TBD	U.S. Agency for International Development		
70224	[Placeholder]	TBD	U.S. Agency for International Development		
70225	[Placeholder]	TBD	U.S. Agency for International Development		
70226	[Placeholder]	TBD	U.S. Agency for International Development		
70227	[Placeholder]	TBD	U.S. Agency for International Development		
70510	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator		
80017	International Organization for Migration	Multi-lateral Agency	U.S. Department of Health and Human	GHP-State	400,000
80018	TBD	TBD	Redacted	Redacted	Redacted
80019	TBD	TBD	Redacted	Redacted	Redacted
80020	TBD	TBD	Redacted	Redacted	Redacted
80021	TBD	TBD	Redacted	Redacted	Redacted
80022	TBD	TBD	Redacted	Redacted	Redacted
80032	TBD	TBD	Redacted	Redacted	Redacted
80034	United Nations	Multi-lateral	U.S. Department		



Children's Fund	Agency	of Health and	
		Human	
		Services/Centers	
		for Disease	
		Control and	
		Prevention	



Implementing Mechanism(s)

Implementing Mechanism Details

mpionioning moonamen botano			
Mechanism ID: 7314	Mechanism Name: ASSIST (Applying Science to Strengthen and Improve Systems)		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: University Research Corporation, LLC			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 0				
Funding Source	Funding Amount			

Cross-Cutting Budget Attribution(s)

(No data provided.)

Daagot Coao IIII of III ation			
Mechanism ID:	7314		
Mechanism Name:	ASSIST (Applying Science to Strengthen and Improve Systems)		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7315	Mechanism Name: Food and Nutrition Technical Assistance III (FANTA-III)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: FHI 360			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information		
Mechanism ID: 7315		
Mechanism Name:	Food and Nutrition Technical Assistance III (FANTA-III)	
Prime Partner Name:	FHI 360	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing meentanes betane		
Mechanism ID: 7328	Mechanism Name: MEASURE EVALUATION Phase IV	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	MEASURE EVALUATION Phase IV University of North Carolina at Chapel Hill. Carolina Population	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7387	Mechanism Name: Oversight for 16 Type II RHC & 3 Warehouses	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Arquiplan, Lda		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information		
Mechanism ID:	7387	
Mechanism Name:	Oversight for 16 Type II RHC & 3 Warehouses	
Prime Partner Name:	Arquiplan, Lda	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing moonament bottome		
Mechanism ID: 7388	Mechanism Name: Construction of 11 Type II Rural Health Centers	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Técnicos Construtores (TEC), Lda		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	7388	
Mechanism Name:	Construction of 11 Type II Rural	Health Centers
Prime Partner Name:	Técnicos Construtores (TEC), L	da
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9564	Mechanism Name: ASCP	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: American Society of Clinical Pathology		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 545,632	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 545,632		
Funding Source Funding Amount		
GHP-State	545,632	



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information		
Mechanism ID:	9564	
Mechanism Name:	e: ASCP	
Prime Partner Name:	American Society of Clinical Par	thology
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	463,787
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	81,845
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 9568	Mechanism Name: ASM	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: American Society for Microbiology		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,143,268	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,143,268		
Funding Source Funding Amount		
GHP-State	1,143,268	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		pgy
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	674,700
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	468,568
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9570	Mechanism Name: PAS Small Grants
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipe	eline Amount: 0
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID:	9570	
Mechanism Name:	Mechanism Name: PAS Small Grants	
Prime Partner Name:	U.S. Department of State	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9725	Mechanism Name: Twinning - AIHA
--------------------	---------------------------------



Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: American International Health Alliance Twinning Center		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9811	Mechanism Name: Friends in Global Health	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Vanderbilt University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	-	
G2G: No	Managing Agency:	

Total All Funding Sources: 31,899,994	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 31,899,994		
Funding Source Funding Amount		
GHP-State	31,899,994	

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach



	workers
Key Populations: FSW	100,000
Gender: GBV	360,760
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Motor Vehicles: Purchased	100,000
Human Resources for Health	7,850,812
Food and Nutrition: Policy, Tools, and Service	325,380
Delivery	
Adolescent Girls and Young Women (AGYW)	1,594,007
Condom programming	350,000
Renovation	407,833

Budget Code Information

Budget Code Illiorniation		
Mechanism ID:	9811	
Mechanism Name:	Friends in Global Health	
Prime Partner Name:	Vanderbilt University	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	2,657,683
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	2,391,917
Strategic Area	Budget Code	Planned Amount
Care	PDCS	531,536
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	3,189,222
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	2,719,007
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	2,604,157
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	16,477,629
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,328,843

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	15,604
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	217,319
PMTCT_ART_DSD	New on ART	8,521
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7,083
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,864
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	66,183
PMTCT_ART_TA	New on ART	1,058
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	806
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	217,319
PMTCT_STAT_DSD	Number of new ANC and L&D clients	224,517
PMTCT_STAT_DSD	By Age (Denominator): 10-14	1,124
PMTCT_STAT_DSD	By Age (Denominator): <15-19	33,133
PMTCT_STAT_DSD	By Age (Denominator): 20-24	59,219



PMTCT_STAT_DSD	By Age (Denominator): 50+	8
PMTCT_STAT_DSD	By Number of known positives: 10-14	1
PMTCT_STAT_DSD	By Number of known positives: 15-19	418
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,643
PMTCT_STAT_DSD	By Number of known positives: 50+	9
PMTCT_STAT_DSD	By Number of new positives: <10	12
PMTCT_STAT_DSD	By Number of new positives: 15-19	615
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,578
PMTCT_STAT_DSD	By Number of new positives: 50+	67
PMTCT_STAT_DSD	By Number of new negative: <10	339
PMTCT_STAT_DSD	By Number of new negative: 10-14	1,778
PMTCT_STAT_DSD	By Number of new negative: 15-19	44,856
PMTCT_STAT_DSD	By Number of new negative: 20-24	60,762
PMTCT_STAT_DSD	By Number of new negative: 50+	606
PMTCT_STAT_DSD	By Age (Numerator): <10	351
PMTCT_STAT_DSD	By Age (Numerator): 10-14	1,783
PMTCT_STAT_DSD	By Age (Numerator): 15-19	46,188
PMTCT_STAT_DSD	By Age (Numerator): 20-24	64,122
PMTCT_STAT_DSD	By Age (Numerator): 50+	687
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	32,639
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	32,747
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	32,690
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	32,957
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,036
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	90,086
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	2,657
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,049
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	2,324



	30-34, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	414
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	1,035
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,324
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	416
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	1,040
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,839
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	416
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	94,011
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,791
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	3,402
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,912
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	66,183
PMTCT_STAT_TA	Number of new ANC and L&D clients	68,330
PMTCT_STAT_TA	By Age (Denominator): 10-14	238
PMTCT_STAT_TA	By Age (Denominator): 15-19	9,608
PMTCT_STAT_TA	By Age (Denominator): 20-24	18,064
PMTCT_STAT_TA	By Age (Denominator): 50+	11
PMTCT_STAT_TA	By known positives: 10-14	30
PMTCT_STAT_TA	By known positives: 15-19	105
PMTCT_STAT_TA	By known positives: 20-24	502
PMTCT_STAT_TA	By new positives: 15-19	184
PMTCT_STAT_TA	By new positives: 20-24	490
PMTCT_STAT_TA	By new positives: 50+	6



PMTCT_STAT_TA	By new negatives: 10-14	438
PMTCT_STAT_TA	By new negatives: 15-19	13,119
PMTCT_STAT_TA	By new negatives: 20-24	19,142
PMTCT_STAT_TA	By new negatives: 50+	131
PMTCT_STAT_TA	By Age (Numerator): 10-14	468
PMTCT_STAT_TA	By Age (Numerator): : 15-19	13,504
PMTCT_STAT_TA	By Age (Numerator): 20-24	20,177
PMTCT_STAT_TA	By Age (Numerator): 50+	138
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	9,732
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	10,898
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	9,714
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	10,065
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	303
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	29,565
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	853
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	301
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	135
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	297
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	135
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	299
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	135
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	30,786
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	438
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	315



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	314
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,355
PrEP_NEW_DSD	Male 15-19	180
PrEP_NEW_DSD	Male 20-24	180
PrEP_NEW_DSD	Female 15-19	362
PrEP_NEW_DSD	Female 20-24	362
PrEP_NEW_DSD	FSW	1,883
PrEP_NEW_DSD	MSM	471
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	362
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	180
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	362
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	180
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	150
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	37
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	546
PrEP_NEW_TA	Male 15-19	41
PrEP_NEW_TA	Male 20-24	41
PrEP_NEW_TA	Female 15-19	84
PrEP_NEW_TA	Female 20-24	84
PrEP_NEW_TA	FSW	436
PrEP_NEW_TA	MSM	109
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Female	84
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 25-29, Male	41
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Female	84
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 30-34, Male	41
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Female	35
PrEP_NEW_TA	PrEP_NEW_N_TA_Age_Sex_v2 35-39, Male	9
HTC_TST_DSD	Number of individuals who received T&C services for	584,570



	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	842
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	797
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	817
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	133
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	137
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	23



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	805
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	7,175
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	214
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,017
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	279
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	340
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	692
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	342
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	425
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	587
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,399
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male,	1,241



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,185
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	262
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	644
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	5,581
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	658
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,893
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	345
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,031
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	972
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	1,115
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	7,136
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	323
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	24



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	473
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	331
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	29,140
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	1,453
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	66,853
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	3,043
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,990
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,480
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,387
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	758
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,401
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	300
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	9,058
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female,	2,078



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,446
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1,260
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,494
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	633
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,614
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	629
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	672
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	6,474
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	406
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	5,203
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	209
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	6,543
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	272
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	5,766
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	8,664
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	960
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male,	3,223



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	322
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	33,199
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	1,380
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	21,771
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	2,381
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	11,131
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	1,177
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	14,868
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1,474
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	9,871
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	1,001
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	14,868
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	1,474
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	9,871
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	1,001
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	14,868
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39,	1,480



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	9,871
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1,001
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	14,868
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1,480
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	9,871
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	1,001
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	3,895
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	449
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	3,738
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	439
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	3,691
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	390
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	2,294
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	269
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	3,691
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	390
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34,	2,294



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	269
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	3,691
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	390
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	2,294
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	269
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	3,691
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	390
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	2,294
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	269
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	324
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	324
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34,	44



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	324
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	324
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	314
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	314
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	314
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	314
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29,	21,517



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	976
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	21,517
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	976
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	21,517
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	976
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	21,517
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	976
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	539
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	821
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	539
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	821
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	539
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39,	57



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	821
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	539
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	821
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	5,170
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	1,187
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,700
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	1,078
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	5,170
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	1,187
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,700
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	1,078
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	5,170
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1,187
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39,	4,700



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	1,078
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	5,170
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1,187
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	4,700
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	1,078
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	252,298
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	84
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	77
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	207
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	368
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	187
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	17



HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: -1, Negative HTC_TST_TA Service Delivery Point (Facility) Pediatric: -5 Negative HTC_TST_TA Service Delivery Point (Facility) Pediatric: -5 Negative HTC_TST_TA Service Delivery Point (Facility) Pediatric: -5 Negative HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive			
HTC_TST_TA Bervice Delivery Point (Facility) Inpatient: <1, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative 698 HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Negative HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Negative HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Positive 18 HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative Negative Service Delivery Point (Facility) TB: 15-19, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative	HTC_TST_TA		171
HTC_TST_TA Service Delivery Point (Facility) Inpatient: <1, Positive HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive HTC_TST_TA Service Delivery Point (Facility) Pediatric: <5 Negative HTC_TST_TA Service Delivery Point (Facility) Pediatric: <5 Negative 18 HTC_TST_TA Service Delivery Point (Facility) Pediatric: <5 Positive 18 HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative Service Delivery Point (Facility) TB: 15-19, Female, Positive Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50-4, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive	HTC_TST_TA	1	12
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Negative HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive HTC_TST_TA Service Delivery Point (Facility) Pediatric: <5 Negative 311 HTC_TST_TA Service Delivery Point (Facility) Pediatric: <5 Negative 18 HTC_TST_TA Service Delivery Point (Facility) Pediatric: <5 Positive 18 HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive TSERVICE Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive TSERVICE Delivery Point (Facility) TB: 50+, Male, Positive	HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	78
HTC_TST_TA Service Delivery Point (Facility) Inpatient: 1-9, Positive HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Negative 311 HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Negative 18 HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Positive 18 HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive AHTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive	HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Negative HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Positive 18 HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Positive 18 HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50-4, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative	HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	698
HTC_TST_TA Service Delivery Point (Facility) Pediatric : <5 Positive HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative Service Delivery Point (Facility) TB: 15-19, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative Service Delivery Point (Facility) TB: 20-24, Female, Negative Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative Service Delivery Point (Facility) TB: 20-24, Male, Negative Service Delivery Point (Facility) TB: 50-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative Service Delivery Point (Facility) TB: 50+, Female, Positive Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive TS HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative A HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative A HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative A HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative	HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	16
HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Negative Service Delivery Point (Facility) TB: 15-19, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50-4, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive TSERVICE Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive TSERVICE DELIVERY POINT (Facility) TB: 50+, Male, Positive	HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	311
HTC_TST_TA Service Delivery Point (Facility) TB: 15-19, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative Service Delivery Point (Facility) Index: 10-14, Female, Negative	HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	18
HTC_TST_TA Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive TO Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative A Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative A Positive	HTC_TST_TA		54
HTC_TST_TA Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive T HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive Service Delivery Point (Facility) Index: 10-14, Female, Positive	HTC_TST_TA		1
HTC_TST_TA Positive HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive 7 HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive Service Delivery Point (Facility) Index: 10-14, Female, Positive	HTC_TST_TA		269
HTC_TST_TA Negative Service Delivery Point (Facility) TB: 20-24, Male, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Female, Positive Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative TO HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive TO HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative Service Delivery Point (Facility) Index: 10-14, Female, Positive A Positive 4	HTC_TST_TA		10
HTC_TST_TA Positive Service Delivery Point (Facility) TB: 50+, Female, Negative Positive Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative TO Service Delivery Point (Facility) TB: 50+, Male, Positive TO Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive 4	HTC_TST_TA		127
HTC_TST_TA Negative Service Delivery Point (Facility) TB: 50+, Female, Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive 7 HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive A Positive	HTC_TST_TA		5
HTC_TST_TA Positive HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive 7 HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive 4	HTC_TST_TA	, , , , , ,	251
HTC_TST_TA Negative HTC_TST_TA Service Delivery Point (Facility) TB: 50+, Male, Positive 7 Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive 4	HTC_TST_TA	, , , , ,	9
HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Negative HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Female, Positive 4	HTC_TST_TA		173
HTC_TST_TA Negative Negative Service Delivery Point (Facility) Index: 10-14, Female, Positive 4	HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_TA Positive 4	HTC_TST_TA		118
HTC_TST_TA Service Delivery Point (Facility) Index: 10-14, Male, 103	HTC_TST_TA		4
	HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male,	103



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,357
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	64
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	484
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	23
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	4,148
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	193
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,925
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	122
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	423
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	912
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	95
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	597
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	11,867
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	154
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	24,235



HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	376
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	274
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	203
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,195
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	354
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	609
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	74
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	5,475
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	618
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3,421
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	402
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	601
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	79
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,805
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	228



HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	94
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	897
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	41
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	504
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	444
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	4,789
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Positive	252
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Negative	1,682
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Positive	88
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	2,547
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	71
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	398
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Positive	6
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	14,180
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Positive	684
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Negative	6,572



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Positive	331
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	10,495
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Positive	490
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	5,377
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Positive	279
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	10,495
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Positive	490
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	5,377
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Positive	279
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	10,495
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Positive	490
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	5,377
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Positive	279
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	10,495
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Positive	490
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	5,377
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Positive	279



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	1,479
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Positive	68
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	3,110
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Positive	156
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	2,967
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	126
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	1,547
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	75
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	2,967
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	126
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	1,547
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	75
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	2,967
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	126
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	1,547
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	75
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	2,967



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	126
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	1,547
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	75
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	160
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	160
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	160
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	160
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	18



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	7,028
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	106
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	7,028
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	106
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	7,028
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	106
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	7,028
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	106
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	232
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	215
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	232
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	215



	_	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	232
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	215
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	232
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	215
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	3,270
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	369
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	3,230
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	369
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	3,270
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	369
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	3,230
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	369



	_	
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	3,270
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	369
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	3,230
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	369
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	3,270
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	369
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	3,230
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	369
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	12,026
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	12,026
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	855
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,173
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	852
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,134
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases,	1,087



	during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6,041
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	740
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,161
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,082
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3,082
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	142
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	187
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,213
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,536
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	166
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,436
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	166



TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,313
GEND_GBV_DSD	Number of people receiving post-GBV care	4,681
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,904
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,695
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,165
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	87
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	180
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	93
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	52
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	194
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	375
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	52
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	324
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	398
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	455
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	533
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	173
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	249
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	167
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	249
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	162
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	229



GEND_GBV_TA	Number of people receiving post-GBV care	475
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	199
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	269
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	212
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	11
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	21
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	12
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	11
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	21
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	45
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	5
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	38
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	49
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	61
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	21
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	30
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	20
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	21
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	32
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,052



	,	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	47
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,954
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,970
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	537
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	257
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	263



	- -	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	16,260
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	13,005
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,255
PMTCT_EID_DSD	Sum of Infant Age disaggregates	16,260
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,857
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,482
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	375
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,857
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	221,059
TX_CURR_DSD	Age/Sex: 15-19 Male	1,025
TX_CURR_DSD	Age/Sex: 15-19 Female	9,235
TX_CURR_DSD	Sum of age/sex disaggregates	10,260
TX_CURR_DSD	Age/Sex: <1	959
TX_CURR_DSD	Age/Sex: <1-9	10,753
TX_CURR_DSD	Age/Sex: 10-14 Male	1,022
TX_CURR_DSD	Age/Sex: 10-14 Female	1,369
TX_CURR_DSD	Age/Sex: 20-24 Male	5,462
TX_CURR_DSD	Age/Sex: 50+ Male	8,503
TX_CURR_DSD	Age/Sex: 20-24 Female	30,771
TX_CURR_DSD	Age/Sex: 50+ Female	9,856
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	25,002
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	10,501
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	25,007



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	10,500
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	25,008
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	10,497
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	25,010
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	10,482
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	34,816
TX_CURR_TA	Age/Sex: 15-19 Male	166
TX_CURR_TA	Age/Sex: 15-19 Female	1,392
TX_CURR_TA	Sum of Age/Sex disaggregations	1,558
TX_CURR_TA	Age/Sex: <1	423
TX_CURR_TA	Age/Sex: 1-9	1,301
TX_CURR_TA	Age/Sex: 10-14 Male	127
TX_CURR_TA	Age/Sex: 10-14 Female	158
TX_CURR_TA	Age/Sex: 20-24 Male	686
TX_CURR_TA	Age/Sex: 50+ Male	1,373
TX_CURR_TA	Age/Sex: 20-24 Female	4,538
TX_CURR_TA	Age/Sex: 50+ Female	1,268
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	3,922
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,919
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	3,926
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1,919
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	3,928



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,919
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	3,923
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,917
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	60,579
TX_NEW_DSD	By Age/Sex: <1	1,107
TX_NEW_DSD	By Age/Sex: 1-9	3,348
TX_NEW_DSD	By Age/Sex: 10-14 Male	390
TX_NEW_DSD	By Age/Sex: 15-19 Male	475
TX_NEW_DSD	By Age/Sex: 20-24 Male	3,404
TX_NEW_DSD	By Age/Sex: 50+ Male	1,785
TX_NEW_DSD	By Age/Sex: 10-14 Female	361
TX_NEW_DSD	By Age/Sex: 15-19 Female	4,143
TX_NEW_DSD	By Age/Sex: 20-24 Female	9,502
TX_NEW_DSD	By Age/Sex: 50+ Female	2,084
TX_NEW_DSD	Sum of Age/Sex disaggregates	22,144
TX_NEW_DSD	Pregnancy status	10,544
TX_NEW_DSD	Breastfeeding status	850
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,876
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,708
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,859
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,698
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,858
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,674



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4,783
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,653
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,903
TX_NEW_TA	By Age/Sex: <1	118
TX_NEW_TA	By Age/Sex: 1-9	396
TX_NEW_TA	By Age/Sex: 10-14 Male	46
TX_NEW_TA	By Age/Sex: 15-19 Male	65
TX_NEW_TA	By Age/Sex: 20-24 Male	727
TX_NEW_TA	By Age/Sex: 50+ Male	151
TX_NEW_TA	By Age/Sex: 10-14 Female	52
TX_NEW_TA	By Age/Sex: 15-19 Female	946
TX_NEW_TA	By Age/Sex: 20-24 Female	2,809
TX_NEW_TA	By Age/Sex: 50+ Female	246
TX_NEW_TA	Sum of Age/Sex disaggregates	5,042
TX_NEW_TA	Pregnancy status	2,858
TX_NEW_TA	Breastfeeding status	259
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,152
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	972
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,147
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	972
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,140
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	971
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,110



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	896
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	142,923
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	6,505
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	2,433
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	97,101
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	36,884
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	21,125
TX_PVLS_TA	<15, Undocumented Test Indication, Female	951
TX_PVLS_TA	<15, Undocumented Test Indication, Male	417
TX_PVLS_TA	15+, Undocumented Test Indication, Female	13,912
TX_PVLS_TA	15+, Undocumented Test Indication, Male	5,845
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	70,892
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	78,677
TX_RET_DSD	Numerator by Status: Pregnant	13,288
TX_RET_DSD	Numerator by Status: Breastfeeding	1,401
TX_RET_DSD	Denominator by Status: Pregnant	16,576
TX_RET_DSD	Denominator by Status: Breastfeeding	1,485
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,242
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,143
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	5,853



	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45,529
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,687
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,363
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,326
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49,174
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,126
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,083
TX_RET_TA	Numerator by Status: Pregnant	873
TX_RET_TA	Numerator by Status: Breastfeeding	104
TX_RET_TA	Denominator by Status: Pregnant	1,580
TX_RET_TA	Denominator by Status: Breastfeeding	182
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of	468



<u> </u>	
adults and children who are still alive and on treatment	
at 12 months after initiating ART)	
Aggregated Age/Sex: 15+ Male (Numerator: Number of	
adults and children who are still alive and on treatment	1,921
at 12 months after initiating ART)	
Aggregated Age/Sex: <15 Female (Numerator: Number	
of adults and children who are still alive and on	1,099
treatment at 12 months after initiating ART)	
Aggregated Age/Sex: 15+ Female (Numerator: Number	
of adults and children who are still alive and on	4,617
treatment at 12 months after initiating ART)	
Aggregated Age/Sex: <15 Male (Denominator: Total	
number of adults and children who initiated ART in the	
12 months prior to the beginning of the reporting period,	529
including those who have died, those who have	
stopped ART, and those lost to follow-up)	
Aggregated Age/Sex: 15+ Male (Denominator: Total	
number of adults and children who initiated ART in the	
12 months prior to the beginning of the reporting period,	2,228
including those who have died, those who have	
stopped ART, and those lost to follow-up)	
Aggregated Age/Sex: <15 Female (Denominator: Total	
number of adults and children who initiated ART in the	
12 months prior to the beginning of the reporting period,	1,208
including those who have died, those who have	
stopped ART, and those lost to follow-up)	
Aggregated Age/Sex: 15+ Female (Denominator: Total	
number of adults and children who initiated ART in the	
12 months prior to the beginning of the reporting period,	5,096
including those who have died, those who have	
stopped ART, and those lost to follow-up)	
HTS_SELF_N_DSD	7,024
HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	
Female, Directly-Assisted	263
HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	176
	at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) HTS_SELF_N_DSD HTS_SELF_N_DSD HTS_SELF_N_DSD HTS_SELF_N_DSD HTS_SELF_N_DSD HTS_SELF_N_DSD



	T	
	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	658
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	439
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	658
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	439
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	658
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	439
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	658
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	439
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,317
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	878
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	7,024
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	7,024
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	38,434
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	51,223



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,318
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,195
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	30,869
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	17,820
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	991
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	842
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	23,589
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	13,017
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	10,243
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	40,980
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	7,685
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	30,749
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	6,714
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	8,950
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	232
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	207
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	5,397
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	3,115
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	173
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	149



TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	4,120
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	2,273
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,791
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	7,161
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,344
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,370
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	221,062
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	8,839
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	7,385
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	149,467
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	53,955
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,631
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2,631
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	150,257
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	17,620
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	48,573
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	4,355
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	34,813
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,302
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,036
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	23,435



TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	8,973
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	23,658
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,769
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	7,644
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	681

Implementing Mechanism Details

Mechanism ID: 9818	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 228,197	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 228,197		
Funding Source Funding Amount		
GHP-State	228,197	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID: 9818		
Mechanism Name:	Mechanism Name: APHL	
Prime Partner Name:	Association of Public Health Laboratories	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	114,099
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	114,098
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9856	Mechanism Name: MISAU BS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Ministry of Health, Mozambique		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: Yes Managing Agency: HHS/CDC		

Total All Funding Sources: 138,154	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 138,154		
Funding Source Funding Amount		
GHP-State	138,154	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code Planned Amount	
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	138,154
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10971	Mechanism Name: FADM, Department of Defense Support	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: U.S. Department of Defense (Defense)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID:	10971	
Mechanism Name:	: FADM, Department of Defense Support	
Prime Partner Name:	U.S. Department of Defense (Defense)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11463	Mechanism Name: United States Peace Corps/ Mozambique
Funding Agency: PC	Procurement Type: USG Core



Prime Partner Name: U.S. Peace Corps		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 260,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 260,000		
Funding Source Funding Amount		
GHP-State	260,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	United States Peace Corps/ Mozambique	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	30,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	115,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	115,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,066
PP_PREV_DSD	Age/sex: 10-14 Female	5,379
PP_PREV_DSD	Age/sex: 15-19 Female	5,958
PP_PREV_DSD	Age/sex: 20-24 Female	2,115
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,452
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	
PP_PREV_TA	Age/sex: 15-19 Male	19
PP_PREV_TA	Age/sex: 10-14 Female	107
PP_PREV_TA	Age/sex: 15-19 Female	23
PP_PREV_TA	Sum of Age/Sex disaggregates	149
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS April 1987 198	
OVC_SERV_DSD	Age/Sex: 10-14 Male	264
OVC_SERV_DSD	Age/Sex: 15-17 Male	179



OVC_SERV_DSD	By: Age/sex: Male 18-24	82
OVC_SERV_DSD	By: Age/sex: Male 25+	63
OVC_SERV_DSD	Age/Sex: 10-14 Female	286
OVC_SERV_DSD	Age/Sex: 15-17 Female	177
OVC_SERV_DSD	By: Age/sex: 18-24 Female	116
OVC_SERV_DSD	By: Age/sex: 25+ Female	116
OVC_SERV_DSD	Sum of Age/Sex disaggregates	906
OVC_SERV_DSD	Age/Sex: <1	41
OVC_SERV_DSD	Age/Sex: 1-9	748
OVC_SERV_DSD	Program Completion: Active	2,066
OVC_SERV_DSD	Program Completion: Graduation	8
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	44
OVC_SERV_TA	Age/Sex: 10-14 Male	6
OVC_SERV_TA	Age/Sex: 15-17 Male	3
OVC_SERV_TA	By age/sex: 18-24 Male	1
OVC_SERV_TA	By age/sex: 25+ Male	2
OVC_SERV_TA	Age/Sex: 10-14 Female	6
OVC_SERV_TA	Age/Sex: 15-17 Female	3
OVC_SERV_TA	By age/sex: 18-24 Female	1
OVC_SERV_TA	By age/sex: 25+ Female	4
OVC_SERV_TA	Sum of Age/Sex disaggregates	18
OVC_SERV_TA	Age/Sex: <1	1
OVC_SERV_TA	Age/Sex: 1-9	17
OVC_SERV_TA	Program Completion: Active	31
OVC_SERV_TA	Program Completion: Graduated	13
OVC_HIVSTAT_TA	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	0
OVC_HIVSTAT_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	44



Implementing Mechanism Details

Mechanism ID: 11580	Mechanism Name: Johns Hopkins	
Mechanish ib. 11300	mechanism mame. Johns mopkins	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 27,295,040	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	eline Amount: 27,295,040	
Funding Source	Funding Amount	
GHP-State	27,295,040	

Cross-Cutting Budget Attribution(s)

Gender: GBV	235,280
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Condom programming	450,000
Human Resources for Health	1,260,171
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Adolescent Girls and Young Women (AGYW)	745,280

Mechanism ID:	11580



Mechanism Name: Prime Partner Name:	•	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	700,043
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	630,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	1,052,058
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	14,946,381
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	5,221,278
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	510,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,056,128
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,589,576
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,589,576

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	202,527
VMMC_CIRC_DSD	By Age: 10-14	80,555
VMMC_CIRC_DSD	By Age: 15-19	55,009
VMMC_CIRC_DSD	By Age: 20-24	35,712
VMMC_CIRC_DSD	By Age: 25-29	19,685
VMMC_CIRC_DSD	By Age: 50+	594



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	171,870
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	191,555
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	202,527
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,732
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,731
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	5,463
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	405,534
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	829
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	16,332
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1,817
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	829
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	16,332
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	1,817
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	21,252
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	514
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	30,024
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	803
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	11,293
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	331



HTC_TST_DSD	By Key Population: FSW, Negative	526
HTC_TST_DSD	By Key Population: FSW, Positive	72
HTC_TST_DSD	By Key Population: MSM, Negative	1,728
HTC_TST_DSD	By Key Population: MSM, Positive	198
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	357
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	3,290
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	2,558
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	3,977
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1,614
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	2,939
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1,151
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	5,725
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	2,359
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3,984
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1,647
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2,288



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	909
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	3,516
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1,389
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	397
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	9,262
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	309
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	828
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	16,332
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	1,818
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	828
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	16,333
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	1,817
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	7,330
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	2,888



	_	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	7,110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	2,852
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	7,330
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2,888
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	7,110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	2,852
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	7,330
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	2,888
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	7,110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	2,852
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	7,330
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	2,888
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	7,110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	2,852
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	33,095
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	1,101
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	33,095



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	1,101
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	33,095
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	1,101
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	33,095
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	1,101
GEND_GBV_DSD	Number of people receiving post-GBV care	1,166
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	265
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	376
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	303
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	19
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	41
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	13
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	41
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	102
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	10
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	81
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	102
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	122
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	143
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	41
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	61
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	41



	30-34, Female, Physical and/or Emotional Violence	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	61
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	41
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	61
HTS_SELF_DSD	HTS_SELF_N_DSD	2,224
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	83
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	55
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	209
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	138
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	209
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	138
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	209
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	138
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	209
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	138
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	417
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	278
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	2,224
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM,	2,226



Implementing Mechanism Details

Mechanism ID: 12149	Mechanism Name: SCIP Zambezia	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Vision International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,760,160	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,760,160		
Funding Source	Funding Amount	
GHP-State	1,760,160	

Cross-Cutting Budget Attribution(s)

Gender: GBV	160,000	
Focus Area:	GBV Prevention	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Condom programming	51,000	
Human Resources for Health	195,016	
Adolescent Girls and Young Women (AGYW)	496,656	

Baagot Godo information	
Mechanism ID:	12149
Mechanism Name:	SCIP Zambezia



Prime Partner Name:	World Vision International	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	471,371
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	97,978



Strategic Area	Budget Code	Planned Amount	
Prevention	HVCT	792,133	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVOP	398,678	
Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	MTCT	0	
Strategic Area	Budget Code Planned Amoun		
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	Treatment HTXS		
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	0	

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	24,855
PP_PREV_DSD	Age/sex: 10-14 Female	8,699
PP_PREV_DSD	Age/sex: 15-19 Female	12,427
PP_PREV_DSD	Age/sex: 20-24 Female	3,728
PP_PREV_DSD	Sum of Age/Sex disaggregates	24,854
HTC_TST_DSD	Number of individuals who received T&C services for	16,460



	HIV and received their test results during the past 12	
	months	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	598
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	465
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	449
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,049
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	407
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	463
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	181
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	234
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	92
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	359
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	141



T		
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	71
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,681
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,011
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	394
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	780
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,011
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	394
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	780
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,011
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	394
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	780
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,011



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	394
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	780
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	303

Implementing Mechanism Details

Mechanism ID: 12150	Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services (SIAPS)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Management Science	es for Health	
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Systems for Improved Access to Pharmaceuticals and Services Mechanism Name: (SIAPS) Prime Partner Name: Management Sciences for Health



Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 12159	Mechanism Name: Strengthening HIV and GBV Prevention within the Police	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: United Nations Development Programme		
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Budget Code information		
Mechanism ID:		
Mechanism Name:	Strengthening HIV and GBV Pre	vention within the Police
Prime Partner Name:	United Nations Development Programme	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	o
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	o	

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 12165	Mechanism Name: Strategic Information Improvement in Mozambique (SIIM) Project	
Funding Agency: USAID	Procurement Type: Grant	
Prime Partner Name: Health Alliance International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 12168	Mechanism Name: PATHFINDER	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Pathfinder International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Budget Code Information		
Mechanism ID:	12168	
Mechanism Name:	PATHFINDER	
Prime Partner Name:	Pathfinder International	
Strategic Area	Budget Code	Planned Amount
Care	нвнс	o
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12619	Mechanism Name: AABB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Association of Blood Banks	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 262,482	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 262,482		
Funding Source Funding Amount		
GHP-State	262,482	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	12619	
Mechanism Name:	AABB	
Prime Partner Name:	American Association of Blood Banks	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	262,482
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 12648	Mechanism Name: Promoting the Quality of Medicines (PQM)	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: United States Pharmacopeia		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information		
Mechanism ID:	12648	
Mechanism Name:	Promoting the Quality of Medicines (PQM)	
Prime Partner Name:	United States Pharmacopeia	
Strategic Area	Budget Code Planned Amount	
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

<u> </u>		
Mechanism ID: 12665	Mechanism Name: DPS Cabo Delgado Province	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Provincial Directorate of Health, Cabo Delgado		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 274,675	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 274,675			
Funding Source Funding Amount			
GHP-State	274,675		

Cross-Cutting Budget Attribution(s)

(No data provided.)

	DPS Cabo Delgado Province	
Prime Partner Name:	Provincial Directorate of Health,	Cabo Delgado
Strategic Area	Budget Code Planned Amount	
Care	HBHC	31,891
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	8,698
Strategic Area	Budget Code	Planned Amount
Care	PDCS	11,597
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	207,993
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	14,496

(No data provided.)

Mechanism ID: 12681	Mechanism Name: JEMBI	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: JEMBI		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 4,037,531	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pip	eline Amount: 4,037,531
Funding Source	Funding Amount
GHP-State	4,037,531



(No data provided.)

Budget Code Information		
Mechanism ID:	12681	
Mechanism Name:	JEMBI	
Prime Partner Name:	JEMBI	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	317,002
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	867,506
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,536,021
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	317,002

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 12702	Mechanism Name: UCSF	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at San Francisco		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 667,958	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 357,688		
Total All Funding Sources and Applied Pipeline Amount: 1,025,646		
Funding Source Funding Amount		
GHP-State	667,958	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	12702	
Mechanism Name:	UCSF	
Prime Partner Name:	University of California at San F	rancisco
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	667,958
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12998	Mechanism Name: DPS Maputo Province	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Provincial Directorate of Health, Maputo		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 179,934	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 179,934		
Funding Source Funding Amount		
GHP-State	179,934	

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information			
Mechanism ID: 12998			
Mechanism Name:	Mechanism Name: DPS Maputo Province		
Prime Partner Name:	Provincial Directorate of Health, Maputo		
Strategic Area	Budget Code Planned Amount		
Care	НВНС	20,891	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	5,698	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	7,597	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	136,252
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	9,496

(No data provided.)



Mechanism ID: 13022	Mechanism Name: Clinical Services System Strenghening (CHASS)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 21,359,253	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	line Amount: 21,359,253	
Funding Source Funding Amount		
GHP-State	21,359,253	

Gender: GBV	530,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	4,572,824
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection



Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: GBV	530,000
Focus Area:	GBV Prevention
Renovation	785,714
Food and Nutrition: Policy, Tools, and Service Delivery	320,000
Condom programming	500,000
Human Resources for Health	4,291,281
Adolescent Girls and Young Women (AGYW)	300,000

Mechanism ID:	12022
Wiechanisin id.	13022



Mechanism Name: Prime Partner Name:	, , ,	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,840,105
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	217,066
Strategic Area	Budget Code	Planned Amount
Care	PDCS	351,845
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	271,543
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount	
Prevention	HVCT	846,269	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVOP	777,903	
Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	MTCT	2,089,461	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	14,187,085	
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	777,976	

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	21,230
	(MTCT) during pregnancy	_1,_5
	Number of pregnant women with known HIV status	
PMTCT_ART_DSD	(includes women who were tested for HIV and received	269,940
	their results)	
PMTCT_ART_DSD	New on ART	11,998
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	9,232



PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,922
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	151,180
PMTCT_ART_TA	New on ART	2,611
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,311
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	269,940
PMTCT_STAT_DSD	Number of new ANC and L&D clients	278,269
PMTCT_STAT_DSD	By Age (Denominator): 10-14	1,971
PMTCT_STAT_DSD	By Age (Denominator): <15-19	59,489
PMTCT_STAT_DSD	By Age (Denominator): 20-24	89,764
PMTCT_STAT_DSD	By Age (Denominator): 50+	155
PMTCT_STAT_DSD	By Number of known positives: 10-14	7
PMTCT_STAT_DSD	By Number of known positives: 15-19	486
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,819
PMTCT_STAT_DSD	By Number of new positives: 15-19	1,111
PMTCT_STAT_DSD	By Number of new positives: 20-24	2,595
PMTCT_STAT_DSD	By Number of new negative: 10-14	1,223
PMTCT_STAT_DSD	By Number of new negative: 15-19	58,708
PMTCT_STAT_DSD	By Number of new negative: 20-24	72,185
PMTCT_STAT_DSD	By Number of new negative: 50+	175
PMTCT_STAT_DSD	By Age (Numerator): 10-14	1,282
PMTCT_STAT_DSD	By Age (Numerator): 15-19	60,944
PMTCT_STAT_DSD	By Age (Numerator): 20-24	77,142
PMTCT_STAT_DSD	By Age (Numerator): 50+	176
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	33,081
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	31,909
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	31,887
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	30,013



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,537
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	96,145
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	3,533
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,541
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	7,748
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	1,124
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	1,510
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	7,654
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	1,029
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	1,502
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	7,186
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1,020
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	101,277
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	10,329
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	9,497
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	9,000
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	151,180
PMTCT_STAT_TA	Number of new ANC and L&D clients	155,252
PMTCT_STAT_TA	By Age (Denominator): 10-14	1,566
PMTCT_STAT_TA	By Age (Denominator): 15-19	34,218



PMTCT_STAT_TA	By Age (Denominator): 20-24	47,622
PMTCT_STAT_TA	By Age (Denominator): 50+	16
PMTCT_STAT_TA	By known positives: 10-14	4
PMTCT_STAT_TA	By known positives: 15-19	365
PMTCT_STAT_TA	By known positives: 20-24	1,044
PMTCT_STAT_TA	By new positives: 15-19	807
PMTCT_STAT_TA	By new positives: 20-24	1,717
PMTCT_STAT_TA	By new negatives: 10-14	1,213
PMTCT_STAT_TA	By new negatives: 15-19	24,344
PMTCT_STAT_TA	By new negatives: 20-24	28,853
PMTCT_STAT_TA	By Age (Numerator): 10-14	1,312
PMTCT_STAT_TA	By Age (Numerator): : 15-19	25,994
PMTCT_STAT_TA	By Age (Numerator): 20-24	31,801
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	18,382
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	18,523
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	18,011
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	16,914
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	945
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	30,023
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	2,212
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	958
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	18,609
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	751
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	919
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	18,091



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	757
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	921
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	17,852
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	754
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	33,382
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	20,344
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	19,251
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	19,003
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,722
PrEP_NEW_DSD	Male 15-19	132
PrEP_NEW_DSD	Male 20-24	132
PrEP_NEW_DSD	Female 15-19	265
PrEP_NEW_DSD	Female 20-24	265
PrEP_NEW_DSD	FSW	1,377
PrEP_NEW_DSD	MSM	345
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	265
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	132
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	265
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	132
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	110
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	28
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,473
PP_PREV_DSD	Age/sex: 10-14 Female	3,414
PP_PREV_DSD	Age/sex: 15-19 Female	4,661
PP_PREV_DSD	Age/sex: 20-24 Female	1,908



PP_PREV_DSD	Sum of Age/Sex disaggregates	9,983
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,284,565
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,382
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,297
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	333
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,292
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	462
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	592
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	444



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,314
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	11,731
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	301
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,591
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	321
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	451
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	122
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1,322
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1,218
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1,231
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	1,381
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	3,763
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female,	70



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	3,316
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	4,946
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	431
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,529
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	14,605
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1,236
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	6,038
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	531
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	8,863
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	781
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,755
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	336
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	3,095
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	19,001
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	388
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14,	2,341



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	142
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	1,820
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	109
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,850
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1,102
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,040
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	389
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	5,586
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	2,131
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3,254
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1,256
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,670
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	646
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2,734
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1,063
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	283
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1,	17



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	6,587
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	396
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	39,761
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	1,952
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	94,488
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	4,781
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,231
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,661
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5,654
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	676
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,526
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	151
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	13,220
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,643
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	6,479
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male,	772



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	6,192
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	872
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,891
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	496
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	761
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	7,260
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	270
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	13,244
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	274
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	16,696
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	338
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	14,706
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	289
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	22,708
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	1,765
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	7,163
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	555
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9,	84,687



	Unknown Sex, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	1,714
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	60,172
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	4,770
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	24,948
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	2,019
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	36,203
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	2,885
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	29,514
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	2,399
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	36,203
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	2,885
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	29,514
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	2,399
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	36,203
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	2,885
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	29,514
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male,	2,399



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	36,151
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	2,885
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	29,274
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	2,399
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	41,831
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	3,390
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	16,629
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	1,297
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	9,281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	779
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	7,075
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	628
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	9,281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	779
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	7,075
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	628
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39,	9,281



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	779
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	7,075
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	628
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	9,281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	779
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	7,075
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	628
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	820
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	712
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	820
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	712
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	820
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39,	108



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	712
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	820
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	712
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	4,165
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1,540
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	4,400
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1,622
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	4,165
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1,540
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	4,400
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1,622
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	4,165
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1,540
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39,	4,400



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1,622
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	4,165
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1,540
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	4,400
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1,622
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	33,250
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,688
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	33,250
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,688
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	33,250
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1,688
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	33,250
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,688
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1,927
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	100



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1,927
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1,927
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	1,927
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	7,744
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	975
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	7,247
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	995
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34,	7,743



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	975
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	7,246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	995
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	7,743
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	975
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	7,246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	995
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	7,743
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	975
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	7,246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	995
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	725,166
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	36
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	180
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	648
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	38
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	100
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	264
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	597
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	195
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	6



HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	456
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	806
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	24
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	731
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	645
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	4,678
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	171
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,985
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	116
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	12,660
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	491
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	4,959
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	188
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	4,389
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female,	548



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	2,490
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	393
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	587
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	3,664
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	64
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	174
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	136
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	88
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	34
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	494
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	192
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	176
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	68
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 50+,	121



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	47
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	121
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	47
HTC_TST_TA	Service Delivery Point (Community) Index Mod: <1, Negative	21
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 1-9, Negative	489
HTC_TST_TA	Service Delivery Point (Community) Index Mod: 1-9, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	13,943
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	268
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	36,661
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	609
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	274
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	204
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,075
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	123
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	836
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	63



HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	6,117
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	346
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,952
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	135
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,558
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	137
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,071
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	95
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	98
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	896
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	45
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	19,025
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Positive	213
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	16,787
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Positive	196
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	14,809
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Positive	650
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Negative	12,146



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Positive	486
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	96,464
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	1,086
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	15,179
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Positive	172
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	43,579
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Positive	1,918
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Negative	17,627
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Positive	776
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	26,233
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Positive	1,145
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	20,936
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Positive	913
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	26,233
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Positive	1,145
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	20,936
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Positive	913



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	26,233
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Positive	1,145
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	20,936
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Positive	913
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	26,015
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Positive	1,136
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	20,429
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Positive	892
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	14,570
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Positive	643
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	8,424
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Positive	1,107
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	7,648
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	288
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	5,784
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	222
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	7,354



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	511
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	5,612
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	283
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	7,354
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	874
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	5,612
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	451
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	7,272
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	675
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	5,612
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	510
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	63
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	63
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	8



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	63
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	63
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 25-29, Female, Negative	296
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 25-29, Female, Positive	115
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 25-29, Male, Negative	234
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 25-29, Male, Positive	91
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 30-34, Female, Negative	296
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 30-34, Female, Positive	115
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 30-34, Male, Negative	234



HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 30-34, Male, Positive	91
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 35-39, Female, Negative	296
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 35-39, Female, Positive	115
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 35-39, Male, Negative	234
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 35-39, Male, Positive	91
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 40-49, Female, Negative	296
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 40-49, Female, Positive	115
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 40-49, Male, Negative	234
HTC_TST_TA	HTS_TST_N_TA_NdxMod_Age_Sex_Result 40-49, Male, Positive	91
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	13,418
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	243
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	13,418
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	243
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	13,418
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	243
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	13,418
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	243



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	568
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	729
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	568
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	729
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	568
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	729
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	28
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	568
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	729
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	3,769



HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	201
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	3,010
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	173
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	3,769
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	201
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	3,010
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	173
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	3,769
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	201
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	3,010
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	173
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	3,769
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	201
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	3,010
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	173
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	24,878
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	24,878



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	1,361
15_01/(1_505	documented HIV status, during the reporting period)	1,001
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_DSD	registered new and relapsed TB cases with	11,602
	documented HIV status, during the reporting period)	,
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	970
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	10,942
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	1,623
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	12,202
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	1,311
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	9,746
	during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with	8,867
ID_OTAT_TA	documented HIV status, during the reporting period.	0,007
TB_STAT_TA	Total number of registered new and relapsed TB cases,	8,867
ID_OTAT_TA	during the reporting period.	0,007
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	626
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	775
	during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total	3,679



	number of registered new and relapsed TB cases,	
	during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,788
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	702
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,688
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	517
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,944
GEND_GBV_DSD	Number of people receiving post-GBV care	14,428
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5,859
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	8,380
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	6,747
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	279
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	565
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	284
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	290
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	565
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1,401
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	142
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	145
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,131
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,407
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,681



GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,965
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	561
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	827
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	559
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	808
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	562
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	815
GEND_GBV_TA	Number of people receiving post-GBV care	3,105
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,049
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,559
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	1,288
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	57
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	122
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	71
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	73
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	121
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	299
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	31
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	38
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	244
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	297
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	358
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	418
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	118



GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	180
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	118
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	180
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	117
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	180
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,745
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	175
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,719
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	147
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,506
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,237
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	45



	TD trootment during the remediate region	
	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	548
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	36
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	543
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	21,030
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	16,899
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	4,131
PMTCT_EID_DSD	Sum of Infant Age disaggregates	21,030
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,913
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	3,924
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	989
PMTCT_EID_TA	Sum of Infant Age disaggregates	4,913
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	357,268
TX_CURR_DSD	Age/Sex: 15-19 Male	2,140
TX_CURR_DSD	Age/Sex: 15-19 Female	10,171
TX_CURR_DSD	Sum of age/sex disaggregates	12,311
TX_CURR_DSD	Age/Sex: <1	1,510
TX_CURR_DSD	Age/Sex: <1-9	19,474



TX_CURR_DSD	Age/Sex: 10-14 Male	3,393
TX_CURR_DSD	Age/Sex: 10-14 Female	3,783
TX_CURR_DSD	Age/Sex: 20-24 Male	5,263
TX_CURR_DSD	Age/Sex: 50+ Male	18,206
TX_CURR_DSD	Age/Sex: 20-24 Female	35,244
TX_CURR_DSD	Age/Sex: 50+ Female	20,587
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	40,865
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	18,487
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	40,859
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	18,483
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	40,859
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	18,485
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	40,856
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	18,476
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	81,102
TX_CURR_TA	Age/Sex: 15-19 Male	719
TX_CURR_TA	Age/Sex: 15-19 Female	2,472
TX_CURR_TA	Sum of Age/Sex disaggregations	3,191
TX_CURR_TA	Age/Sex: <1	967
TX_CURR_TA	Age/Sex: 1-9	5,578
TX_CURR_TA	Age/Sex: 10-14 Male	676
TX_CURR_TA	Age/Sex: 10-14 Female	752
TX_CURR_TA	Age/Sex: 20-24 Male	1,388
TX_CURR_TA	Age/Sex: 50+ Male	3,652



TX_CURR_TA	Age/Sex: 20-24 Female	8,372
TX_CURR_TA	Age/Sex: 50+ Female	4,201
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	8,772
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	4,282
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	8,784
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	4,285
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	8,781
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	4,281
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	8,783
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	4,195
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	91,715
TX_NEW_DSD	By Age/Sex: <1	1,268
TX_NEW_DSD	By Age/Sex: 1-9	3,525
TX_NEW_DSD	By Age/Sex: 10-14 Male	559
TX_NEW_DSD	By Age/Sex: 15-19 Male	570
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,727
TX_NEW_DSD	By Age/Sex: 50+ Male	3,098
TX_NEW_DSD	By Age/Sex: 10-14 Female	575
TX_NEW_DSD	By Age/Sex: 15-19 Female	4,834
TX_NEW_DSD	By Age/Sex: 20-24 Female	12,255
TX_NEW_DSD	By Age/Sex: 50+ Female	3,135
TX_NEW_DSD	Sum of Age/Sex disaggregates	27,753
TX_NEW_DSD	Pregnancy status	15,209
TX_NEW_DSD	Breastfeeding status	1,056



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	8,734
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	6,098
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	8,735
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6,079
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8,683
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	6,074
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,666
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,048
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	23,445
TX_NEW_TA	By Age/Sex: <1	320
TX_NEW_TA	By Age/Sex: 1-9	1,200
TX_NEW_TA	By Age/Sex: 10-14 Male	209
TX_NEW_TA	By Age/Sex: 15-19 Male	118
TX_NEW_TA	By Age/Sex: 20-24 Male	579
TX_NEW_TA	By Age/Sex: 50+ Male	909
TX_NEW_TA	By Age/Sex: 10-14 Female	212
TX_NEW_TA	By Age/Sex: 15-19 Female	1,826
TX_NEW_TA	By Age/Sex: 20-24 Female	2,847
TX_NEW_TA	By Age/Sex: 50+ Female	642
TX_NEW_TA	Sum of Age/Sex disaggregates	7,342
TX_NEW_TA	Pregnancy status	5,105
TX_NEW_TA	Breastfeeding status	136
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	2,128



	·	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,533
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	2,120
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1,531
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	2,117
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,528
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	2,067
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,489
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	232,961
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	9,023
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	3,531
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	154,216
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	66,191
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	51,780
TX_PVLS_TA	<15, Undocumented Test Indication, Female	2,152
TX_PVLS_TA	<15, Undocumented Test Indication, Male	949
TX_PVLS_TA	15+, Undocumented Test Indication, Female	34,065
TX_PVLS_TA	15+, Undocumented Test Indication, Male	14,612
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	74,782
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	83,220



TX_RET_DSD	Numerator by Status: Pregnant	14,759
TX_RET_DSD	Numerator by Status: Breastfeeding	962
TX_RET_DSD	Denominator by Status: Pregnant	17,202
TX_RET_DSD	Denominator by Status: Breastfeeding	894
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,261
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,381
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,817
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	48,139
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,493
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25,662
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,056
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	52,853



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,999
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,373
TX_RET_TA	Numerator by Status: Pregnant	1,972
TX_RET_TA	Numerator by Status: Breastfeeding	80
TX_RET_TA	Denominator by Status: Pregnant	2,164
TX_RET_TA	Denominator by Status: Breastfeeding	99
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	137
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,292
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	328
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,151
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	163
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,889
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	363



	12 months prior to the beginning of the reporting period,	
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	7,876
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	The number of ART patients who completed a course	
TB_PREV_DSD	of TB preventive therapy or at least 6 months of	58,642
	Isoniazid Preventive Therapy (IPT) during the reporting	,-
	period	
	The number of ART patients who were newly started on	
	TB preventive therapy (including those who newly	
	started on TB preventive therapy in this reporting period	
TB_PREV_DSD	and those who started in the previous reporting period	78,168
	but had not been reported as they did not fulfill the	
	minimum requirements for the previous reporting	
TD DDEV DCD	period).	2.022
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,023
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,829
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	47,118
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	27,199
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,496
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,289
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	36,000
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	19,862
TD DDEV DOD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	45.000
TB_PREV_DSD	Life-long ART, Already, Positive	15,630
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	00.500
	Life-long ART, New, Positive	62,538
TD DDEV DOD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT,	44.700
TB_PREV_DSD	Life-long ART, Already, Positive	11,732
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT,	46,910
·		



	Life-long ART, New, Positive	
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	15,950
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	21,237
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	542
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	490
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	12,797
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	7,391
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	428
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	330
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	9,789
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	5,408
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	16,988
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,184
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	12,766
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	352,935
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	14,671
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	13,424
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	223,109
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	96,236



TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,427
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	5,427
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	239,934
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	28,177
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	77,582
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	6,999
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	81,102
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	3,139
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	2,897
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	51,875
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	22,914
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,483
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2,483
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	55,084
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	6,426
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	17,778
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,554

Implementing Mechanism Details



Mechanism ID: 13160	Mechanism Name: DPS Zambezia Province	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Provincial Directorate of Health	n, Zambezia	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 551,437	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 551,437		
Funding Source Funding Amount		
GHP-State	551,437	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	386.006
raman recourses for realist	333,333

Budget Code Information

Mechanism ID:	13160	
Mechanism Name:	DPS Zambezia Province	
Prime Partner Name:	Provincial Directorate of Health,	, Zambezia
Strategic Area	Budget Code	Planned Amount
Care	НВНС	64,025
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	17,461
Strategic Area	Budget Code	Planned Amount
Care	PDCS	23,282
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	417,567
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	29,102

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13313	Mechanism Name: National Public Health Reference Laboratory	
Funding Agency: State/AF	Procurement Type: USG Core	
Prime Partner Name: Regional Procurement Support Office/Frankfurt		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information			
Mechanism ID:	13313		
Mechanism Name:	lame: National Public Health Reference Laboratory		
Prime Partner Name:	Regional Procurement Support Office/Frankfurt		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 13583	Mechanism Name: ICAP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 24,588,688	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline	Amount: 24,588,688
Funding Source	Funding Amount
GHP-State	24,588,688

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	110,000
Focus Area:	Training of health workers and community outreach
	workers
Key Populations: FSW	110,000
Gender: GBV	272,200
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Implementation
Food and Nutrition: Policy, Tools, and Service	230,050
Delivery	
Renovation	241,100



Condom programming	300,000
Adolescent Girls and Young Women (AGYW)	287,500
Human Resources for Health	3,172,610
Motor Vehicles: Purchased	100,000

Budget Code Information

Budget Code Information		
Mechanism ID:	13583	
Mechanism Name:	ICAP	
Prime Partner Name:	Columbia University Mailman School of Public Health	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	1,162,854
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,162,854
Strategic Area	Budget Code	Planned Amount
Care	PDCS	465,142
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	9,667,313
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,395,423
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,150,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	2,142,847
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	6,279,401
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,162,854

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	8,060
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	214,441
PMTCT_ART_DSD	New on ART	5,929
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,131
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,588
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	163,286
PMTCT_ART_TA	New on ART	2,562
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,026
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	214,441
PMTCT_STAT_DSD	Number of new ANC and L&D clients	221,337
PMTCT_STAT_DSD	By Age (Denominator): 10-14	2,369
PMTCT_STAT_DSD	By Age (Denominator): <15-19	39,398
PMTCT_STAT_DSD	By Age (Denominator): 20-24	56,986
PMTCT_STAT_DSD	By Number of known positives: 15-19	200
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,232
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	415
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,025
PMTCT_STAT_DSD	By Number of new negative: 10-14	787
PMTCT_STAT_DSD	By Number of new negative: 15-19	18,324



PMTCT_STAT_DSD	By Number of new negative: 20-24	25,748
PMTCT_STAT_DSD	By Age (Numerator): 10-14	843
PMTCT_STAT_DSD	By Age (Numerator): 15-19	19,191
PMTCT_STAT_DSD	By Age (Numerator): 20-24	28,141
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	29,642
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	31,502
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	30,993
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	30,447
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,571
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	40,766
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,560
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,591
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	39,706
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	677
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	1,584
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	38,659
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	671
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	1,572
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	37,584
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	638
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	43,924



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	41,980
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	40,652
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	39,544
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	163,286
PMTCT_STAT_TA	Number of new ANC and L&D clients	167,887
PMTCT_STAT_TA	By Age (Denominator): 10-14	3,174
PMTCT_STAT_TA	By Age (Denominator): 15-19	29,908
PMTCT_STAT_TA	By Age (Denominator): 20-24	40,353
PMTCT_STAT_TA	By known positives: 15-19	135
PMTCT_STAT_TA	By known positives: 20-24	531
PMTCT_STAT_TA	By new positives: 15-19	348
PMTCT_STAT_TA	By new positives: 20-24	758
PMTCT_STAT_TA	By new negatives: 10-14	812
PMTCT_STAT_TA	By new negatives: 15-19	10,898
PMTCT_STAT_TA	By new negatives: 20-24	14,993
PMTCT_STAT_TA	By Age (Numerator): 10-14	846
PMTCT_STAT_TA	By Age (Numerator): : 15-19	11,516
PMTCT_STAT_TA	By Age (Numerator): 20-24	16,335
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	21,931
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	24,530
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	24,297
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	23,694
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	798
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	24,798
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,116
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	823
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	35,452



	30-34, Female, Newly Identified Negative	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	555
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	815
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	34,240
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	538
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	812
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	33,629
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	538
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	26,847
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	36,855
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	35,403
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	34,783
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	65,568
VMMC_CIRC_DSD	By Age: 10-14	23,503
VMMC_CIRC_DSD	By Age: 15-19	19,305
VMMC_CIRC_DSD	By Age: 20-24	12,525
VMMC_CIRC_DSD	By Age: 25-29	6,879
VMMC_CIRC_DSD	By Age: 50+	173
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	55,506
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	62,385
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	65,568
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	797
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	797
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,594



	Number of individuals who have been newly enrolled on	
PrEP_NEW_DSD	oral antiretroviral pre-exposure prophylaxis (PrEP) in	2,425
	the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	184
PrEP_NEW_DSD	Male 20-24	184
PrEP_NEW_DSD	Female 15-19	373
PrEP_NEW_DSD	Female 20-24	373
PrEP_NEW_DSD	FSW	1,940
PrEP_NEW_DSD	MSM	485
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	373
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	184
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	373
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	184
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	155
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	39
	Number of individuals who received T&C services for	
HTC_TST_DSD	HIV and received their test results during the past 12	611,702
	months	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	232
HIC_181_080	Female, Negative	232
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	5
1110_101_000	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	216
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	5
	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19,	94
	Female, Negative	<u> </u>
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19,	16
	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male,	47
	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male,	4



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	530
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	407
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	221
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,964
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,665
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	476
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	46



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	259
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	601
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	558
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	9,881
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	9,512
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	137
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,500
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	980
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	863
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,783
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	122
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,372



	,	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	7,404
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	353
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	4,123
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	204
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,747
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,481
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	784
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	4,999
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	31,382
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	989
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	75,215
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	2,301
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	340
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	253



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,955
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	210
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	595
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,840
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	607
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,782
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	222
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	794
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,103
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	200
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,105
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	3,788
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	97



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	4,779
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	4,211
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	10,513
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	538
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	6,725
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	348
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	24,222
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	599
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	26,168
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1,412
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	15,212
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	825
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	15,588
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	946
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	10,720



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	670
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	15,472
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	966
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	10,720
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	658
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	15,495
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	946
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	10,627
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	656
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	15,495
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	944
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	10,743
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	656
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	6,972
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	439
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	5,392
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	320



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	4,614
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	266
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	2,725
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	4,614
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	266
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	2,725
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	4,614
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	266
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	2,725
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	4,614
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	266
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	2,725
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	246



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	225
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	25,233
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	757



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	25,233
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	757
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	25,233
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	757
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	25,233
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	757
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	517
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	675
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	517
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	675
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	517
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	675



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	517
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	675
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,307
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	2,277
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	293
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,307
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,277
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	293
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,307
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,277
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	293



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,307
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2,277
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	293
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	10,993
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	10,993
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	10,993
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	10,993
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	115
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	530,767
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	425
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	398
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male,	4



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	199
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	289
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	801
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	77
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	386
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	402
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	535
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	53
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	405
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,614
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	837
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	46
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	112
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female,	8



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	279
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	287
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	397
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	346
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	24
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,174
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,040
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3,045
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	118
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,471



	·	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	53
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	10,009
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	383
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	4,032
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	153
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,840
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	68
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	2,120
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	81
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	936
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	5,968
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	74
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	28,513
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	484
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	54,183
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	929
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	208
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	157



HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	601
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	64
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	377
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,706
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	203
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,286
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	149
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	880
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	910
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	67
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	682
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	37
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	5,016
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Positive	60



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	4,422
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Positive	54
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	10,791
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Positive	466
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Negative	5,366
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Positive	231
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	25,443
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	312
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	3,988
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Positive	49
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	35,411
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Positive	1,532
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Negative	14,210
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Positive	614
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	16,667
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Positive	724
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	14,211



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Positive	616
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	16,667
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Positive	724
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	14,211
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Positive	616
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	16,667
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Positive	724
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	14,211
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Positive	616
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	16,667
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Positive	724
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	14,211
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Positive	616
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	6,310
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Positive	270
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	7,384
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Positive	319



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	4,716
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	186
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	4,011
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	161
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	4,716
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	186
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	4,011
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	161
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	4,716
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	186
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	4,011
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	161
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	4,716
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	186
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	4,011
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	161
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	620



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	58
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	730
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	620
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	58
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	730
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	59
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	620
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	58
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	730
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	59
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	620
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	58
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	730
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	59
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	19,203
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	326



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	19,203
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	326
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	19,203
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	326
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	19,203
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	326
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	330
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	541
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	35
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	330
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	541
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	330
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	541



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	35
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	330
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	541
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	35
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	1,747
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	122
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	2,569
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	140
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	1,747
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	122
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	2,569
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	140
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	1,747
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	122
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	2,569
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	140



HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	1,747
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	122
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	2,569
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	140
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,366
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	8,366
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	529
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,120
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	562
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,155
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	549
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,235
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	565
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases,	3,017



	1	
	during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,596
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	5,596
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	327
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	371
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,255
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,646
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	354
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,599
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	351
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,269
GEND_GBV_DSD	Number of people receiving post-GBV care	1,882
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	759
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,085
GEND_GBV_DSD	By PEP service provision (related to sexual violence	868



	services provided)	
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	37
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	73
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	37
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	37
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	80
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	192
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	17
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	149
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	188
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	222
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	265
05115 051/ 505	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	_,
GEND_GBV_DSD	25-29, Female, Physical and/or Emotional Violence	74
OEND ODV DOD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	444
GEND_GBV_DSD	25-29, Female, Sexual Violence (Post-Rape Care)	111
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	74
GEND_GBV_D3D	30-34, Female, Physical and/or Emotional Violence	74
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	111
OLND_ODV_DOD	30-34, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	74
	35-39, Female, Physical and/or Emotional Violence	• • •
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	111
	35-39, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_TA	Number of people receiving post-GBV care	644
GEND GBV TA	By type of service: Physical and/or Emotional Violence	233
	(Other Post-GBV Care)	
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	346
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	267
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	13
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	19



GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	11
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	23
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	59
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	7
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	46
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	54
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	65
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	72
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	23
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	23
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	23
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	27
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,557
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	42
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	795
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	37



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	642
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	696
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	318
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	305
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,957
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	6,372
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,585
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,957
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,589



	T T	
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,868
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	721
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,589
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	90,516
TX_CURR_DSD	Age/Sex: 15-19 Male	347
TX_CURR_DSD	Age/Sex: 15-19 Female	3,434
TX_CURR_DSD	Sum of age/sex disaggregates	3,781
TX_CURR_DSD	Age/Sex: <1	703
TX_CURR_DSD	Age/Sex: <1-9	4,761
TX_CURR_DSD	Age/Sex: 10-14 Male	460
TX_CURR_DSD	Age/Sex: 10-14 Female	391
TX_CURR_DSD	Age/Sex: 20-24 Male	1,910
TX_CURR_DSD	Age/Sex: 50+ Male	4,118
TX_CURR_DSD	Age/Sex: 20-24 Female	10,707
TX_CURR_DSD	Age/Sex: 50+ Female	4,897
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	9,599
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	5,030
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	9,598
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,030
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	9,610
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5,027
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	9,610
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	5,023



	Positive	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	39,662
TX_CURR_TA	Age/Sex: 15-19 Male	279
TX_CURR_TA	Age/Sex: 15-19 Female	1,783
TX_CURR_TA	Sum of Age/Sex disaggregations	2,062
TX_CURR_TA	Age/Sex: <1	536
TX_CURR_TA	Age/Sex: 1-9	2,492
TX_CURR_TA	Age/Sex: 10-14 Male	165
TX_CURR_TA	Age/Sex: 10-14 Female	267
TX_CURR_TA	Age/Sex: 20-24 Male	1,089
TX_CURR_TA	Age/Sex: 50+ Male	1,658
TX_CURR_TA	Age/Sex: 20-24 Female	4,837
TX_CURR_TA	Age/Sex: 50+ Female	1,644
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	3,950
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	2,244
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	3,919
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2,285
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	3,949
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	2,260
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	3,965
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	2,268
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	27,775
TX_NEW_DSD	By Age/Sex: <1	520



TX_NEW_DSD	By Age/Sex: 1-9	1,455
TX_NEW_DSD	By Age/Sex: 10-14 Male	127
TX_NEW_DSD	By Age/Sex: 15-19 Male	186
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,066
TX_NEW_DSD	By Age/Sex: 50+ Male	850
TX_NEW_DSD	By Age/Sex: 10-14 Female	84
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,642
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,442
TX_NEW_DSD	By Age/Sex: 50+ Female	796
TX_NEW_DSD	Sum of Age/Sex disaggregates	9,193
TX_NEW_DSD	Pregnancy status	6,010
TX_NEW_DSD	Breastfeeding status	516
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,314
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,842
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,315
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,842
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,315
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,838
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,307
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,832
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	16,807
TX_NEW_TA	By Age/Sex: <1	174
TX_NEW_TA	By Age/Sex: 1-9	586
TX_NEW_TA	By Age/Sex: 10-14 Male	54



TX_NEW_TA	By Age/Sex: 15-19 Male	213
TX_NEW_TA	By Age/Sex: 20-24 Male	958
TX_NEW_TA	By Age/Sex: 50+ Male	486
TX_NEW_TA	By Age/Sex: 10-14 Female	75
TX_NEW_TA	By Age/Sex: 15-19 Female	1,091
TX_NEW_TA	By Age/Sex: 20-24 Female	2,425
TX_NEW_TA	By Age/Sex: 50+ Female	640
TX_NEW_TA	Sum of Age/Sex disaggregates	5,942
TX_NEW_TA	Pregnancy status	3,932
TX_NEW_TA	Breastfeeding status	218
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,475
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,056
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,478
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1,058
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,478
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,058
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,476
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,055
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	57,581
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	2,609
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	1,822
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	33,386
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	19,765



TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	23,766
TX_PVLS_TA	<15, Undocumented Test Indication, Female	1,148
TX_PVLS_TA	<15, Undocumented Test Indication, Male	607
TX_PVLS_TA	15+, Undocumented Test Indication, Female	14,871
TX_PVLS_TA	15+, Undocumented Test Indication, Male	7,140
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,702
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	17,457
TX_RET_DSD	Numerator by Status: Pregnant	3,440
TX_RET_DSD	Numerator by Status: Breastfeeding	1,163
TX_RET_DSD	Denominator by Status: Pregnant	3,999
TX_RET_DSD	Denominator by Status: Breastfeeding	1,214
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	170
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,528
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	346
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,635
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	198



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,549
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	382
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,306
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,164
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,513
TX_RET_TA	Numerator by Status: Pregnant	755
TX_RET_TA	Numerator by Status: Breastfeeding	221
TX_RET_TA	Denominator by Status: Pregnant	855
TX_RET_TA	Denominator by Status: Breastfeeding	237
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	938
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	103
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number	2,061



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	55
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,093
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	108
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,239
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	17,604
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	23,467
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	603
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	551



	•	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	14,146
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	8,165
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	446
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	393
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	10,805
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	5,963
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,695
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	18,773
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,521
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	14,083
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	11,956
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	15,938
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	414
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	375
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	9,605
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	5,544
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	305
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	265
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	7,338
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	4,049
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT,	3,188



	Life-long ART, Already, Positive	
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	12,753
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,394
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	9,562
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	90,515
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,888
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,601
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	47,338
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	36,489
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,041
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	4,041
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	61,535
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	7,227
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	19,898
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,796
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	39,667
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	974
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,107
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	17,424
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	18,689
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic	443



	diagnosis of active TB disease	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	443
TX_TB_TA	TX TB D TA TBScreen NewExistingART HIV	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	3,163
TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive		8,720
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	784

Implementing Mechanism Details

Mechanism ID: 13654	Mechanism Name: UCM	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Catholic University of Mozambique		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID:	13654	
Mechanism Name: UCM		
Prime Partner Name:	Catholic University of Mozambique	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13661	Mechanism Name: CISM - Manhica Research Center - Follow On	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Barcelona Centre for Internation	nal Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 300,000	
Funding Source	Funding Amount	
GHP-State	300,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

	e: CISM - Manhica Research Center - Follow On		
Strategic Area	Barcelona Centre for Internation Budget Code	Planned Amount	
Care	НВНС	150,000	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13668	Mechanism Name: ARIEL	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Fundacao ARIEL Contra a SIDA Pediatrica		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 24,300,001	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 24,300,001		
Funding Source Funding Amount		
GHP-State	24,300,001	

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	150,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	280,400
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Motor Vehicles: Purchased	100,000
Human Resources for Health	6,083,356
Condom programming	200,000
Food and Nutrition: Policy, Tools, and Service Delivery	220,000
Renovation	427,851
Adolescent Girls and Young Women (AGYW)	200,000

Budget Code Information

Budget Code Information			
Mechanism ID:	13668		
Mechanism Name:	ARIEL		
Prime Partner Name:	Fundacao ARIEL Contra a SIDA	Pediatrica	
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	2,540,345	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	1,616,583	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	461,881	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	2,771,285
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	200,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	1,005,960
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	13,394,542
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	2,309,405

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	17,528
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,992
PMTCT_ART_DSD	New on ART	9,241
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8,287
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,611
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,025
PMTCT_ART_TA	New on ART	932
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	679
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,992
PMTCT_STAT_DSD	Number of new ANC and L&D clients	136,135
PMTCT_STAT_DSD	By Age (Denominator): 10-14	1,014
PMTCT_STAT_DSD	By Age (Denominator): <15-19	25,189
PMTCT_STAT_DSD	By Age (Denominator): 20-24	29,802



PMTCT_STAT_DSD	By Age (Denominator): 50+	70
PMTCT_STAT_DSD	By Number of known positives: 10-14	1
PMTCT_STAT_DSD	By Number of known positives: 15-19	317
PMTCT_STAT_DSD	By Number of known positives: 20-24	863
PMTCT_STAT_DSD	By Number of known positives: 50+	31
PMTCT_STAT_DSD	By Number of new positives: 10-14	105
PMTCT_STAT_DSD	By Number of new positives: 15-19	639
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,502
PMTCT_STAT_DSD	By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Number of new negative: <10	2
PMTCT_STAT_DSD	By Number of new negative: 10-14	2,021
PMTCT_STAT_DSD	By Number of new negative: 15-19	31,982
PMTCT_STAT_DSD	By Number of new negative: 20-24	32,655
PMTCT_STAT_DSD	By Number of new negative: 50+	50
PMTCT_STAT_DSD	By Age (Numerator): <10	2
PMTCT_STAT_DSD	By Age (Numerator): 10-14	2,181
PMTCT_STAT_DSD	By Age (Numerator): 15-19	33,404
PMTCT_STAT_DSD	By Age (Numerator): 20-24	35,178
PMTCT_STAT_DSD	By Age (Numerator): 50+	83
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	25,683
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	18,892
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	17,675
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	17,810
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,021
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	55,295
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	2,004
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	820
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	644



	30-34, Female, Newly Identified Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	806
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	645
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	801
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	643
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	58,480
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,492
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,012
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,004
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,025
PMTCT_STAT_TA	Number of new ANC and L&D clients	39,988
PMTCT_STAT_TA	By Age (Denominator): 10-14	594
PMTCT_STAT_TA	By Age (Denominator): 15-19	6,539
PMTCT_STAT_TA	By Age (Denominator): 20-24	7,652
PMTCT_STAT_TA	By Age (Denominator): 50+	2
PMTCT_STAT_TA	By known positives: 10-14	21
PMTCT_STAT_TA	By known positives: 15-19	76
PMTCT_STAT_TA	By known positives: 20-24	262
PMTCT_STAT_TA	By new positives: 15-19	192
PMTCT_STAT_TA	By new positives: 20-24	442
PMTCT_STAT_TA	By new negatives: 10-14	519
PMTCT_STAT_TA	By new negatives: 15-19	7,550
PMTCT_STAT_TA	By new negatives: 20-24	8,560
PMTCT_STAT_TA	By new negatives: 50+	1
PMTCT_STAT_TA	By Age (Numerator): 10-14	616
PMTCT_STAT_TA	By Age (Numerator): : 15-19	7,943
PMTCT_STAT_TA	By Age (Numerator): 20-24	9,315



PMTCT_STAT_TA	By Age (Numerator): 50+	1
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	6,540
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	6,106
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	6,281
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	6,274
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	231
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	7,961
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	646
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	230
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,627
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	193
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	228
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,568
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	194
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	228
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,540
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	193
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	8,843
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	3,062
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	2,857
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	2,827



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,305,153
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,420
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,328
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	256
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	754
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	139
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	384
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,149
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	225
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	779
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male,	152



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,348
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	12,025
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,740
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	213
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	418
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	265
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	632
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	661
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	5,204
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	51



	_	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	4,568
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	5,647
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	435
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,004
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	15,109
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1,008
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,926
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	239
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	5,606
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	358
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,989
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	276
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	4,128
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	26,331
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	289
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,158



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	900
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,501
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	973
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,198
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	467
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,778
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1,081
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,420
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	553
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2,942
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	1,144
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2,766
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1,076
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	140
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	1



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	3,254
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	19,162
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	1,632
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	34,279
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	3,179
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,524
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,887
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	10,311
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1,216
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,092
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	231
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	25,987
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	3,139
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	8,487
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	990



-		
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	12,611
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1,472
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	10,804
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1,259
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	861
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	8,239
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	193
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	18,143
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	192
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	22,840
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	255
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	20,117
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	223
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	20,459
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	1,214
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	3,988
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	226
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	115,820



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	1,270
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	58,826
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	3,509
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	15,428
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	881
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	43,438
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	2,629
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	30,408
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	1,820
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	43,438
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	2,629
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	30,408
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	1,820
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	43,438
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	2,629
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	30,408
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1,820



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	43,232
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	2,629
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	30,161
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	1,816
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	23,272
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	1,368
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	16,170
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	950
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	11,449
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	809
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	8,399
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	656
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	11,449
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	809
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	8,399
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	656
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	11,449



HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	809
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	8,399
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	656
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	11,194
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	796
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	8,399
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	656
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,010
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	213
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	743
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	157
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,010
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	213
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	743
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	157
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,010
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	213
	Female, Positive HTS_TST_N_DSD_Index_Age_Sex_Result 35-39,



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	743
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,010
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	213
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	743
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	3,674
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1,428
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	4,191
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1,630
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	3,674
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1,428
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	4,191
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1,630
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	3,674
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1,428
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	4,191



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1,630
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	3,674
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1,428
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	4,191
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1,630
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	14,168
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	14,168
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	14,168
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	1,329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	14,168
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,329
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	615
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	855
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	52



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	615
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	855
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	615
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	855
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	615
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	855
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	23,239
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	2,820
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	17,310
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	2,097
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	23,239



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	2,820
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	17,310
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	2,097
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	23,239
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	2,820
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	17,310
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	2,097
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	23,239
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	2,820
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	17,310
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	2,097
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	71,425
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	28
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	26
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24,	52



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	16
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	241
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	190
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	179
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	105
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	85
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female,	174



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	153
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	130
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	217
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	138
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	158
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	123
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	139
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	888
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	7,078
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	176
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	11,071
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	302



HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	75
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	56
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	168
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	83
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	296
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	102
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	112
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	153
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	26



HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	247
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	5
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	1,212
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Positive	14
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	1,070
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	529
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Positive	22
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Negative	83
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	6,161
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	82
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	962
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Positive	12
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	1,630
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Positive	68
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Negative	695
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Positive	28



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	1,134
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	1,199
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Positive	51
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	1,134
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	1,199
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Positive	51
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	1,134
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	1,199
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Positive	51
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	1,134
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	1,199
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Positive	51
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	649



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	507
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Positive	21
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	200
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	193
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	200
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	193
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	200
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	193
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	200
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	3



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	193
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	35
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	35
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	35
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	35



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,796
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	136
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,796
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	136
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,796
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	136
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,796
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	136
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	106
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	106
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	106



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	106
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	260
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	346
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	260
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	346
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	260
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	O
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	346
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	260



HTC_TST_TA HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive HTC_TST_TA HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative HTC_TST_TA HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period. Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)			
HTC_TST_TA HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative HTC_TST_TA HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period. Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	HTC_TST_TA		9
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. Total number of registered new and relapsed TB cases, during the reporting period. Total number of registered new and relapsed TB cases, during the reporting period. Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male,	346
TB_STAT_DSD documented HIV status, during the reporting period. TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period. Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, 5,992 during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, 5,992 during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, 5,992 during the reporting period)	HTC_TST_TA	_	14
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, 497	TB_STAT_DSD	_	11,496
TB_STAT_DSD registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, 497	TB_STAT_DSD		11,496
TB_STAT_DSD registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, 497	TB_STAT_DSD	registered new and relapsed TB cases with	575
TB_STAT_DSD of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, 497	TB_STAT_DSD	registered new and relapsed TB cases with	5,824
TB_STAT_DSD of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, 497	TB_STAT_DSD	of registered new and relapsed TB cases with	438
TB_STAT_DSD number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, 497	TB_STAT_DSD	of registered new and relapsed TB cases with	4,627
TB_STAT_DSD number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, 497	TB_STAT_DSD	number of registered new and relapsed TB cases,	574
TB_STAT_DSD number of registered new and relapsed TB cases, 497	TB_STAT_DSD	number of registered new and relapsed TB cases,	5,992
	TB_STAT_DSD	number of registered new and relapsed TB cases,	497
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, 4,424	TB_STAT_DSD	number of registered new and relapsed TB cases,	4,424
TB_STAT_TA Number of registered new and relapsed TB cases with 1,147	TB_STAT_TA	Number of registered new and relapsed TB cases with	1,147



	documented HIV status, during the reporting period.	
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,147
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	38
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	63
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	445
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	599
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	65
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	586
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	454
GEND_GBV_DSD	Number of people receiving post-GBV care	2,959
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,204
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,732
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,395
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	53



GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	114
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	40
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	53
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	123
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	271
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	29
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	230
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	294
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	351
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	391
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	120
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	167
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	113
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	166
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	117
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	166
GEND_GBV_TA	Number of people receiving post-GBV care	827
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	337
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	488
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	393
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	14
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	35
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	15
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	15



GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	34
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	83
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	9
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	69
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	84
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	95
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	114
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	30
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	50
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	30
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	49
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	30
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	50
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,438
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	134
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,598
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	90



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,388
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	191
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	105
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	75
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	17,532
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	14,019
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,513
PMTCT_EID_DSD	Sum of Infant Age disaggregates	17,532
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,614
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,296



	<u></u>	
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	318
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,614
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	284,561
TX_CURR_DSD	Age/Sex: 15-19 Male	1,409
TX_CURR_DSD	Age/Sex: 15-19 Female	7,073
TX_CURR_DSD	Sum of age/sex disaggregates	8,482
TX_CURR_DSD	Age/Sex: <1	705
TX_CURR_DSD	Age/Sex: <1-9	13,073
TX_CURR_DSD	Age/Sex: 10-14 Male	2,643
TX_CURR_DSD	Age/Sex: 10-14 Female	2,884
TX_CURR_DSD	Age/Sex: 20-24 Male	2,699
TX_CURR_DSD	Age/Sex: 50+ Male	15,860
TX_CURR_DSD	Age/Sex: 20-24 Female	21,270
TX_CURR_DSD	Age/Sex: 50+ Female	24,384
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	34,068
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	14,040
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	34,026
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	14,051
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	34,050
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	14,037
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	34,036
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	14,042
TX_CURR_TA	Number of adults and children receiving antiretroviral	9,984



	therapy (ART)	
TX_CURR_TA	Age/Sex: 15-19 Male	29
TX_CURR_TA	Age/Sex: 15-19 Female	344
TX_CURR_TA	Sum of Age/Sex disaggregations	373
TX_CURR_TA	Age/Sex: <1	105
TX_CURR_TA	Age/Sex: 1-9	731
TX_CURR_TA	Age/Sex: 10-14 Male	49
TX_CURR_TA	Age/Sex: 10-14 Female	80
TX_CURR_TA	Age/Sex: 20-24 Male	158
TX_CURR_TA	Age/Sex: 50+ Male	436
TX_CURR_TA	Age/Sex: 20-24 Female	1,045
TX_CURR_TA	Age/Sex: 50+ Female	528
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,094
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	510
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,094
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	511
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,090
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	516
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,094
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	512
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	103,920
TX_NEW_DSD	By Age/Sex: <1	684
TX_NEW_DSD	By Age/Sex: 1-9	2,095
TX_NEW_DSD	By Age/Sex: 10-14 Male	291



TX_NEW_DSD	By Age/Sex: 15-19 Male	570
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,186
TX_NEW_DSD	By Age/Sex: 50+ Male	4,604
TX_NEW_DSD	By Age/Sex: 10-14 Female	361
TX_NEW_DSD	By Age/Sex: 15-19 Female	4,991
TX_NEW_DSD	By Age/Sex: 20-24 Female	12,787
TX_NEW_DSD	By Age/Sex: 50+ Female	6,395
TX_NEW_DSD	Sum of Age/Sex disaggregates	32,185
TX_NEW_DSD	Pregnancy status	15,982
TX_NEW_DSD	Breastfeeding status	2,131
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	10,824
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	6,435
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	10,823
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6,438
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	10,822
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	6,437
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	10,821
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,436
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,710
TX_NEW_TA	By Age/Sex: <1	30
TX_NEW_TA	By Age/Sex: 1-9	121
TX_NEW_TA	By Age/Sex: 10-14 Male	12
TX_NEW_TA	By Age/Sex: 15-19 Male	1
TX_NEW_TA	By Age/Sex: 20-24 Male	48



TX_NEW_TA	By Age/Sex: 50+ Male	56
TX_NEW_TA	By Age/Sex: 10-14 Female	22
TX_NEW_TA	By Age/Sex: 15-19 Female	83
TX_NEW_TA	By Age/Sex: 20-24 Female	224
TX_NEW_TA	By Age/Sex: 50+ Female	63
TX_NEW_TA	Sum of Age/Sex disaggregates	509
TX_NEW_TA	Pregnancy status	312
TX_NEW_TA	Breastfeeding status	34
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	149
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	110
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	150
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	111
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	150
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	109
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	146
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	104
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	175,792
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	7,773
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	3,037
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	119,195
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	45,787
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	6,753



	and /or laboratory records in the past 12 months.	
TX_PVLS_TA	<15, Undocumented Test Indication, Female	300
TX_PVLS_TA	<15, Undocumented Test Indication, Male	127
TX_PVLS_TA	15+, Undocumented Test Indication, Female	4,467
TX_PVLS_TA	15+, Undocumented Test Indication, Male	1,859
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	56,561
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	62,912
TX_RET_DSD	Numerator by Status: Pregnant	8,763
TX_RET_DSD	Numerator by Status: Breastfeeding	4,115
TX_RET_DSD	Denominator by Status: Pregnant	9,482
TX_RET_DSD	Denominator by Status: Breastfeeding	4,140
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	378
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,941
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	863
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	39,243
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	452
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	18,435



	12 months prior to the beginning of the reporting period,	
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	955
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	42,945
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
TV DET T4	Number of adults and children who are still alive and on	4 000
TX_RET_TA	treatment at 12 months after initiating ART	1,636
	Total number of adults and children who initiated ART	
	in the 12 months prior to the beginning of the reporting	
TX_RET_TA	period, including those who have died, those who have	1,813
	stopped ART, and those lost to follow-up	
TX_RET_TA	Numerator by Status: Pregnant	221
TX_RET_TA	Numerator by Status: Breastfeeding	120
TX_RET_TA	Denominator by Status: Pregnant	282
TX_RET_TA	Denominator by Status: Breastfeeding	111
	Aggregated Age/Sex: <15 Male (Numerator: Number of	
TX_RET_TA	adults and children who are still alive and on treatment	9
	at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of	
TX_RET_TA	adults and children who are still alive and on treatment	482
	at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	22
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	1,103
_	treatment at 12 months after initiating ART)	



TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	568
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,196
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	66,225
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	88,278
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,283
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2,073
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	53,211
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	30,720



TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,698
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,467
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	40,647
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	22,424
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	17,651
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	70,596
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	13,239
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	52,986
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,154
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,531
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	38
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	33
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	923
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	532
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	37
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	18
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	707
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	392
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	306
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT,	1,222



	Life-long ART, New, Positive	
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	233
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	921
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	284,561
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	11,153
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	10,136
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	189,279
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	72,505
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,874
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	63
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,811
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	193,431
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	22,686
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	62,529
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	5,622
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	9,988
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	396
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	368
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	6,458
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	2,675
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic	226



	diagnosis of active TB disease	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	121
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	105
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	6,775
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	783
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,179
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	183

Implementing Mechanism Details

mpromorphism 2 dame		
Mechanism ID: 13776	Mechanism Name: CCS	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Center for Collaboration in Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 8,250,004	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0	Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeli	ine Amount: 8,250,004		
Funding Source	Funding Amount		
GHP-State	8,250,004		

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach
	workers



Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions
	for SWs consistent with PEPFAR guidance on
	sexual prevention
Gender: GBV	252,520
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Human Resources for Health	2,338,680
Motor Vehicles: Purchased	100,000
Food and Nutrition: Policy, Tools, and Service	186,000
Delivery	
Renovation	1,739,530
Condom programming	150,000

Budget Code Information

Baagot Ocac IIII of III ation		
Mechanism ID:	13776	
Mechanism Name:	ccs	
Prime Partner Name:	Center for Collaboration in Heal	th
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,011,905
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,011,904
Strategic Area	Budget Code	Planned Amount
Care	PDCS	233,516



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	778,386
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	466,134
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,969,773
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	778,386

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	6,643
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,990
PMTCT_ART_DSD	New on ART	3,354
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,289
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	37,990
PMTCT_STAT_DSD	Number of new ANC and L&D clients	39,023
PMTCT_STAT_DSD	By Age (Denominator): 10-14	80
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,616
PMTCT_STAT_DSD	By Age (Denominator): 20-24	9,279
PMTCT_STAT_DSD	By Number of known positives: 15-19	46
PMTCT_STAT_DSD	By Number of known positives: 20-24	186
PMTCT_STAT_DSD	By Number of new positives: 15-19	117
PMTCT_STAT_DSD	By Number of new positives: 20-24	311
PMTCT_STAT_DSD	By Number of new negative: 10-14	98
PMTCT_STAT_DSD	By Number of new negative: 15-19	8,415



PMTCT_STAT_DSD	By Number of new negative: 20-24	10,760
PMTCT_STAT_DSD	By Age (Numerator): 10-14	99
PMTCT_STAT_DSD	By Age (Numerator): 15-19	8,654
PMTCT_STAT_DSD	By Age (Numerator): 20-24	11,285
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	5,725
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	6,192
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	6,059
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	6,072
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	214
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	16,439
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	513
PMTCT_STAT_DSD	PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	78
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	214
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	205
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	79
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	17,206
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	296
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	215
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	206
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	149,054



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	225
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	228
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,028
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,473
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	241
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	436
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	619
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	542
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male,	17



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	457
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	999
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	89
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	534
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	374
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	283
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	487
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	3,138
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,461
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	369
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	9,760
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,038



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,329
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	990
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,161
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	159
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	413
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,376
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	322
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,055
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	968
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	133
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	911
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	125



HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	450
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	4,329
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	205
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	2,504
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	3,150
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	2,774
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	1,858
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	153
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	751
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	15,968
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	4,029
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	328
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	2,201
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	178
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	2,893
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	2,055



	_ ,	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	2,893
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	2,055
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	2,893
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	2,055
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	2,893
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	2,055
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	1,545
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	1,139
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	91



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	727
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	530
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	727
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	530
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	727
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	530
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	727
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	530
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	65



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,423
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	472



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,423
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	472
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,423
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	472
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,423
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	472
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	389
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	621
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	389
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	621
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	389
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	621



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	389
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	621
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	2,222
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,450
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	2,222
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,450
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,222
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,450
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	200



	_	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	2,222
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	303
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,450
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	200
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7,821
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	7,821
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	250
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,244
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	187
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,140
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	276
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,263
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	221
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases,	3,067



	during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	4,051
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,661
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,389
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,910
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	77
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	163
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	77
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	78
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	163
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	403
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	40
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	323
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	403
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	484
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	566
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	163
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	243
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	163
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	243
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	163
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	243
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	2,594



	during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	76
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,327
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	53
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,059
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,714
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,368
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,346
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,714
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	157,897
TX_CURR_DSD	Age/Sex: 15-19 Male	920
TX_CURR_DSD	Age/Sex: 15-19 Female	2,803
TX_CURR_DSD	Sum of age/sex disaggregates	3,723
TX_CURR_DSD	Age/Sex: <1	132
TX_CURR_DSD	Age/Sex: <1-9	3,723
TX_CURR_DSD	Age/Sex: 10-14 Male	1,823
TX_CURR_DSD	Age/Sex: 10-14 Female	1,910
TX_CURR_DSD	Age/Sex: 20-24 Male	1,134



TX_CURR_DSD	Age/Sex: 50+ Male	9,392
TX_CURR_DSD	Age/Sex: 20-24 Female	9,621
TX_CURR_DSD	Age/Sex: 50+ Female	13,721
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	20,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	8,129
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	20,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	8,129
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	20,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	8,129
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	20,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	8,128
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,928
TX_NEW_DSD	By Age/Sex: <1	260
TX_NEW_DSD	By Age/Sex: 1-9	740
TX_NEW_DSD	By Age/Sex: 10-14 Male	192
TX_NEW_DSD	By Age/Sex: 15-19 Male	108
TX_NEW_DSD	By Age/Sex: 20-24 Male	258
TX_NEW_DSD	By Age/Sex: 50+ Male	692
TX_NEW_DSD	By Age/Sex: 10-14 Female	212
TX_NEW_DSD	By Age/Sex: 15-19 Female	542
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,662
TX_NEW_DSD	By Age/Sex: 50+ Female	736
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,402
TX_NEW_DSD	Pregnancy status	1,740



TX_NEW_DSD	Breastfeeding status	50
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,567
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,072
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,567
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,072
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,566
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,072
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,568
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,070
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	110,745
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	2,823
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	1,492
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	71,618
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	34,812
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,985
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	16,701
TX_RET_DSD	Numerator by Status: Pregnant	528
TX_RET_DSD	Numerator by Status: Breastfeeding	1,001
TX_RET_DSD	Denominator by Status: Pregnant	463
TX_RET_DSD	Denominator by Status: Breastfeeding	1,313



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	245
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,085
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	570
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,060
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	276
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,662
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	637
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,100
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	10,160



	period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	13,543
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	348
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	318
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	8,160
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,714
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	261
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	226
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	6,235
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,438
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,709
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,835
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,033
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	8,127
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	157,897
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	5,017
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	4,511
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	101,855
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	42,679
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,486
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	1,486



	Specimen Sent]: Smear Only	
TX_TB_D_DSD_TBScreen_NewExistingART_HI Life-long ART, Already, TB Screen - Negative, Posi		107,356
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	12,618
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	34,723
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	3,145

Implementing Mechanism Details

Mechanism ID: 13784	Mechanism Name: INS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Instituto Nacional de Saúde	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 639,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 1,753,000		
Total All Funding Sources and Applied Pipeline Amount: 2,392,000		
Funding Source Funding Amount		
GHP-State	639,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

agot ocao inicimation	
Mechanism ID:	13784



Mechanism Name:	INS	
Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	319,500
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	319,500
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 14597	Mechanism Name: DevResults
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: DevResults	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Budget Code information		
Mechanism ID:	14597	
Mechanism Name:	DevResults	
Prime Partner Name:	DevResults	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	O
Strategic Area	Budget Code	Planned Amount
Care	HKID	О
Strategic Area	Budget Code	Planned Amount
Care	HVTB	o
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	o	

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14598	Mechanism Name: Health Policy Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Daaget Coac information		
Mechanism ID:	14598	
Mechanism Name:	Health Policy Project	
Prime Partner Name:	Futures Group	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 14639	Mechanism Name: Learning Capacity Development Task Order 1	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: EUROSIS - Cosultoria e Formacao em Gestao, Lda		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
D: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		



Funding Source	Funding Amount

(No data provided.)

Budget Code Information		
Mechanism ID: 14639		
Mechanism Name:	Learning Capacity Development Task Order 1	
Prime Partner Name:	EUROSIS - Cosultoria e Formacao em Gestao, Lda	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing meenament betails		
Mechanism ID: 14644	Mechanism Name: Design and Build of Nampula Regional Pharmaceutical Warehouse	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Resolve Solution Partners (PTY), Ltd		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name:	Design and Build of Nampula Regional Pharmaceutical Warehouse	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 14647	Mechanism Name: Construction of Rural Health Centers - 5 in Zambezia	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: ASNA Construções & Engenharia		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information		
Mechanism ID: 14647		
Mechanism Name:	Construction of Rural Health Centers - 5 in Zambezia	
Prime Partner Name:	ASNA Construções & Engenharia	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14650	TBD: Yes
REDA	ACTED

Implementing Mechanism Details

Mechanism ID: 14652	Mechanism Name: Health Management Twinning	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Columbia University Mailman School of Public Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

budget code information		
Mechanism ID:	14652	
Mechanism Name:	Health Management Twinning	
Prime Partner Name:	Columbia University Mailman School of Public Health	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 14670	Mechanism Name: Strengthening Health and Social Service System	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Foundation for Community Development, Mozambique		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
------------------------------	-------------------------------



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Mechanism ID:	14670		
Mechanism Name:	Mechanism Name: Strengthening Health and Social Service System		
Prime Partner Name:	Foundation for Community Dev	elopment, Mozambique	
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing Mechanism Details		
	Mechanism Name: Accelerating Strategies for	
Mechanism ID: 14732	Practical Innovation & Research in Economic	
	Strengthening (ASPIRES)	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	Accelerating Strategies for Practical Innovation & Research in Fconomic Strengthening (ASPIRES)	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 14739	Mechanism Name: Strengthen Family and Community Support to Orphan and Vunerable Children (FORCA Project)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: World Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 7,619,318	Total Mechanism Pipeline: N/A		
	Total moonanen i ipomor i i//		
Applied Pipeline Amount: 20,469			
Total All Funding Sources and Applied Pipeline Amount: 7,639,787			
Funding Source	Funding Amount		
GHP-State	7,619,318		

Food and Nutrition: Policy, Tools, and Service	155,000
Delivery	
Human Resources for Health	679,715
Water	55,953
Adolescent Girls and Young Women (AGYW)	2,820,277
Economic Strengthening	2,446,316
Education	2,183,423

Mechanism ID: Mechanism Name: Prime Partner Name:	Strengthen Family and Community Support to Orphan and Vunerable Children (FORCA Project)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	4,799,041
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	1,030,655
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,789,622
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	32,977
PP_PREV_DSD	Age/sex: 10-14 Female	12,106
PP_PREV_DSD	Age/sex: 15-19 Female	15,549
PP_PREV_DSD	Age/sex: 20-24 Female	5,323
PP_PREV_DSD	Sum of Age/Sex disaggregates	32,978
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	132,127
OVC_SERV_DSD	Age/Sex: 10-14 Male	16,481
OVC_SERV_DSD	Age/Sex: 15-17 Male	12,274
OVC_SERV_DSD	By: Age/sex: Male 18-24	6,532
OVC_SERV_DSD	By: Age/sex: Male 25+	3,763
OVC_SERV_DSD	Age/Sex: 10-14 Female	22,896
OVC_SERV_DSD	Age/Sex: 15-17 Female	18,335
OVC_SERV_DSD	By: Age/sex: 18-24 Female	6,530
OVC_SERV_DSD	By: Age/sex: 25+ Female	9,603



OVC_SERV_DSD	Sum of Age/Sex disaggregates	69,986
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	17,778
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	14,564
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	3,487
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	18
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	4,575
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	3,111
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	28,927
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	7,488
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	5,399
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	17,816
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	13,949
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	10,740
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,160
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,010
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	2,260
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	1,931
OVC_SERV_DSD	Age/Sex: <1	3,915



OVC_SERV_DSD	Age/Sex: 1-9	31,794
OVC_SERV_DSD	Program Completion: Active	94,526
OVC_SERV_DSD	Program Completion: Graduation	37,601
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	105,700
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	132,127

Implementing Mechanism Details

Mechanism ID: 14748	Mechanism Name: UNICEF MCH Umbrella Grant	
Funding Agency: USAID	Procurement Type: Grant	
Prime Partner Name: United Nations Children's Fund		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 500,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	line Amount: 500,000	
Funding Source	Funding Amount	
GHP-State	500,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

get oode iiiioiiiiatioii	
Mechanism ID:	14748



Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	500,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14789	Mechanism Name: EGPAF	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Elizabeth Glaser Pediatric AID	S Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 20,965,858	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 20,965,858			
Funding Source	Funding Amount		
GHP-State	20,965,858		

Cross-Cutting Budget Attribution(s)

Gender: GBV	256,620
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Key Populations: FSW	10,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	10,000
Motor Vehicles: Purchased	100,000
Human Resources for Health	5,613,760
Food and Nutrition: Policy, Tools, and Service Delivery	191,000
Adolescent Girls and Young Women (AGYW)	542,064
Condom programming	200,000
Renovation	507,967

Budget Code Information

Mechanism ID:	14789	
Mechanism Name:	EGPAF	
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	1,825,894
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,130,359
Strategic Area	Budget Code	Planned Amount
Care	PDCS	730,359
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	2,191,074



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	542,064
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,764,849
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	10,955,365
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,825,894

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
	Number of HIV-positive pregnant women who received	
PMTCT_ART_DSD	ART to reduce risk of mother-to-child-transmission	8,764
	(MTCT) during pregnancy	
	Number of pregnant women with known HIV status	
PMTCT_ART_DSD	(includes women who were tested for HIV and received	60,915
	their results)	
PMTCT_ART_DSD	New on ART	3,651
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	5,113
	Number of HIV-positive pregnant women who received	
PMTCT_ART_TA	ART to reduce risk of mother-to-child-transmission	385
	(MTCT) during pregnancy	



PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	3,768
FWICI_ARI_IA	their results)	3,700
PMTCT_ART_TA	New on ART	172
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	213
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	60,915
PMTCT_STAT_DSD	Number of new ANC and L&D clients	63,471
PMTCT_STAT_DSD	By Age (Denominator): 10-14	187
PMTCT_STAT_DSD	By Age (Denominator): <15-19	12,572
PMTCT_STAT_DSD	By Age (Denominator): 20-24	20,643
PMTCT_STAT_DSD	By Number of known positives: 15-19	220
PMTCT_STAT_DSD	By Number of known positives: 20-24	647
PMTCT_STAT_DSD	By Number of new positives: 15-19	494
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,098
PMTCT_STAT_DSD	By Number of new negative: 10-14	226
PMTCT_STAT_DSD	By Number of new negative: 15-19	13,205
PMTCT_STAT_DSD	By Number of new negative: 20-24	14,346
PMTCT_STAT_DSD	By Age (Numerator): 10-14	229
PMTCT_STAT_DSD	By Age (Numerator): 15-19	14,287
PMTCT_STAT_DSD	By Age (Numerator): 20-24	16,221
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	7,957
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	7,749
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	7,500
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	6,863
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	431
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	26,286
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,661
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	430



	30-34, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	343
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	421
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	343
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	424
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	343
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	28,422
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	776
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	427
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	426
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,768
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,923
PMTCT_STAT_TA	By Age (Denominator): 10-14	13
PMTCT_STAT_TA	By Age (Denominator): 15-19	966
PMTCT_STAT_TA	By Age (Denominator): 20-24	1,219
PMTCT_STAT_TA	By known positives: 15-19	29
PMTCT_STAT_TA	By known positives: 20-24	68
PMTCT_STAT_TA	By new positives: 15-19	60
PMTCT_STAT_TA	By new positives: 20-24	138
PMTCT_STAT_TA	By new negatives: 10-14	12
PMTCT_STAT_TA	By new negatives: 15-19	799
PMTCT_STAT_TA	By new negatives: 20-24	988
PMTCT_STAT_TA	By Age (Numerator): 10-14	12
PMTCT_STAT_TA	By Age (Numerator): : 15-19	928
PMTCT_STAT_TA	By Age (Numerator): 20-24	1,211
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	451



PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	439
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	420
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	415
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	40
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,167
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	184
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	41
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	50
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	40
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	50
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	41
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	50
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	1,416
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	97
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	48
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	46
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	701,531
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	780
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	733



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	155
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	161
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	346
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	741
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	6,622
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	4,008
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	226
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	27



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	237
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	276
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	5,200
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	4,588
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,602
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	180
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male,	599



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	7,070
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	473
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,969
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	159
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3,984
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	272
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,090
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	222
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	4,145
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	26,136
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	353
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	2,402
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	1,868
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	6,411
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	2,494



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	3,924
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1,526
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	906
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	353
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	427
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	167
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	527
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	205
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	468
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	182
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	290
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	6,757
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	130
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	6,449
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	447
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	16,672
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,155
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	5



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	955
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	708
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	939
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	232
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,016
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	418
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,090
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,754
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	244
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	251
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	325
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	3,113
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	17,700
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	22,279
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	301
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	19,627
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	251
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	10,858
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	680
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	2,374
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	112,996
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	1,495
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	29,736
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1,825
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	8,180
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	518



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	24,392
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1,478
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	18,157
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	1,107
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	24,392
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	1,478
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	18,157
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	1,107
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	24,392
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	1,478
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	18,157
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1,107
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	24,392
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1,478
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	18,157
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	1,107
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	17,034



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	1,041
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	13,054
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	778
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	5,775
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	384
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	4,314
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	299
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	5,767
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	400
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	4,302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	5,767
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	420
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	4,302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	5,767
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	396



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	4,302
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	310
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	131



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,230
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	480
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	329
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,230
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	480
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	329
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,230
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	480
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	329
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,230
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	480
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	329



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	7,071
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	486
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	7,071
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	486
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	7,071
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	486
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	7,069
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	486
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	165



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	323
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	3,050
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	408
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	2,538
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	351
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3,050
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	408
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,538
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	351
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	3,050
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	408



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,538
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	351
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	3,050
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	408
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2,538
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	351
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	41,893
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	41
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	39
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	344
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	183
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male,	2



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	156
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	137
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	254
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	570
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	612
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	448



HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female,	28
HTC_TST_TA	Positive Service Delivery Point (Facility) Index: 50+, Male, Negative	323
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	123
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	784
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	322
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	1,002
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	42
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	23
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	161
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	25



	-	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	99
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	2
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	659
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	583
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Positive	12
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	1,058
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Positive	56
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	3,346
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	72
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	524
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Positive	10
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	2,387
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Positive	125
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Negative	2,591
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male,	131



	Positive	
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	1,815
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Positive	102
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	1,406
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Positive	85
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	1,815
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Positive	102
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	1,406
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Positive	85
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	1,815
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Positive	102
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	1,406
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Positive	85
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	1,815
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Positive	102
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	1,406
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Positive	85
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female,	1,903



	Negative	
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Positive	116
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	1,354
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Positive	85
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	432
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	336
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	432
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	336
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	432
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	336
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	23
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	432
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49,	25



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	336
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	23
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	32
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	32
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	32
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male,	32



	Negative	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	510
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	510
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	510
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	510
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male,	4



	Positive	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	128
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	128
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39,	128



	Fomela Nagativa	
HTC_TST_TA	Female, Negative HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	128
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	130
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	18
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	9,201
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	9,201
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	637
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,016
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	513
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,043
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	612



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases,	4,127
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	526
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	3,942
	during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	318
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	318
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	18
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	16
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	165
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	120
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	17
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	120
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_TA	of registered new and relapsed TB cases with	18
	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number	162



	of registered new and relapsed TB cases with	
	documented HIV status, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	10,070
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,099
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5,894
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	4,715
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	194
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	385
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	193
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	193
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	389
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	951
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	91
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	96
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	780
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	961
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,162
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,339
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	389
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	568
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	388
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	569
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	387
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	579
TB_ART_DSD	The number of registered new and relapse TB cases	6,592



	with documented HIV-positive status who are on ART	
	during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	313
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,814
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	260
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,785
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	189
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	109



	documented HIV-positive status who are on ART during		
	TB treatment during the reporting period)		
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	8,751	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	s 6,998	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,753	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	8,751	
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	383	
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	308	
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	75	
PMTCT_EID_TA	Sum of Infant Age disaggregates	383	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	188,335	
TX_CURR_DSD	Age/Sex: 15-19 Male	819	
TX_CURR_DSD	Age/Sex: 15-19 Female	3,820	
TX_CURR_DSD	Sum of age/sex disaggregates	4,639	
TX_CURR_DSD	Age/Sex: <1	903	
TX_CURR_DSD	Age/Sex: <1-9	11,750	
TX_CURR_DSD	Age/Sex: 10-14 Male	2,051	
TX_CURR_DSD	Age/Sex: 10-14 Female	2,189	
TX_CURR_DSD	Age/Sex: 20-24 Male	1,203	
TX_CURR_DSD	Age/Sex: 50+ Male	10,296	
TX_CURR_DSD	Age/Sex: 20-24 Female	12,397	
TX_CURR_DSD	Age/Sex: 50+ Female	20,129	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	23,108	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	7,565	



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	23,114	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	7,561	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	23,113	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	7,562	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	23,119	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	7,564	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,442	
TX_CURR_TA	Age/Sex: 15-19 Male	8	
TX_CURR_TA	Age/Sex: 15-19 Female	231	
TX_CURR_TA	Sum of Age/Sex disaggregations	239	
TX_CURR_TA	Age/Sex: <1	116	
TX_CURR_TA	Age/Sex: 1-9	936	
TX_CURR_TA	Age/Sex: 10-14 Male	83	
TX_CURR_TA	Age/Sex: 10-14 Female	109	
TX_CURR_TA	Age/Sex: 20-24 Male	46	
TX_CURR_TA	Age/Sex: 50+ Male	317	
TX_CURR_TA	Age/Sex: 20-24 Female	585	
TX_CURR_TA	Age/Sex: 50+ Female	504	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	609	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	236	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	609	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	236	



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	609	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive		
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	e, 699	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	257	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	37,970	
TX_NEW_DSD	By Age/Sex: <1	805	
TX_NEW_DSD	By Age/Sex: 1-9	1,999	
TX_NEW_DSD	By Age/Sex: 10-14 Male	413	
TX_NEW_DSD	By Age/Sex: 15-19 Male	234	
TX_NEW_DSD	By Age/Sex: 20-24 Male	715	
TX_NEW_DSD	By Age/Sex: 50+ Male	1,371	
TX_NEW_DSD	By Age/Sex: 10-14 Female	482	
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,860	
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,324	
TX_NEW_DSD	By Age/Sex: 50+ Female	2,045	
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,444	
TX_NEW_DSD	Pregnancy status	4,628	
TX_NEW_DSD	Breastfeeding status	324	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,758	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,271	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,738	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,256	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,691	



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,256	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive		
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,163	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,996	
TX_NEW_TA	By Age/Sex: <1	80	
TX_NEW_TA	By Age/Sex: 1-9	213	
TX_NEW_TA	By Age/Sex: 10-14 Male	38	
TX_NEW_TA	By Age/Sex: 15-19 Male	10	
TX_NEW_TA	By Age/Sex: 20-24 Male	34	
TX_NEW_TA	By Age/Sex: 50+ Male	39	
TX_NEW_TA	By Age/Sex: 10-14 Female	40	
TX_NEW_TA	By Age/Sex: 15-19 Female	111	
TX_NEW_TA	By Age/Sex: 20-24 Female	214	
TX_NEW_TA	By Age/Sex: 50+ Female	83	
TX_NEW_TA	Sum of Age/Sex disaggregates	569	
TX_NEW_TA	Pregnancy status	283	
TX_NEW_TA	Breastfeeding status	28	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	189	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	129	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	199	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	122	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	172	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	101	



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive		
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive		
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	120,030	
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	5,540	
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	1,737	
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	86,675	
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	26,078	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,092	
TX_PVLS_TA	<15, Undocumented Test Indication, Female	200	
TX_PVLS_TA	<15, Undocumented Test Indication, Male	69	
TX_PVLS_TA	15+, Undocumented Test Indication, Female	2,883	
TX_PVLS_TA	15+, Undocumented Test Indication, Male	940	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	46,338	
TX_RET_DSD	Numerator by Status: Pregnant	6,524	
TX_RET_DSD	Numerator by Status: Breastfeeding	684	
TX_RET_DSD	Denominator by Status: Pregnant	7,639	
TX_RET_DSD	Denominator by Status: Breastfeeding	764	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	f	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,542	



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	797
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29,997
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	341
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,142
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	864
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32,923
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	387
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	432
TX_RET_TA	Numerator by Status: Pregnant	88
TX_RET_TA	Denominator by Status: Pregnant	97
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of	5



	adults and children who are still alive and on treatment	
	at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of	
TX_RET_TA	adults and children who are still alive and on treatment	107
	at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	13
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	257
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	6
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	121
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	15
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	285
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	The number of ART patients who completed a course	
TD DDEV DOD	of TB preventive therapy or at least 6 months of	24,190
TB_PREV_DSD	Isoniazid Preventive Therapy (IPT) during the reporting	24,190
	period	



TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	32,245	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	831	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	755	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	19,430	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	11,222	
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	617	
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	535	
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	14,847	
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	8,197	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive		
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	25,803	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,839	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	19,351	
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,274	
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,697	



TB_PREV_TA	By Age/Sex (Denominator): <15, Female	44	
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	41	
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	1,023	
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	592	
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	32	
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	29	
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	781	
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	432	
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	340	
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,359	
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	255	
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,019	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period		
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	8,112	
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	7,071	
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	132,893	
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	39,778	
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,805	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,635	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,165	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	128,023	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	15,028	



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	41,393	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	3,722	
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	6,443	
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	329	
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	265	
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	4,562	
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	1,244	
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	130	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	70	
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	59	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	4,379	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	512	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,413	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	126	

Mechanism ID: 14792	Mechanism Name: ISCISA	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: ISCISA- Superior Institution of Health Sciences		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Budget Code information		
Mechanism ID:	14792	
Mechanism Name:	ISCISA	
	ISCISA- Superior Institution of Health Sciences	
Fillie Faither Name.	13Cl3A- Superior institution of r	leanti Sciences
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	o	

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14806	Mechanism Name: P/E Quick Impact Program	
Funding Agency: State/AF	Procurement Type: Grant	
Prime Partner Name: U.S. Department of State		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 271,519	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 501,481		
Total All Funding Sources and Applied Pipeline Amount: 773,000		
Funding Source Funding Amount		
GHP-State	271,519	

Cross-Cutting Budget Attribution(s)

Gender: GBV	125,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Condom programming	10,000
Adolescent Girls and Young Women (AGYW)	75,000
Human Resources for Health	30,000



Budget Code Information		
Mechanism ID: Mechanism Name: Prime Partner Name:	P/E Quick Impact Program	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	85,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	80,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	21,519
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	42,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	42,500
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,399
PP_PREV_DSD	Age/sex: 10-14 Female	1,847
PP_PREV_DSD	Age/sex: 15-19 Female	2,443
PP_PREV_DSD	Age/sex: 20-24 Female	807



PP_PREV_DSD	Sum of Age/Sex disaggregates	5,097
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,288
OVC_SERV_DSD	Age/Sex: 10-14 Male	932
OVC_SERV_DSD	Age/Sex: 15-17 Male	500
OVC_SERV_DSD	By: Age/sex: Male 18-24	183
OVC_SERV_DSD	By: Age/sex: Male 25+	288
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,099
OVC_SERV_DSD	Age/Sex: 15-17 Female	628
OVC_SERV_DSD	By: Age/sex: 18-24 Female	258
OVC_SERV_DSD	By: Age/sex: 25+ Female	726
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,159
OVC_SERV_DSD	Age/Sex: <1	170
OVC_SERV_DSD	Age/Sex: 1-9	2,502
OVC_SERV_DSD	Program Completion: Active	5,233
OVC_SERV_DSD	Program Completion: Graduation	2,055
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	3,133
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,288

Mechanism ID: 14822	Mechanism Name: ITECH
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 5,801,877	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 5,801,877		
Funding Source	Funding Amount	
GHP-State	5,801,877	

II D	4.050.000
Human Resources for Health	1,350,000

Machaniam ID:	4 4000	
Mechanism ID:		
Mechanism Name:	ITECH	
Prime Partner Name:	University of Washington	
Strategic Area	Budget Code	Planned Amount
Care	нвнс	300,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	O
Strategic Area	Budget Code	Planned Amount
Care	HVTB	351,467
Strategic Area	Budget Code	Planned Amount
Care	PDCS	o
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	480,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	637,800
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	1,667,187
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	379,778
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,524,067



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	461,578

(No data provided.)

Implementing Mechanism Details

implementing meenanism betans		
Mechanism ID: 16052	Mechanism Name: UCSF-HQ	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at San Francisco		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,325,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeli	ne Amount: 1,325,000
Funding Source	Funding Amount
GHP-State	1,325,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	16052
Mechanism Name:	UCSF-HQ
Prime Partner Name:	University of California at San Francisco



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	132,500
Strategic Area	Budget Code	Planned Amount
Care	PDCS	265,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	927,500

(No data provided.)

Mechanism ID: 16671	Mechanism Name: Foundation for Innovative New Diagnostics - FIND FOLLOW ON
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Innova	ative New Diagnostics
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

budget Code information		
	16671 Foundation for Innovative New Diagnostics - FIND FOLLOW ON Foundation for Innovative New Diagnostics	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	o
-----------	------	---

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16802	Mechanism Name: DPS Inhambane Province
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health, Inhambane	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 142,037	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 142,037		
Funding Source Funding Amount		
GHP-State	142,037	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code information		
Mechanism ID:	16802	
Mechanism Name:	DPS Inhambane Province	
Prime Partner Name:	Provincial Directorate of Health, Inhambane	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	16,491
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	4,498
Strategic Area	Budget Code	Planned Amount
Care	PDCS	5,997
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	107,555
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	7,496

(No data provided.)

Mechanism ID: 16879	Mechanism Name: World Food Program
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: World Food Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,044,871	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,955,129	



Total All Funding Sources and Applied Pipeline Amount: 3,000,000	
Funding Source Funding Amount	
GHP-State	1,044,871

Franks IN Office Occurs Pffee	4 0 4 4 0 7 4
Food and Nutrition: Commodities	1,044,871

Mechanism ID:	16970	
Mechanism Name:	World Food Program	
Prime Partner Name:	World Food Program	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	1,044,871
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing Mechanism Details		
Mechanism ID: 16900	Mechanism Name: Mobile Solutions Technical Assistance and Research (mSTAR)	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Mobile Solutions Technical Assistance and Research (mSTAR)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

3		
Mechanism ID: 16998	Mechanism Name: DPS Gaza Province	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Provincial Directorate of Health, Gaza		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 274,676	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 274,676		
Funding Source	Funding Amount	



GHP-State	274,676

(No data provided.)

Budget Code Information	Budget Code Information		
Mechanism ID:	16998		
Mechanism Name:	DPS Gaza Province		
Prime Partner Name:	Provincial Directorate of Health,	Provincial Directorate of Health, Gaza	
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	31,891	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	8,698	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	11,597	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	207,994
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	14,496



(No data provided.)

Implementing Mechanism Details

impromortang incondition because			
Mechanism ID: 16999	Mechanism Name: DPS Nampula Province		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Provincial Directorate of Health, Nampula			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: Yes	Managing Agency: HHS/CDC		

Total All Funding Sources: 198,894	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 198,894				
Funding Source	Funding Amount			
GHP-State	198,894			

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	16999		
Mechanism Name:	DPS Nampula Province		
Prime Partner Name:	Provincial Directorate of Health, Nampula		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	23,093	



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	6,298
Strategic Area	Budget Code	Planned Amount
Care	PDCS	8,397
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	150,609
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	10,497

(No data provided.)

Mechanism ID: 17044	Mechanism Name: Ministry of Health (MISAU)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health, Mozambique		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 3,444,445	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 3,444,445		
Funding Source	Funding Amount	
GHP-State	3,444,445	



Gender: GBV	22,787
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Key Populations: FSW	50,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	50,000
Human Resources for Health	110,900

Mechanism ID:	17044	
Mechanism Name:	Ministry of Health (MISAU)	
Prime Partner Name:	Ministry of Health, Mozambique	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	355,689
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	511,303
Strategic Area	Budget Code	Planned Amount
Care	PDCS	111,153
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	300,000



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	87,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	76,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	204,765
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	66,692
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	75,839
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	477,783
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	533,534
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	644,687

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17104	Mechanism Name: Demographic and Health Survey"s Program- Phase 7	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: ICF Macro		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	17104



Mechanism Name: Prime Partner Name:	5 .	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 17169	Mechanism Name: Mozambique Strategic Information Program (M-SIP)	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: John Snow Inc (JSI)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		



G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	eline Amount: 0	
Funding Source	Funding Amount	

(No data provided.)

Budget Code information		
Mechanism ID: Mechanism Name: Prime Partner Name:	Mozambique Strategic Information Program (M-SIP)	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

implementing wechanism betans		
Mechanism ID: 17171	Mechanism Name: N"weti - Strengthening Civil Society Engagement to Improve Sexual and Reproductive Health and Service Delivery for Youth	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: N'WETI - Comunicação para S	Saúde	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Daagot Goad IIII oi iii atioii	
Mechanism ID:	17171



	N"weti - Strengthening Civil Soc Sexual and Reproductive Health N'WETI - Comunicação para Sac	and Service Delivery for Youth
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 17259	Mechanism Name: Fortalecimento do Sistema de Monitoria e Avaliacao do MMAS	
Funding Agency: USAID	Procurement Type: Grant	
Prime Partner Name: JEMBI		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/	'A	
G2G: No Managing Agency:		
Total All Funding Sources: 0 Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied	Pipeline Amount: 0	
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Fortalecimento do Sistema de Monitoria e Avaliacao do MMAS	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17260	Mechanism Name: Esperança de Vida	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	17260



Mechanism Name: Esperança de Vida Prime Partner Name: REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 17261	Mechanism Name: Improving Integrated HIV Homecare Services
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Associacao Nacional dos Enfermeiros de Mocambique (ANEMO)	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
	L	
otal All Funding Sources: 0 Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Improving Integrated HIV Homecare Services Associacao Nacional dos Enfermeiros de Mocambique	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17567	Mechanism Name: NASTAD	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Alliance of State and Territorial AIDS Directors		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 369,945	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 369,945		
Funding Source Funding Amount		
GHP-State	369,945	

Cross-Cutting Budget Attribution(s)

(No data provided.)

	_
Mechanism ID:	17567



Mechanism Name:	NASTAD	
Prime Partner Name:	National Alliance of State and T	erritorial AIDS Directors
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	369,945
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 17571	Mechanism Name: Nursing Capacity Building Program
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	eline Amount: 0	
Funding Source	Funding Amount	

(No data provided.)

Budget Code information			
Mechanism ID:	17571		
Mechanism Name:	Nursing Capacity Building Program		
Prime Partner Name:	Columbia University Mailman S	Columbia University Mailman School of Public Health	
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

	Mechanism Name: Food Security Innovation	
Mechanism ID: 17652	Lab: Collaborative Research on Assets and	
	Market Access	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Baaget Godo information	
Mechanism ID:	17652



Mechanism Name: Food Security Innovation Lab: Collaborative Research on Prime Partner Name: Assets and Market Access University of California		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVCT	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVOP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	MTCT	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	0	

(No data provided.)

Mechanism ID: 17723	Mechanism Name: FADM Prevention and Circumcision Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No Managing Agency:	

Total All Funding Sources: 3,924,897	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	eline Amount: 3,924,897	
Funding Source	Funding Amount	
GHP-State	3,924,897	

(No data provided.)

Mechanism ID:	17723	
Mechanism Name:	FADM Prevention and Circumcision Program	
Prime Partner Name:	JHPIEGO	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,858,097
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,066,800
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	34,343
VMMC_CIRC_DSD	By Age: 10-14	16,359
VMMC_CIRC_DSD	By Age: 15-19	11,266
VMMC_CIRC_DSD	By Age: 20-24	4,754
VMMC_CIRC_DSD	By Age: 25-29	1,838
VMMC_CIRC_DSD	By Age: 50+	126
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	32,505
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	34,343
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	34,343
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,141
PP_PREV_DSD	Age/sex: 10-14 Female	6,699
PP_PREV_DSD	Age/sex: 15-19 Female	9,571
PP_PREV_DSD	Age/sex: 20-24 Female	2,871
PP_PREV_DSD	Sum of Age/Sex disaggregates	19,141
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,175
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	4



	_ ,	
	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	226
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	209
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	35



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	2,116
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,116
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,709
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	202
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	3,700
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	7,300
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	2,000
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male,	21



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,093
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	219
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,824
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	268
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,967
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,420
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	4,043
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	283
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	67
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14,	3



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1,336
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	64
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,114
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	53
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,225
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3,007
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	144
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	223
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1,225
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	189
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,	9



	Docking	
	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	346
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	135
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,250
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	187
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	577
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	635
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,058
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	158
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	17



HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	137
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male,	162



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male,	12



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	2,677
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	2,240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	2,677
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	2,240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	2,677
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	2,240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	2,677
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	2,240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29,	197



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2,116
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	24



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,116
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	891
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	947
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	891
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	947
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	891
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	947
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	891
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49,	947



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	185
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,053
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	185
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,053
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34,	157



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	185
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,053
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	185
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,053
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	157
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	5,250
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	5,250
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	5,250
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	5,250
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	53



Implementing Mechanism Details

	Mechanism Name: Linkages Across the	
Mechanism ID: 18099	Continuum of HIV Services for Key Populations	
	affected by HIV (LINKAGES) Project	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Linkages Across the Continuum of HIV Services for Key Populations affected by HIV (LINKAGES) Project	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

	Mechanism Name: Primary School Retention and Transition to Secondary School for Vulnerable Girls in Zambezia	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Ajuda de Desenvolvimento de	Povo para Povo	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount



(No data provided.)

Budget Code Information		
Mechanism ID: Mechanism Name: Prime Partner Name:	Primary School Retention and Transition to Secondary School for Vulnerable Girls in Zambezia	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18101	Mechanism Name: Maternal and Child Survival Program (MCSP)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Maternal and Child Survival Program (MCSP)	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18102	Mechanism Name: Communication for Improved Health Outcomes (CIHO)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Johns Hopkins University Center for Communication Programs		
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,595,949	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 617,000		
Total All Funding Sources and Applied Pipeline Amount: 4,212,949		
Funding Source Funding Amount		
GHP-State	3,595,949	



Motor Vehicles: Purchased	180,000
Condom programming	100,000
Human Resources for Health	439,070

Budget Code Information		
Mechanism ID: 18102		
Mechanism Name:	Communication for Improved Health Outcomes (CIHO)	
Prime Partner Name:	Johns Hopkins University Center for Communication Programs	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	120,178
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	120,178
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,600,065
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	116,997
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	141,575
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	173,034
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	298,214
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	25,708



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18103	Mechanism Name: Service Delivery and Support for Orphans and Vulnerable Children	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	o New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 15,636,714	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 15,636,714			
Funding Source Funding Amount			
GHP-State	15,636,714		

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,047,556
Economic Strengthening	2,206,244
Adolescent Girls and Young Women (AGYW)	1,533,089
Water	551,126
Food and Nutrition: Policy, Tools, and Service	150,000
Delivery	



Mechanism ID: Mechanism Name: Children Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	12,395,171
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,708,454
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	1,533,089
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,807
PP_PREV_DSD	Age/sex: 10-14 Female	3,389
PP_PREV_DSD	Age/sex: 15-19 Female	1,029
PP_PREV_DSD	Age/sex: 20-24 Female	389



PP_PREV_DSD	Sum of Age/Sex disaggregates	4,807
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	344,247
OVC_SERV_DSD	Age/Sex: 10-14 Male	40,701
OVC_SERV_DSD	Age/Sex: 15-17 Male	22,113
OVC_SERV_DSD	By: Age/sex: Male 18-24	9,462
OVC_SERV_DSD	By: Age/sex: Male 25+	20,656
OVC_SERV_DSD	Age/Sex: 10-14 Female	40,313
OVC_SERV_DSD	Age/Sex: 15-17 Female	19,198
OVC_SERV_DSD	By: Age/sex: 18-24 Female	12,159
OVC_SERV_DSD	By: Age/sex: 25+ Female	43,870
OVC_SERV_DSD	Sum of Age/Sex disaggregates	122,325
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	284
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	247
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	40
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	485
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	106
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	41
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	282
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	221
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	168
OVC_SERV_DSD	Age/Sex: <1	8,810
OVC_SERV_DSD	Age/Sex: 1-9	126,855



OVC_SERV_DSD	Program Completion: Active	247,501
OVC_SERV_DSD	Program Completion: Graduation	96,746
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	258,205
Number of active beneficiaries served by PEPFAR OVC_HIVSTAT_DSD OVC programs for children and families affected by HIV/AIDS		344,247

Implementing Mechanism Details

mipromontally moonamon botano		
Mechanism ID: 18104	Mechanism Name: MMEMS	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Management Systems International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Gode information		
Mechanism ID:	18104	
Mechanism Name:	MMEMS	
Prime Partner Name:	Management Systems International	



Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18108	Mechanism Name: FADM HIV Treatment Scale-Up Program	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 3,883,509	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 237,846			
Total All Funding Sources and Applied Pipeline Amount: 4,121,355			
Funding Source Funding Amount			
GHP-State	3,883,509		

Condom nuonummina	100,000
Condom programming	100,000

Baaget oode iiiioiiiiatioii			
Mechanism ID:	18108		
Mechanism Name:	FADM HIV Treatment Scale-Up Program		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	675,011	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	187,503	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	37,501	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	80,350	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	39,575
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	13,523
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,812,545



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	37,501

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	471
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,132
PMTCT_ART_DSD	New on ART	214
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	257
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,132
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,132
PMTCT_STAT_DSD	By Age (Denominator): 10-14	6
PMTCT_STAT_DSD	By Age (Denominator): <15-19	747
PMTCT_STAT_DSD	By Age (Denominator): 20-24	987
PMTCT_STAT_DSD	By Number of known positives: 15-19	55
PMTCT_STAT_DSD	By Number of known positives: 20-24	105
PMTCT_STAT_DSD	By Number of new positives: 15-19	22
PMTCT_STAT_DSD	By Number of new positives: 20-24	57
PMTCT_STAT_DSD	By Number of new negative: 10-14	8
PMTCT_STAT_DSD	By Number of new negative: 15-19	180
PMTCT_STAT_DSD	By Number of new negative: 20-24	510
PMTCT_STAT_DSD	By Age (Numerator): 10-14	6
PMTCT_STAT_DSD	By Age (Numerator): 15-19	747
PMTCT_STAT_DSD	By Age (Numerator): 20-24	987



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	1,199
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	71
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	64
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	58
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	105
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	435
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	48
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	75
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	435
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	48
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	425
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	48
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	61
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	399
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	46
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	1,199
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	71
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	64
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	58
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	3,132



	months	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	61
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	780
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	780
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	404
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	370
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total	6



number of registered new and relapsed TB cases,	
during the reporting period)	
Aggregated Age/Sex: Male 15+ (Denominator: Total	
number of registered new and relapsed TB cases,	404
during the reporting period)	
Aggregated Age/Sex: Female 15+ (Denominator: Total	
number of registered new and relapsed TB cases,	370
during the reporting period)	
The number of registered new and relapse TB cases	
with documented HIV-positive status who are on ART	455
during TB treatment during the reporting period	
Aggregated Age/Sex: Male <15 (Numerator: The	
number of registered new and relapse TB cases with	0
documented HIV-positive status who are on ART during	9
TB treatment during the reporting period)	
Aggregated Age/Sex: Male 15+ (Numerator: The	
number of registered new and relapse TB cases with	000
documented HIV-positive status who are on ART during	260
TB treatment during the reporting period)	
Aggregated Age/Sex: Female <15 (Numerator: The	
number of registered new and relapse TB cases with	-
documented HIV-positive status who are on ART during	5
TB treatment during the reporting period)	
Aggregated Age/Sex: Female 15+ (Numerator: The	
number of registered new and relapse TB cases with	400
documented HIV-positive status who are on ART during	182
TB treatment during the reporting period)	
Number of infants who had a virologic HIV test within	
12 months of birth during the reporting period	377
By infants who received a virologic test within 2 months	000
of birth	302
By infants who received their first virologic HIV test	75
between 2 and 12 months of age	75
Sum of Infant Age disaggregates	377
Number of adults and children receiving antiretroviral	17,295
	during the reporting period) Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) Number of infants who had a virologic HIV test within 12 months of birth during the reporting period By infants who received a virologic test within 2 months of birth By infants who received their first virologic HIV test between 2 and 12 months of age



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	142
TX_CURR_DSD	Age/Sex: 15-19 Female	269
TX_CURR_DSD	Sum of age/sex disaggregates	411
TX_CURR_DSD	Age/Sex: <1	6
TX_CURR_DSD	Age/Sex: <1-9	183
TX_CURR_DSD	Age/Sex: 10-14 Male	78
TX_CURR_DSD	Age/Sex: 10-14 Female	79
TX_CURR_DSD	Age/Sex: 20-24 Male	176
TX_CURR_DSD	Age/Sex: 50+ Male	2,371
TX_CURR_DSD	Age/Sex: 20-24 Female	571
TX_CURR_DSD	Age/Sex: 50+ Female	1,866
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,873
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,015
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,873
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,015
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,873
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,015
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,873
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,015
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,635
TX_NEW_DSD	By Age/Sex: <1	34
TX_NEW_DSD	By Age/Sex: 1-9	43
TX_NEW_DSD	By Age/Sex: 10-14 Male	10



TX_NEW_DSD	By Age/Sex: 15-19 Male	39
TX_NEW_DSD	By Age/Sex: 20-24 Male	177
TX_NEW_DSD	By Age/Sex: 50+ Male	545
TX_NEW_DSD	By Age/Sex: 10-14 Female	10
TX_NEW_DSD	By Age/Sex: 15-19 Female	263
TX_NEW_DSD	By Age/Sex: 20-24 Female	409
TX_NEW_DSD	By Age/Sex: 50+ Female	308
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,761
TX_NEW_DSD	Pregnancy status	214
TX_NEW_DSD	Breastfeeding status	161
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	497
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	452
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	497
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	452
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	497
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	452
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	497
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	452
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,736
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	232
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	160
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	6,822
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	4,522
1V_L \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	15+, Undocumented Test Indication, Male	4,322



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,989
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,432
TX_RET_DSD	Numerator by Status: Pregnant	221
TX_RET_DSD	Numerator by Status: Breastfeeding	79
TX_RET_DSD	Denominator by Status: Pregnant	369
TX_RET_DSD	Denominator by Status: Breastfeeding	127
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,421
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,487
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,594
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	56



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,748
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	6,434
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	16,085
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	415
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	377
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	9,695
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	5,597
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	162
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	144
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,949
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,179
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,217
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	12,868
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,287
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,147



TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	17,295
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	336
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	210
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	10,392
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	6,355
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	79
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	79
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	11,761
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,384
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	3,805
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	345

Mechanism ID: 18110	Mechanism Name: ARC - Nursing Council	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: African Health Profession Regulatory Collaborative for Nurses and Midwives		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information		
Mechanism Name:	Mechanism ID: Mechanism Name: Prime Partner Name: African Health Profession Regulatory Collaborative for Nurses and Midwives	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing meenament betane		
Mechanism ID: 18122	Mechanism Name: Family Planning Integrated Activity	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Pathfinder International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

	•		
Mechanism ID:	18122		
Mechanism Name:	Family Planning Integrated Activity		
Prime Partner Name:	Pathfinder International		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18123	Mechanism Name: Parceria Civica para Boa Governacao	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Counterpart International		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information		
Mechanism ID: 18123		
Mechanism Name: Parceria Civica para Boa Governacao Prime Partner Name: Counterpart International		nacao
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Mechanism ID: 18275	Mechanism Name: Strengthening High Impact Interventions for an AIDS-Free Generation (AIDSFree) Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: John Snow Inc (JSI)		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 6,755,741	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 298,987		
Total All Funding Sources and Applied Pipeline Amount: 7,054,728		
Funding Source Funding Amount		
GHP-State	6,755,741	

Human Resources for Health	1,831,368
Taman Recourse for Floatin	1,001,000

Mechanism ID: Mechanism Name:	Strengthening High Impact Interventions for an AIDS-Free Generation (AIDSFree) Project	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	6,755,741
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
	Number of males circumcised as part of the voluntary	
VMMC_CIRC_DSD	medical male circumcision (VMMC) for HIV prevention	128,548
	program within the reporting period	
VMMC_CIRC_DSD	By Age: 10-14	33,853
VMMC_CIRC_DSD	By Age: 15-19	44,926
VMMC_CIRC_DSD	By Age: 20-24	29,031
VMMC_CIRC_DSD	By Age: 25-29	15,934
VMMC_CIRC_DSD	By Age: 50+	239
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	108,049
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	123,983
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	128,548
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,137
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,142
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,288
HTC_TST_DSD	Number of individuals who received T&C services for	128,551



	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	15,378
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	16,798
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	3,172
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	23,115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	23,115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	23,115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	23,115
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	138

Mechanism ID: 18280	Mechanism Name: Integrated HIV Prevention and Health Services for Key and Priority Populations (HIS-KP)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted Agreement End Date: Redacted		



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,005,629	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipel	line Amount: 6,005,629	
Funding Source Funding Amount		
GHP-State	6,005,629	

Key Populations: MSM and TG	1,576,408
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Collection and use of strategic information
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Training of health workers and community outreach workers
Key Populations: FSW	4,729,222
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Conducting epidemiologic, social science, and



	operational research among SWs, their partners, and clients
Human Resources for Health	1,353,265
Condom programming	250,000
Motor Vehicles: Purchased 120,000	

Budget Code Information		
Mechanism ID: Mechanism Name: Mechanism Name: Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	2,147,348
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	3,858,281
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Indicator Number	Label	2019
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	62,076
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,406
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	33,465
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	313
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	51
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	17,841
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	39,754



	months	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	4,277
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	479
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	4,676
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	523
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	4,257
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	480
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	4,676
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	523
HTC_TST_DSD	By Key Population: FSW, Negative	18,146
HTC_TST_DSD	By Key Population: FSW, Positive	2,442
HTC_TST_DSD	By Key Population: MSM, Negative	5,695
HTC_TST_DSD	By Key Population: MSM, Positive	781
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	9,986
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	872
HTC_TST_DSD	By Key Population: PWID, Negative	159
HTC_TST_DSD	By Key Population: PWID, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	4,254
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	481
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	4,676
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	523



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	4,254
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	477
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	4,676
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	522
HTS_SELF_DSD	HTS_SELF_N_DSD	5,577
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	208
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	140
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	521
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	346
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	521
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	346
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	521
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	346
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	521
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	346
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,046
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	697



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	5,577
LITE CELE DOD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM,	E
HTS_SELF_DSD	Directly-Assisted	5,577

Implementing Mechanism Details

implementing Mechanism Details		
Mechanism ID: 18282	Mechanism Name: Global Health Supply Chain Program	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Global Health Supply Chain Program		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 62,646,584	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	line Amount: 62,646,584	
Funding Source	Funding Amount	
GHP-State	62,646,584	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	235,395	

Mechanism ID:	18282	
Mechanism Name:	Global Health Supply Chain Program	
Prime Partner Name:	Global Health Supply Chain Program	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	682,363



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	2,236,784
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	676,437
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	2,498,749
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	3,532,427
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	204,833
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	24,187,059
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	27,180,797
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,447,135

(No data provided.)

Mechanism ID: 18311	Mechanism Name: Community Based HIV Services for the Southern Region	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: N'WETI - Comunicação para Saúde		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,947,948	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,947,948		



Funding Source	Funding Amount
GHP-State	1,947,948

oross outling budget Attribution(s)		
Gender: GBV	50,000	
Focus Area:	GBV Prevention	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Condom programming	70,000	
Adolescent Girls and Young Women (AGYW)	1,013,258	
Human Resources for Health	251,745	

Mechanism ID: 18311		
Mechanism Name:	Community Based HIV Services for the Southern Region	
Prime Partner Name:	N'WETI - Comunicação para Sau	úde
Strategic Area	Budget Code	Planned Amount
Care	HBHC	692,426
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	242,265
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,013,257
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,135
PP_PREV_DSD	Age/sex: 10-14 Female	2,147
PP_PREV_DSD	Age/sex: 15-19 Female	3,068
PP_PREV_DSD	Age/sex: 20-24 Female	920
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,135
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,326
HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Female, Negative Service Delivery Point (Community) Index Mod: 10-14, Female, Positive HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Male, Negative HTC_TST_DSD Service Delivery Point (Community) Index Mod: 10-14, Male, Positive Service Delivery Point (Community) Index Mod: 10-14, Male, Positive Service Delivery Point (Community) Index Mod: 15-19, Female, Negative		702
		25
		546
		19
		424
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	166
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	143



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	523
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	203
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	387
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	151
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	482
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	188
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	527
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	204
HTC_TST_DSD Service Delivery Point (Community) Index Negative		84
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,975
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	536
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	446
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29,	172



	·	
	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	536
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	446
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	172
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	536
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	446
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	172
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	536
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	446
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	172

Mechanism ID: 18312	Mechanism Name: Integrating Early Child Development (ECD - GDA)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source Funding Amount	

(No data provided.)

Budget Code information		
Mechanism ID:		. (500
	Integrating Early Child Develop	
Prime Partner Name:	Program for Appropriate Techno	ology in Health
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

implementing meenanism betans	
Mechanism ID: 18319	Mechanism Name: HIV Community-Based Services (Nampula)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Associação Para o Desenvolvimento Sócio-Económico	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	18319
Mechanism Name:	HIV Community-Based Services (Nampula)
Prime Partner Name:	Associação Para o Desenvolvimento Sócio-Económico



Strategic Area	Budget Code	Planned Amount
-	-	
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18336	Mechanism Name: 4 Children (Coordinating Comprehensive Care for Children)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Catholic Relief Service	es	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	·	
G2G: No	Managing Agency:	



Total All Funding Sources: 390,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 390,000		
Funding Source	Funding Amount	
GHP-State	390,000	

	• •	
Human Resources for Health		220,000

Mechanism ID:	18336	
Mechanism Name:	4 Children (Coordinating Comprehensive Care for Children)	
Prime Partner Name:	Catholic Relief Services	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	390,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18366	Mechanism Name: Health Finance and Governance Project (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	18366
Mechanism Name:	Health Finance and Governance Project (HFG)
Prime Partner Name:	Abt Associates



Strategic Area	Budget Code	Planned Amount
-	-	
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
i iorenien		Ü
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18367	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 917,411	Total Mechanism Pipeline: N/A
------------------------------------	-------------------------------



Applied Pipeline Amount: 0 Total All Funding Sources and Applied Pipeline Amount: 917,411		
Funding Source Funding Amount		
GHP-State	917,411	

(No data provided.)

Budget Code information		
Mechanism ID: Mechanism Name:		
Prime Partner Name:	Right To Care, South Africa	
Strategic Area	Budget Code	Planned Amount
Care	нвнс	o
Strategic Area	Budget Code	Planned Amount
Care	HKID	O
Strategic Area	Budget Code	Planned Amount
Care	HVTB	O
Strategic Area	Budget Code	Planned Amount
Care	PDCS	o
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	O
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	o



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	917,411
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	o	

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 18368	Mechanism Name: Health Communication Capacity Collaborative (HC3)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	18368	
Mechanism Name:	Health Communication Capacity Collaborative (HC3)	
Prime Partner Name:	Johns Hopkins University Bloomberg School of Public Health	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18372	Mechanism Name: CMAM Agreement
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Central de Medicamentos e Artigos Medicos (CMAM)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: USAID

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Budget Code Information		
Mechanism ID:	18372	
Mechanism Name:	CMAM Agreement	
Prime Partner Name:	Central de Medicamentos e Arti	gos Medicos (CMAM)
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18373	Mechanism Name: Health Policy Plus (HP+)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Palladium Group		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 220,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 220,000		
Funding Source Funding Amount		
GHP-State	220,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Duaget Code IIII of III date		
Mechanism ID:	18373	
Mechanism Name:	Health Policy Plus (HP+)	
Prime Partner Name:	Palladium Group	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	220,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18429	Mechanism Name: DPS Zambezia
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Directorate of Health	n, Zambezia
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information		
Mechanism ID:	18429	
Mechanism Name:	: DPS Zambezia	
Prime Partner Name:	Provincial Directorate of Health,	, Zambezia
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18454	Mechanism Name: ASLM	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: African Society for Laboratory Medicine		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18455	TBD: Yes
REDACTED	

Mechanism ID: 18456	Mechanism Name: YouthPower Implementation - Task Order 1	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
----------------	----------------

(No data provided.)

Budget Code Information		
Mechanism ID: Mechanism Name: Prime Partner Name:	YouthPower Implementation -	Task Order 1
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

implementing meenament betans		
Mechanism ID: 18466	Mechanism Name: Project SOAR (Supporting Operational AIDS Research)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Council		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	No New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 300,000		
Funding Source Funding Amount		
GHP-State	300,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	18466	
Mechanism Name:	Project SOAR (Supporting Operational AIDS Research)	
Prime Partner Name:	Population Council	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	300,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18478	Mechanism Name: Mothers Reducing Infections through Support and Education	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Mothers to Mothers (M2M)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 875,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 875,000
Funding Source	Funding Amount



GHP-State	875,000

Human Resources for Health	122,500

Budget Code Information		
Mechanism ID:	18478	
Mechanism Name:	: Mothers Reducing Infections through Support and Education	
Prime Partner Name:	: Mothers to Mothers (M2M)	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	350,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	525,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18503	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 18521	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 18632	Mechanism Name: Last Mile Supply Chain	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Village Reach		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,600,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 2,600,000			
Funding Source Funding Amount			
GHP-State	2,600,000		

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	120,000
Human Resources for Health	182,000



Budget Code Information			
Mechanism ID: 18632			
Mechanism Name:	Mechanism Name: Last Mile Supply Chain		
Prime Partner Name:	artner Name: Village Reach		
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMBL	0	



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,600,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70194	Mechanism Name: [Placeholder - 70194
	Mozambique DOD]



Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70194 Mozambique DOD]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70195	Mechanism Name: [Placeholder - 70195 Mozambique DOD]	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID:	70195	
Mechanism Name: [Placeholder - 70195 Mozambique DOD]		
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70196	Mechanism Name: [Placeholder - 70196 Mozambique DOD]
Funding Agency: DOD	Procurement Type: Grant



Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70196 Mozambique DOD]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70197	Mechanism Name: UNAIDS	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Joint United Nationa Programme on HIV/AIDS		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID:	70197	
Mechanism Name:	UNAIDS	
Prime Partner Name:	Joint United Nationa Programme on HIV/AIDS	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	O
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	307,008
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70198	TBD: Yes	
REDACTED		

Mechanism ID: 70199	Mechanism Name: WHO



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Health Organization		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	39,512
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	39,512
Strategic Area	Budget Code	Planned Amount



Care	PDCS	19,756
Strategic Area	Budget Code	Planned Amount
Strategic Area	Dudget Code	Flamled Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	39,512
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	39,512
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	19,756

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70200	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70201	TBD: Yes	
REDACTED		

Mechanism ID: 70202	Mechanism Name: [Placeholder - 70202 Mozambique HHS/HRSA]	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A	· · · · · · · · · · · · · · · · · · ·	
G2G: No	Managing Agency:	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 0				
Funding Source	Funding Amount			

(No data provided.)

Budget Code information		
Mechanism ID:	70202	
Mechanism Name:	e: [Placeholder - 70202 Mozambique HHS/HRSA]	
Prime Partner Name:		
Timo Farmor Hame	[: ideoneide:]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	мтст	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment PDTX	()
----------------	---	---

(No data provided.)

Implementing Mechanism Details

implementing Mechanism betans		
Mechanism ID: 70203	Mechanism Name: [Placeholder - 70203 Mozambique HHS/HRSA]	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70203	
Mechanism Name:	[Placeholder - 70203 Mozambique HHS/HRSA]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70204	Mechanism Name: [Placeholder - 70204 Mozambique HHS/HRSA]	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
------------------------------	-------------------------------



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Budget Code Information			
Mechanism ID:	70204		
Mechanism Name:	: [Placeholder - 70204 Mozambique HHS/HRSA]		
Prime Partner Name:	[Placeholder]		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	o	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

p.ogogo		
Mechanism ID: 70205	Mechanism Name: [Placeholder - 70205 Mozambique PC]	
Funding Agency: PC	Procurement Type: USG Core	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70205	
Mechanism Name:	[Placeholder - 70205 Mozambique PC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70206	Mechanism Name: [Placeholder - 70206 Mozambique PC]	
Funding Agency: PC	Procurement Type: USG Core	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information		
Mechanism ID: 70206		
	[Placeholder - 70206 Mozambique PC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70207	Mechanism Name: [Placeholder - 70207 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	D: <mark>70207</mark>	
Mechanism Name:	[Placeholder - 70207 Mozambique USAID]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70208	Mechanism Name: [Placeholder - 70208 Mozambique USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information		
Mechanism ID: 70208		
Mechanism Name: Prime Partner Name:	[Placeholder - 70208 Mozambiq [Placeholder]	ue USAID]
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Mechanism ID: 70209	TBD: Yes
REDA	CTED

Implementing Mechanism Details

Mechanism ID: 70210	Mechanism Name: Global Health Supply Chain Program - RTK	
Funding Agency: USAID	Procurement Type: Grant	
Prime Partner Name: Global Health Supply Chain Program		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 6,187,446	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 6,187,446		
Funding Source	Funding Amount	
GHP-State	6,187,446	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70210	
Mechanism Name:	Global Health Supply Chain Program - RTK	
Prime Partner Name:	Global Health Supply Chain Pro	gram
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	4,949,957
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,237,489
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70211	TBD: Yes	
REDA	REDACTED	

Implementing Mechanism Details

Mechanism ID: 70212	TBD: Yes
REDACTED	

Mechanism ID: 70213	TBD: Yes
---------------------	----------



REDACTED

Implementing Mechanism Details

Mechanism ID: 70214	Mechanism Name: OPTIMIZE	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Columbia University Mailman School of Public Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70214	
Mechanism Name:	OPTIMIZE	
Prime Partner Name:	Columbia University Mailman School of Public Health	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	350,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70216	TBD: Yes
REDACTED	

Mechanism ID: 70217	Mechanism Name: [Placeholder - 70217 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

(No data provided.)

Budget Code Information		
Mechanism ID: 70217 Mechanism Name: [Placeholder - 70217 Mozambique USAID] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

inplementing Mechanism Details		
Mechanism ID: 70218	Mechanism Name: [Placeholder - 70218 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name:	70218 [Placeholder - 70218 Mozambiq	ue USAID]
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	o
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70219	Mechanism Name: [Placeholder - 70219 Mozambique USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



(No data provided.)

Budget Code Information			
Mechanism ID:	70219		
Mechanism Name:	nism Name: [Placeholder - 70219 Mozambique USAID]		
Prime Partner Name:	[Placeholder]		
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70220	Mechanism Name: [Placeholder - 70220 Mozambique USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 0	
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70220 Mozambique USAID]	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70221	Mechanism Name: [Placeholder - 70221 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount



(No data provided.)

Budget Code Information		
Mechanism ID: 70221		
	Mechanism Name: [Placeholder - 70221 Mozambique USAID] Prime Partner Name: [Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)



Mechanism ID: 70222	Mechanism Name: [Placeholder - 70222 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70222 Mozambique USAID]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70223	Mechanism Name: [Placeholder - 70223 Mozambique USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID: 70223		
Mechanism Name: [Placeholder - 70223 Mozambique USAID]		
Prime Partner Name:	Prime Partner Name: [Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70224	Mechanism Name: [Placeholder - 70224 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	



Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	[Placeholder - 70224 Mozambique USAID]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70225	Mechanism Name: [Placeholder - 70225 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information		
Mechanism ID: 70225 Mechanism Name: [Placeholder - 70225 Mozambique USAID] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70226	Mechanism Name: [Placeholder - 70226 Mozambique USAID]
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70226	
	[Placeholder - 70226 Mozambique USAID]	
Strategic Area	Budget Code Planned Amount	
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

implementing incenting in betains		
Mechanism ID: 70227	Mechanism Name: [Placeholder - 70227 Mozambique USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID: 70227 Mechanism Name: [Placeholder - 70227 Mozambique USAID] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70510	TBD: Yes	
	REDACTED	

Mechanism ID: 80017	Mechanism Name: IOM
---------------------	---------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: International Organization for Migration		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 400,000		
Funding Source	Funding Amount	
GHP-State	400,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Daaget Gode IIII Gilliation		
Mechanism ID:	80017	
Mechanism Name:	IOM	
Prime Partner Name:	International Organization for Migration	
Strategic Area	Budget Code Planned Amount	
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	400,000
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 80018	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 80019	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 80020	TBD: Yes
REDACTED	

Mechanism ID: 80021	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 80022	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 80032	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 80034	Mechanism Name: UNICEF	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: United Nations Children's Fund		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline A	amount: 0			
Funding Source	Funding Amount			

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID:	80034	
Mechanism Name:	UNICEF	
Prime Partner Name:	United Nations Children's Fund	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0

(No data provided.)



Agency Information - Costs of Doing Business

U.S. Agency for International Development

U.S. Agency i	U.S. Agency for International Development							
Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount		
Computers/IT Services		640,863		640,863	0	640,863		
ICASS		2,795,335		2,795,335	0	2,795,335		
Indirect Costs		552,358		552,358	0	552,358		
Institutional Contractors		1,500,000		1,500,000	0	1,500,000		
Management Meetings/Profes sional Development		554,970		554,970	0	554,970		
Non-ICASS Administrative Costs		1,150,187		1,150,187	0	1,150,187		
Staff Program Travel		1,041,464		1,041,464	0	1,041,464		
USG Staff Salaries and Benefits - Internationally Recruited		1,859,784		1,859,784	0	1,859,784		
USG Staff Salaries and Benefits - Locally		3,405,039		3,405,039	0	3,405,039		



Recruited						
Total	0	13,500,000	0	13,500,000	0	13,500,000

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		3,500		3,500	0	3,500
ICASS		68,364		68,364	0	68,364
Management Meetings/Profes sional Development		10,000		10,000	0	10,000
Staff Program Travel		65,500		65,500	0	65,500
USG Staff Salaries and Benefits - Locally Recruited		228,500		228,500	0	228,500
Total	0	375,864	0	375,864	0	375,864

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and
-------------------------------------	-----	-----------	-----------	-------------------------	---------------------	-------------------------------------



						Applied Pipeline Amount
Capital Security Cost Sharing		1,362,264		1,362,264	0	1,362,264
Computers/IT Services		893,195		893,195	0	893,195
ICASS	2,710,000			2,710,000	0	2,710,000
Management Meetings/Profes sional Development		60,000		60,000	0	60,000
Non-ICASS Administrative Costs		3,605,767		3,605,767	0	3,605,767
Staff Program Travel		1,125,000		1,125,000	0	1,125,000
USG Staff Salaries and Benefits - Internationally Recruited	365,000	6,333,727		6,698,727	0	6,698,727
USG Staff Salaries and Benefits - Locally Recruited		5,278,187		5,278,187	0	5,278,187
Total	3,075,000	18,658,140	0	21,733,140	0	21,733,140

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and
-------------------------------	-----	-----------	-----------	-------------------------	---------------------	-------------------------------



						Applied Pipeline Amount
Capital Security Cost Sharing		0		0	144,199	144,199
ICASS		282,392		282,392	0	282,392
Non-ICASS Administrative Costs		0		0	677,400	677,400
Staff Program Travel		0		0	282,000	282,000
USG Staff Salaries and Benefits - Internationally Recruited		607,608		607,608	0	607,608
USG Staff Salaries and Benefits - Locally Recruited		0		0	466,054	466,054
Total	0	890,000	0	890,000	1,569,653	2,459,653

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative Costs		167,104		167,104	0	167,104



Total	0	2,752,056	0	2,752,056	308,627	3,060,683
Recruited						
Locally						
Benefits -		669,707		669,707	0	669,707
Salaries and						
USG Staff						
Staff Program Travel		76,033		76,033	0	76,033
Peace Corps Volunteer Costs		1,719,212		1,719,212	308,627	2,027,839
Non-ICASS Motor Vehicles		120,000		120,000	0	120,000